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ABSTRACT 
Epigenetic changes consist of DNA methylation, histone modification, micro RNA and genome 
imprinting.  DNA methylation of the CpG islands is one of the main methods of epigenetic 
inactivation of genes and aberrant methylations at promoter regions of tumor suppressor genes 
can alter gene expression and play an important role in cancer development. DNA 
methyltransferase I (Dnmt1) is the enzyme responsible for maintaining methylation patterns 
during cell division and it is overexpressed in many cancers. Thus, Dnmt1 is a promising 
therapeutic target for development of novel anticancer agents and epigenetic modulators. We 
have developed two promising class of lead candidates, compounds 5-hydroxy-2-(4-
hydroxyphenethyl)-3-oxo-N-pentyl-4-(4-(trifluoromethyl)phenyl)isoindoline-1-carboxamide 47, 
2-(2-(1H-indol-3-yl)ethyl)-5-hydroxy-3-oxo-N-pentyl-4-(4-(trifluoromethyl)phenyl)isoindoline-
1-carboxamide 51 and 1-(4-isopropylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 96,  as 
potential  leads compounds that can be optimized  for pharmaceutical applications.. 
The first class of lead compounds are isoindolinones; though originally discovered as hits from 
virtual screening we have designed and synthesized compound 5-hydroxy-2-(4-
hydroxyphenethyl)-3-oxo-N-pentyl-4-(4-(trifluoromethyl)phenyl)isoindoline-1-carboxamide 47 
and 51 as  potential Dnmt1 inhibitors with promising anticancer properties. Compound 47 and 2-
iii 
 
(2-(1H-indol-3-yl)ethyl)-5-hydroxy-3-oxo-N-pentyl-4-(4-(trifluoromethyl)phenyl)isoindoline-1-
carboxamide 51 serves as important lead compounds because of their efficient synthesis. The 
four-component  single pot reaction used to prepare these compounds allows a variety of 
combinations of amines and isocyanide groups important for fine-tuning this class of compounds 
for structural activity relationship. Also, compound 47 and 51 displayed minimal toxicity to 
MCF10, a normal mammary gland cell line, but it was lethal to breast cancer MCF7 cells, which 
is an indication of selectivity. As a result, isoindolinones are being studied further as novel small 
molecules with potential therapeutic application. 
 
Furthermore, using a combined study of pharmacophore modeling and 3-dimensional 
quantitative structure activity relationship (CoMFA), we discovered β-carbolines as another class 
of compounds with promising Dnmt1 inhibition and potent anticancer properties. From a small 
library of  seven compounds synthesized, compound 1-(4-isopropylphenyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole 96 was found to show potent anticancer activity against MCF7 with an 
IC50 close to Tamoxifen a commercial breast cancer drug. Compound 96 is in its early stage of 
development and can be studied and developed further to increase potency. 
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CHAPTER	  1	  
INTRODUCTION	  AND	  BACKGROUND	  OF	  EPIGENETICS	  
 
 
1.0 	  Historical	  Evolution	  of	  Epigenetics	  
	  
DNA methylation at the C5 position of cytosine plays an important role in epigenetic 
regulation and it has been observed that the alteration of DNA methylation patterns is closely 
associated with gene silencing and epigenetic mutations. Also because the enzyme DNA 
methyltransferase1 (Dnmt1) is essential for maintaining methylation patterns during mammalian 
development the enzyme has become an important target for cancer therapies[1]. Therefore, the 
theme of this dissertation concerns the development of small molecules that reversibly bind to 
and inhibit the activity of Dnmt1 and their application as anticancer agents. Herein, we describe 
the molecular modeling, design and synthesis of DNA methyltransferase1 (Dnmt1) inhibitors 
and the use of these compounds as potential cancer therapeutics in MCF-7 breast cancer cell 
lines. The inhibitors are based on nucleoside and non-nucleoside compounds.  The nucleoside 
inhibitors discussed are analogs of cytosine and thymidine, while the non-nucleoside structures 
are derivatives of isoindolinones, β-carbolines and acrylic acid. This introductory chapter 
provides a thorough review on epigenetics, gene regulation and cancer. However, we will 
initially acquaint ourselves with the steady progression of knowledge from Darwinian genetics to 
the prevailing epigenetic model, particularly how the two approaches complement each other and 
help explain the relationship between DNA methylation and gene silencing. 
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1.1 Evolution	  of	  Epigenetic	  and	  Mechanism	  
 
  Darwinian genetics established the principle of change through natural selection; this 
change is seen in traits that show variation from parents to offspring. However, modern synthesis 
(Neo-Darwinism) has advanced Darwinianism to include other paths to variation and heredity 
apart from natural selection such as, random genetic drift, DNA recombination and mutation[2]. 
But the wind of change did not stop there; it has evolved, and probably still evolving, to a new 
concept termed   Epigenetic Synthesis[3]. This new approach describes phenotypic variation due 
to changes in DNA expression without altering DNA sequence, which is determined largely by 
various epigenetic mechanisms [4].  These mechanisms use chromatin structure, DNA 
methylation and microRNA expressions to determine whether certain genes are expressed or 
specific sequences are partially or fully accessible by transcription factors during development 
without altering DNA sequence[5]; and these mechanisms in turn control phenotypic variations.  
1.2 Genetic	  and	  Epigenetic	  Paradigm	  
  In the early to mid-1900s, the views of neo-Darwinian genetics[6], and by extension 
Darwinism, regarding the genetic paradigm of heredity and variation were summarized under 
some assumptions including: (a) genes determine characters in a straightforward and additive 
way, (b) genes are stable and passed on to the next generation, except for rare random mutations, 
and (c) genes are not affected by the environment – that is, no feedback from the environment on 
gene is ever observed[7]. These assumptions, however, have been met with various challenges 
over the years. For example, assumption (a) was revised by Sewell Wright, who argued that 
selection relates to a whole organism, but not to a single gene [8]. Also, great deal of knowledge 
has been added to assumption (b) by the fact that genes undergo mutations, insertions, deletion, 
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amplifications, rearrangements, recombinations, gene-jumping, and gene-conversion in response 
to stress, starvation, or adaptation to new situations. Lastly, if assumption (c) is considered then a 
gene would be said to be completely separated from the other network of genes and regulatory 
machinery, which is not the case as we now know today[1]. In addition, evidence that genes are 
unstable and are directly influenced by the environment is growing. Pollard and Rennie’s studies 
of gene expression revealed some of the complexity and dynamism involve in cellular and 
genetic processes, which may serve to destabilize and alter genomes within the lifetime of an 
organism.[8-9] 
Figure 1.1:  Waddington's Epigenetic Landscape. The model presented by Conrad Waddington 
shows how a cell becomes more and more determined during development and that the possibility 
for differentiation decreases later in development. He compared the development of a cell with a 
ball (depicted in blue) rolling down the illustrated landscape and making its way through different 
valleys and elevations to different end points. Several types of histone modifications in this model 
can influence how cells develop. Various histone modifications such as acetylation and 
phosphorylation can change the fate of the cell to a small degree at a certain time point (green 
arrows), whereas methylations accumulation during development can have more influence on final 
destiny of a cell (red arrow). Although modifications with a fast turnover might not be involved in 
shaping a cell's identity directly, they can still influence long-term memory via interactions with 
methylation readers and writers.[10] Permission requested 
 
 
Meanwhile, as the genetic paradigm undergoes some modifications, there is a revival of 
the epigenetic approach which was first proposed by Jean-Baptiste Lamarck. And according to 
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the Lamarckian theory, the organism is capable of interacting with the environment, and can 
acquire transformations during this process which can be internalized.[11] But the term 
‘epigenetics’, which describes Lamarck’s idea, was not coined until Conrad H. Waddington 
(1942) used ‘epigenetic landscape’ as a metaphor to describe the  flexibility and plasticity of 
gene regulation during development in  his theory of genetic assimilation. In brief, Waddington 
visualized a cell in an embryo as a ball rolling down the ‘landscape’ (Figure 1.1). As it rolls, the 
ball has several ‘options’ or ‘choices’ as to which way to go – just as a developing embryo is 
influenced by genetic and environmental factors to take certain ‘paths’ so also so is the cell. By 
the time it reaches the bottom, the cell would have made several such ‘choices’. The importance 
of the epigenetic landscape, as described by Ho and Saunder, is that its topography is determined 
by all of the genes that are interlinked, and not on specific alleles of particular genes.[8] Ho and 
Saunder’s concept implies that when populations of organisms experience a new environmental 
influence during development a large proportion of the organism give a novel response to these 
new environmental stimuli; it will mean a normal developmental pathway being ‘pushed’ over a 
threshold or in some cases a new pathway emerges in the epigenetic landscape. Now if this 
response is adaptive, then a natural selection for it will be established and it becomes regulated 
so that more or less uniform response results from a range of intensity of the environmental 
stimulus. Ultimately, after some generations, the response become genetically assimilated, that 
is, it arises even without the stimulus.  
Put together, Waddington defined epigenetics as ‘the causal interactions between genes and their 
products, which bring the phenotype into being.[12] His definition was initially centered on 
embryonic development as guided by epigenetic landscape. Today, however, epigenetics has 
advanced to accommodate a wide variety of biological processes and describes heritable changes 
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in gene expression that occur independent of changes in DNA sequence. Also, while 
Waddington’s genetic assimilation was demonstrated, at the time, by changes in cytoplasmic 
organization that could be stably inherited independent of nuclear or cytoplasmic DNA,[13] his 
argument on his epigenetic theory did not specify the mechanism by which the assimilation 
occurs, or as the measure of the ability of a population to produce the same phenotype regardless 
of the environment. But, today from the work of Holliday and colleagues,[14] the mechanism by 
which epigenetics modifications occur have been studied and they include: chromatin 
remodeling, DNA methylation, RNA transcription, MicroRNAs synthesis, and prions formation.  
We shall look at three of these epigenetic regulation mechanisms in more detail. 
Nevertheless, from the ongoing discussion, it is only logical to view epigenetics not as a 
replacement of neo-Darwinism but as an advancement of our current understanding of genetics 
and its many ramifications. Or simply put, epigenetics introduces a chemical switchboard for a 
network of genes to be turned on and off without altering the DNA sequence. Epigenetics 
describes a new concept the ‘epigenome’ that is dynamic and highly sensitive to the 
environment, which complements the already known sequence based DNA molecule. 
1.3 Chromatin	  Remodeling	  and	  DNA	  Methylation	  
 
Eukaryotic DNA is packaged into highly organized chromatin structure, which is important to 
preserve a whole genome inside the nucleus of a cell. On the other hand, the compactness 
represents an obstacle for DNA transcription, replication, repair and recombination[15] because 
these processes require unwound DNA for them to occur. Consequently, there is a dynamic 
balance between genome packaging and genome accessibility. The dynamic balance would 
allow, for example, specific transcription factors to bind to a target sequence on DNA for a 
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particular gene transcription process, or would prevent access to that DNA sequence. Chromatin 
remodeling proteins, histone modification proteins and DNA methylation are multiple 
mechanisms that tightly regulate gene transcription processes.[15] In this section we shall 
summarize the first two processes and discuss DNA methylation extensively. 
The basic structural unit  of a chromatin is the nucleosome, which consist of 
approximately 146 base pairs of DNA wrapped 1.65 turns around a histone octamer core 
containing two molecules in each of core, the histones H2A, H2B, H3 and H4.[16] Neighboring 
nucleosomes are separated by, on average 50 bp of free DNA.  Positive charged residues in the 
histone contact the phosphate backbone of the DNA every 10.4 bp, providing fourteen relatively 
weak histone-DNA interactions.[16] In particular, the histone-DNA interactions are influenced by 
nucleosome-modifying   and nucleosome-remodeling protein complexes. The former makes 
covalent modifications on the histone protein, mostly at the tail of histone H3 and H4, and 
creates markers that will be identified later by transcription regulation proteins.[17] While the 
later, chromatin remodeling complexes restructures, mobilizes and ejects the nucleosomes in 
order to regulate access to the DNA, without covalently modifying the histone protein.[18] 
Remodeling involves the breaking and reforming of the histone-DNA contacts, which results in 
the mobilization of nucleosome on the nucleosome template. The regulators, though believed to 
be independent, are interconnected with DNA methylation, since they are also involved in 
chromatin silencing. There are some speculations that all three epigenetic mechanisms might 
influence each other to some extent.[19]  
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DNA Methylation 
If we shift our focus from covalent modification of histone core proteins to modification 
of DNA base pairs, then we will visit an important epigenetic mechanism by which tissue-
specific gene-expression patterns and global gene silencing are established and maintained.  
 
Figure 1.2:  Links between DNA methylation, histone modification and chromatin remodeling. a) A 
model of DNA methylation directing histone methylation. DNA methylation patterns are 
established through de novo methylation by the DNA methyltransferases Dnmt3A and Dnmt3B, 
and are maintained by Dnmt1. Methyl-CpG-binding proteins (MBD) and histone deacetylase 
(HDAC) complexes, such as the MECP2–Sin3a–HDAC complex, are believed to then be recruited 
to the methylated region to induce histone deacetylation and silencing. The chromatin then attracts 
histone methyltransferases (HMTs), such as Suv39h or G9a, which methylate the lysine 9 residue 
on histone H3 (H3-K9) and stabilize the inactive state of the chromatin. b) A model of histone 
methylation directing DNA methylation. Methyl H3-K9 acts as a signal for inactive chromatin by 
recruiting HP1 to methylated histones, which might in turn recruit DNA methyltransferases 
directly or indirectly (through an unknown factor, factor X) to the silent chromatin  to maintain 
DNA methylation and stabilize the inactive chromatin21,22 . c) A model of chromatin remodelling 
driving DNA methylation. The ATP-dependent chromatin-remodelling and DNA-helicase activities 
of proteins, such as ATRX and Lsh, might facilitate DNA methylation and histone modification by 
unwinding nucleosomal DNA to increase its accessibility to Dnmts, HDACs and HMTs.  The 
disrupted function of these proteins impairs both DNA methylation and histone methylation, as has 
been shown in plants.  The chromatin-remodelling protein (CRP) that is involved in de 
novomethylation has yet to be identified.[19]  Permission requested  
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DNA methylation occurs on both cytosine and adenine bases in prokaryotes, but in humans, 
methylation is restricted to cytosine bases[20]; it is mostly absent from the genome especially at 
short genomic regions called CpG islands, that is, regions with more than 500 base pairs and 
with a GC content greater than 55%[21]. Such stretches of DNA are located within the promoter 
regions of 40% of mammalian genes and are usually free of methylation. Aberrant de novo 
methylation can cause heritable transcriptional silencing, and is usually the hallmark of most 
human cancers[1]. Broadly put, DNA methylation is associated with chromatin compactness and 
gene repression, however, it plays a key role in cell development which we will discuss later[20b]. 
So far, two general mechanisms have been proposed for inhibition of gene expression. First, 
methylated cytosine bases can inhibit the association of DNA binding factors with their specific 
DNA recognition sequence.[22] Second, methyl-CpG-binding proteins (MBPs) can recognize 
methyl-CpG and recruit transcriptional co-repressive molecules[23] to the site of transcription. 
Epigenetic mechanisms are suspected to be interconnected (Figure 1.2), as in the above case, 
MBPs can use co-repressors molecules to silence transcription and possibly modify the 
surrounding chromatin[24] as  noticed with chromatin remodelers. 
 
 
DNA Methyltransferases 
The methylation of CpG sites within the human genome is maintained by a number of DNA 
methyl transferase (enzymes).  Dnmts fit into two general classes based on their preferred DNA 
substrate and function. Dnmt3a and Dnmt3b are known as de novo methyl transferases; they 
introduce cytosine methylation at previously unmethylated CpG sites and establish new DNA-
methylation patterns.[25] While maintenance methyl transferase, Dnmt1, copies pre-existing 
methylation patterns onto the new DNA strand during replication, it restores these DNA-
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methylated patterns by methylating hemi-methylated CpG sites.[25]  Dnmt3L is a Dnmt-related 
protein that does not possess known methyl transferase catalytic action but it is known to 
physically associate with Dnmt3a and Dnmt3b, and modulate their activity.[26] Lastly, there is a 
fourth type DNA methyltransferase, Dnmt2, which only shows a weak DNA methylase activity 
in vitro but is known to methylate small RNA (e.g. tRNAAsp).[27] The major activity and function 
of Dnmt2 is not yet fully understood, however the targeted deletion of the Dnmt2 gene in 
embryonic stem cells had no noticeable effect on global methylation implying that Dnmt2 might 
not be involved in de novo methylation.[28]  
So far, DNA methylation is one of the best understood epigenetic modifications of the 
chromatin. It will be important to consider the structure and mechanism of action of Dnmts; 
particularly we shall revisit Dnmt1 in more detail to discuss its mode of action and implication in 
cancer. 
 
1.4 Epigenetics	  and	  Human	  Disease	  
 
There are several indications that dysfunctions and mutations in epigenetic mechanism can result 
in a number of human diseases, especially cancer.[29] Epigenetic disease could be as a result of 
changes in global or localized methylation patterns, or incorrect histone modification.  Feinberg 
has reviewed the subject in terms monogenic epigenetic disease, and further classified them into 
two. The first type includes those diseases involving mutation in genes that are epigenetically 
regulated, (e.g. imprinted gene), and the second type are those that affect the epigenome as a 
whole, such as the modification of epigenetic mechanism (e.g. DNA methylation).[30]   
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Human diseases related to monogenic epigenetic machinery can either be single-gene disorder 
such as Rubinstein Taybi syndrome[31], ATRX syndrome[32] and Retts syndrome, or a network of 
genes as in the case of disrupted imprinted genes. In the former case, Retts syndrome is an X-
linked neurodevelopmental disorder that involves mutation of the CpG binding protein 2 
(MeCP2), a protein that binds to methylated DNA sequence.[33] On the other hand, gene 
imprinting disorders can lead well known syndromes like Beckwith Weidemann syndrome 
(BWS), Prader-Willie syndrome and Angelman syndrome[34]; but we will not discuss them 
further, instead we will turn our attention to cancer related epigenetic changes. 
1.5 Epigenetics	  and	  Cancer	  
DNA Methylation and Cancer 
The development of cancer involves a complex succession of events, from incipient cells 
acquiring alterations in oncogenes, tumor-suppressor genes and instability of genes to disruption 
of cellular regulatory pathways.[5] Epigenetic alterations in tissues-specific genes or 
housekeeping genes of either oncogenes or tumor-suppressor genes, can lead to a number of 
different malignancies by either hypermethylation or hypomethylation of these genes. We will 
examine some of these gene alterations and the type of cancers involved. 
Hypermethylation 
Since the initial discovery of CpG island hypermethylation of the Rb promoter (tumor suppressor 
gene associated with retinoblastoma)[35], hypermethylation of the CpG islands in the promoter 
regions of (tumor suppressor) genes is now a widely accepted feature in human cancers. 
Epigenetic silencing of tumor suppressor genes can also lead to tumor initiation by serving as the 
second hit in the Knudson’s two hit model for tumor development.[36]  Numerous genes are 
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susceptible to hypermethylation, and they include, cell cycle regulation (p16INK4a, p15INK4a, Rb, 
p14ARF), DNA repair (hMLH1, MGMT, WRN, BRCA1), apoptosis (DAPK, TMS1 SFRP1, WIF-1), 
p53 network (p14ARF, TP73, HIC-1), and angiogenesis.[37]  For example, in many cases of 
leukemia and other hematologic related diseases, p15INK4B, p21Cip1/Waf1, the ER gene, SDC4, MDR 
group of genes were seen to be highly methylated in various hematologic cancers.[38] Also, Yang 
noted that in breast cancer development gene silencing includes steroid receptor genes, cell 
adhesion gene and inhibitors of metalloproteinases.[39]  Some of the genes highly methylated are 
estrogen receptor (ER) alpha, progesterone receptor (PR), p16NKA, BRCA1, GESTP1 and E-
cadherin. The BRCA1 gene is one of the more commonly associated genes in breast cancer, and 
aberrant DNA methylation results in reduced or complete absence of the BCRA1 protein.[40]   
Esteller et al. conducted a gene hypermethylation profile of human cancer with a total of 12 
genes, including well-characterized tumor suppressor genes (p16INK4a, p15INK4b, p14ARF, 
p73, APC, and BRCA1), DNA repair genes (hMLH1, GSTP1, and MGMT), and genes related to 
metastasis and invasion (CDH1, TIMP3, and DAPK).[41]   Each gene possesses a CpG island in 
the 5’ region, which is normally nonmethylated in healthy cells.[20b]  The study sampled over 600 
specimens covering over 15 major tumor types (colon, stomach, pancreas, liver, kidney, lung, 
head and neck, breast, ovary, endometrium, kidney, bladder, brain, and leukemia and 
lymphomas). Their results showed that some genes, such as the cell cycle inhibitor p16INK4a, are 
hypermethylated across many tumor types including colorectal, lung, and breast carcinomas.[42]  
Other studies expanded on  p16INK4a   epigenetic silencing to include neoplasm (Figure 1.3), and 
other types of tumor such as bladder[43]  and cervical tumors[44] or melanomas[45]  and gliomas.[46] 
Also, DNA repair gene MGMT and SAPK share the same wide distribution in cancer types.[47] 
Conversely, hypermethylation of p14ARF and APC are most prevalent in gastrointestinal tumors 
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(i.e., colon and stomach).[48] Likewise, GSTP1 methylation aberration is characteristic of steroid-
related neoplasm such as breast, liver and prostate.[49] Equally noteworthy is the aberrant 
methylations that are very specific in selected tumor types, which may be inheritable. For 
example, BRCA1 hypermethylation is found only in breast and ovarian carcinomas.[50] Female 
individuals carrying a mutated BRCA1 allele have an estimated risk of 87% for breast cancer and 
44% for ovarian cancer by age 70.[51] Another very specific gene is the mismatch repair gene 
hMLH1, which is restricted to three sporadic tumor types characteristic is the hereditary 
nonpolyposis colorectal cancer syndrome: colorectal, endometrial, and gastric tumors with 
microsatellite instability.[52] Likewise, hypermethylation of p73 and p15INK4b is only observed in 
hematological malignancies.[53] 
Interestingly, some epigenetic inactivation may affect all of the molecular pathways involved in 
cell immortalization and transformation. As a result, in any given tumor it is possible to find 
simultaneous inactivation of several pathways by aberrant methylation silencing in cell cycle 
(p16INK4a and p15INK4b), DNA repair (hMLH1, MGMT, and BRCA1), cell adherence and 
metastasis process (CDH1, TIMP3, DAPK), p53 network (p14ARF and p73), metabolic enzymes 
GSTP1), and the APC/b-catenin route (APC).[41] For example, a colorectal tumor may have 
disruption of cell cycle, DNA repair, and metastasis-related process by hypermethylation of 
p16INK4a, hMLH1, and TIMP-3, respectively.[41] Similarly, mammary tumors may affect the same 
pathways by silencing p16INK4a, BRCA1, and CDH, or lung tumor affecting p16INK4a, MGMT, and 
DAPK.[41]  
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Figure 1.3: A, depiction of the profile of gene promoter hypermethylation across human tumor 
types. All cases represent random and unselected populations of each particular tumor type, except 
p, where hMLH1 methylation was determined in colorectal, endometrial, and gastric tumors 
enriched in microsatellite-unstable samples. Analysis of the methylation status was studied in most 
cases by sodium bisulfite modification of DNA and subsequent PCR using primers designed for 
either methylated or unmethylated DNA (PCR conditions and sequences are available upon 
request). Additional samples were analyzed by Southern blot with methyl-sensitive enzymes, 
restriction cut analysis, and bisulfite genomic sequencing. B, numerical distribution of promoter 
hypermethylation according to gene and tumor type[41]. Permission requested  
 
Also obvious from the profile (Figure 1.3) is that certain tumor type share similar gene 
hypermethylation types. Gastrointestinal tumor (colon and gastric) share a set of genes 
undergoing hypermethylation characterized by p16INK4a, p14ARF, MGMT, APC, and hMLH1, 
while  other aerodigestive tumor types, such as lung and head and neck, have a different pattern 
of hypermethylated genes including DAPK, MGMT, and p16INK4a, but not hMLH1 or p14ARF. A 
pattern is also observed for ovarian and breast cancers, where BRCA1, GSTP1, and p16INK4a 
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genes are mostly hypermethylated.[41] Such observations allow a small subset of genes to be used 
as biomarkers for certain cancer types. This represents only a partial picture of the complex 
methylation changes in cancer.  
Whereas, our current focus is on hypermethylation of the CpG islands in the promoter 
region, certain reports suggest that most of the aberrant DNA methylation occurs in CpG island 
shores – that is, a short distance within 2 kb from the CpG island as observed in some colon 
cancers.[54] Also noteworthy is the fact that most changes in the CpG island shore (45-65%) are 
associated with regions highly methylated during tissue differentiation and lastly, differential 
methylation pattern correlates with gene expression at CpG island shores just as it does with 
CpG islands.[55] Whether it is the CpG island or the CpG island shores, global hypomethylation 
and local hypermethylation patterns observed in most cancers are caused by aberrant methylation 
resulting from dysfunctional DNA methyltransferase. High expressions of Dnmt1 and Dnmt3b 
have been observed in many tumor types, however these methylases are regulated by miRNAs as 
well.[56] So, though there are indications of a strong correlation amongst epigenetic regulatory 
machineries, this finding also suggests the involvement of high methylase enzyme in most 
cancers. 
Hypomethylation                                                                                                                              
In contrast to hypermethylation, global hypomethylation is also observed in a wide variety of 
cancers (e.g. prostate, cervical and hepatocellular carcinogenesis), and it occurs mainly at 
repetitive sequences.[57]  Hypermethylation promotes chromosomal instability, translocation, 
gene disruption and activation of oncogene. Simple repeat sequences such as DNA satellites 
contain repeated DNA sequences arranged in tandem. Such satellites are commonly found in 
pericentromeric or subtelomeric heterochromatin and are normally methylated in the genome of 
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a healthy individual. It has also been observed that  hypomethylation of DNA satellites, such as 
the centromeric satα, juxtacentromeric sat2 and sat3, have been linked to ICF syndrome and 
cancers including Wilms tumor, ovarian and breast cancer.[58] In addition, DNA repeats NBL2 
was observed to be hypomethylated in neuroblastomas and hepatocellular cancer.[59]  
Hypomethylation has been linked to oncogenesis by activation of oncogenes such as 
cMYC, H-RAS, MAPSIN in gastric cancer, S-100 in colon cancer and MAGE (melanoma-
associated antigen) in melanoma.[60] It is important to state here that oncogene activation is 
highly complex and the mechanism of action remains a subject of intense investigation. Current 
findings, however, have shown that hypomethylation plays a prominent role in genomic 
instability and increase mutation rates.[61] 
1.6 DNA	  Methylation	  and	  Regulation	  in	  Mammalian	  Genetics	  
 
DNA methylation fundamentally modifies the functional organization of the human 
genome. The first evidence of DNA methylation was found in 1948[62] and decades later, we now 
understand, though not fully, the important role it plays in development, gene regulation and 
disease. It involves an enzymatic covalent transfer of a methyl group from S-Adenosyl 
methionine (SAM) to the N or C atoms of two DNA bases to form methylated bases such as N6-
methyladenine, 5-methylcytosine, and N4-methylcytosine, which become natural components of 
the DNA. Modifications add extra information to the DNA that is not coded in the original 
sequence.  In this chapter we will focus on C5 methylation of cytosine. Particularly, we will 
discuss the basic functions of DNA methylation, and then we will look at structure and function 
of Dnmt1.  
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DNA Methylation and its Basic Functions 
In mammals, during embryogenesis and development, complex and dynamic DNA methylation 
transformations are observed. For instance, active demetheylation occurs in the male pronucleus 
shortly after fertilization, through a process that seems to be independent of DNA replication.[63]  
Also, after formation of the zygote, both maternal and paternal chromosomes undergo 
progressive passive demethylation from both gametes, with the exception of the methylation 
marks at the imprinted loci.[64] Furthermore, embryonic DNA methylation patterns are 
established after implantation through lineage-specific de novo methylation that begins in the 
inner cell mass of blastocyst.[64a, 64b, 65] DNA methylation levels increase rapidly in the primitive 
ectoderm, which gives rise to the entire embryo, whereas methylation is either inhibited or not 
maintained in the trophoblast and the primitive endoderm lineage, which give rise to the placenta 
and yolk sac membrane, respectively.[66]  Also demethylation and de novo methylation occur 
during gametogenesis and they are important for parental-specific marks in imprinted loci 
(genomic imprint)[67], which we shall discuss in a later section. It is important, from the ongoing, 
to acknowledge the critical role DNA methylation plays in cellular differentiation and the normal 
functioning of differentiated cells as well as development in general. 
DNA Methylation and Genomic Imprinting 
In mammals, a small number of genes (50-80) carry an imprint that allows asymmetric 
expression of genes inherited from paternal or maternal copies of the chromosome.[68] Imprinting 
refers to genes that are either silenced when paternally inherited but expressed when maternally 
inherited or vice versa.[68]  For example, monoallelic expression of the maternal copy of the H19 
gene and monoallelic expression of the paternal copy of IGF2 gene is seen to be active in 
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offspring.[69]  The involvement of DNA methylation in imprinting has been observed in several 
studies: genetic studies of the Dnmt3 family members have provided persuasive evidence that 
DNA methylation is essential for genomic imprinting. For example, the disruption of Dnmt3a, 
but not Dnmt3b, in primordial germ cells results in loss of paternal and maternal imprinting.[70] 
Also, Kaneda’s results show that offspring of mutant female mice die in utero if Dnmt3a is 
disrupted and they lack methylation and allele-specific expression at all maternally imprinted 
loci. Furthermore, Dnmt3a conditional mutant male mice show impaired spermatogenesis and 
they lack correct methylation at two paternally imprinted loci. Therefore, appropriate 
methylation and expression of imprinted genes is important for normal development because of 
the developmental and genetic diseases that are associated with imprinting defects. Falls et al.[71] 
reviewed genetic imprinting and human diseases such as, Beckwith–Wiedemann syndrome, 
Silver–Russell syndrome, Angelman syndrome and Prader–Willi syndrome.[71]  
DNA Methylation and X-chromosome Inactivation 
DNA methylation also plays an important role in X-chromosome inactivation. It is well known 
that in mammals, females carry two X chromosomes while males have only one. X-chromosome 
inactivation is described as a dosage compensation mechanism that results in the transcriptional 
silencing of one of the two X chromosome in the female during early embryogenesis. The 
process of inactivation involves specific expression of the Xist (inactive X-specific transcript) 
RNA from the inactivated chromosome, as well as increased methylation and histone 
deacetylation of the inactive chromosome.[72]  Beard et al. and Panny et al. have revealed that 
DNA methylation is not essential for the initiation and development of X-inactivation but very 
much required for stable maintenance of X-chromosome inactivation.[73] Also, the choice of 
which X-chromosome to inactivate is made early in embryogenesis.  In embryonic tissues of one 
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chromosome is selected at random[72], whereas in extraembryogenic tissues the paternal 
chromosome is always the choice for inactivation.[74]   Lastly, X-chromosome inactivation 
depends on CTCF, a candidate trans-acting factor that detects the methylation site of the 
protein.[75] 
DNA Methylation and Selfish Genes 
Genomes are vulnerable to selfish genetic elements (SGEs) such as transposons, 
retrotransposons, and viruses, which enhance their own transmission genome wide but are 
neutral or harmful to the individual.  Startlingly, about 40% of the human genome is composed 
of transposable elements (TEs).[76]  Since such transposable element are not stable, and random 
integration into the genome is a key source of mutation, preventing the insertion of transposable 
element by transcription silencing is important for life and avoidance of disease. DNA 
methylation is known to suppress TEs in both animals and plants[77]: transposons and other 
repetitive DNA sequence are usually relatively rich in GC sequences and are heavily 
methylated.[76a] Also, an increase in the transcription of transposon is known for Dnmt1 knock-
out embryonic stem cells and cell lines.[77-78]  It is important to add here that DNA methylation is 
only one of the many machineries involved in SGE suppression, there are other mechanisms 
such as repeat-induce point mutation in fungi, RNAi, and small RNA suppression pathways that  
are also involved in regulating  transposable elements.[76b, 79]  
Interestingly, there are other important functions of DNA methylation such as reduction in 
transcriptional noise associated with the spurious transcription of genes.[80]  The noise is based 
on the long-standing hypothesis, which posits that ‘gene body’ (transcriptional unit) methylation 
suppresses false transcription within coding regions. Adding that, by so doing, gene body 
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methylation can potentially reduce transcriptional noise. We will not go in depth with this 
subject matter but it is significant to highlight that in general, the levels of gene expression vary 
between cells even with the same genetic materials and under the same biological conditions. 
Understanding the nature and mechanism of this variability, which is commonly referred to as 
‘transcriptional noise’ is crucial and it has a strong link with DNA methylation since most of the 
gene body region is extensively methylated.[79, 81]  
1.7 	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Dnmt1 is the principal DNA methyltransferase (Dnmt) in mammalian cells. It is a very large 
multimodular protein which comprises 1620 amino acids; the actual length depends on the 
species and the expression of tissue-specific exons.[82] The protein is highly dynamic with 
multiple regulatory features that control DNA methylation. In general, Dnmt enzymes are 
divided into a smaller catalytic domain and a larger N-terminal regulatory domain (Figure 1.4).  
Prokaryotic orthologs of Dnmt1 lack the regulatory N-terminal domain; however they share the 
same specificity for CpG sites.[83]  Dnmtt1 follow the same structural organization; composed of 
the N-terminal, which includes the replication foci-targeting domain (RFD), a DNA-binding 
CXXC domain, a pair of bromo-adjacent homology (BAH) domains, and a conserved C-terminal 
catalytic domain. It is important to differentiate hDnmt1 (human Dnmt1) from mDnmt1 (mouse 
Dnmt1) and M.HhaI (bacterial Dnmt1 form Haemophilus haemolyticus) because although the 
catalytic pockets are highly conserved within the enzymes, there some subtle difference 
important for drug design and we are concerned with hDnmt1. Song et al.  solved the crystal 
structure (Figure 1.5) of  mouse Dnmt1 (650-1602 amino acids) at 3.0 Å and HDnmt1 (646-
1600 amino acids) at 3.6Å respectively, and both structures show 85% sequence similarity  
Figure 1.6.[84]  We shall use different sections to discuss the structure and function of both the 
20 
 
catalytic and the regulatory N-terminal mainly of hDnmt1 while contrasting it with mDnmt1 and 
M.Hhal, since the project concerns design and synthesis of hDnmt1 inhibitors.  
 
 
 
 
 
Figure 1.4:  Domain architecture of mammalian DNA MTases. Functional domains in the N-
terminal part of the proteins are shown and the conserved C5 DNA MTase motifs in the C-terminal 
part are labeled. Permission requested 
 
The catalytic C-terminal Domain 
The crystal structure of HhaI[85]  shows that the catalytic domain needs three structural elements 
to support catalytic activity: an AdoMet-binding domain, a target based-binding cavity, and a 
target sequence recognition domain (TRD). The first two domains are highly conserved sequence 
domains and are easily recognizable in most Dnmt enzymes[86], however, the target 
recognition/element domain is not precisely defined by conserved sequence motifs. Similarly, 
the catalytic domain of Dnmt1 folds into two subdomains, designated as the catalytic core and 
the TRD.[84] The catalytic core is dominated by seven-stranded β-sheet that is flanked by three α-
helices on either side (Figure 1.5&1.7). The central β-sheet is further joined by a two-stranded 
anti-parallel β-sheet from the BAH1 domain (Figure 1.5 & 1.8C). In the TRD, there is a hairpin-
like fold at the start of the domain that forms hydrophobic contacts with the catalytic core and 
the BAH1 domain (Figure 1.7B). While, the majority of the TRD folds into an independent 
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structural unit and is stabilized,  in part, by a zinc finger residue, Cys3-His coordinated to Zn2+ 
(Figure 1.8D & 1.9). There are intermolecular contacts between amino acid side chains 
described by Song et al. as primary contacts between arginine residue of the catalytic core, and 
phosphate groups flanking the (C4pG5)•(C5′pG4′) segment of the unmethylated DNA duplex in 
the complex (Figure 1.10) . 
For catalytic activity, Dnmt1 needs at least 1000 amino acid residues from N-terminal to the 
catalytic region. So far, studies have shown that enzymes missing the first 508, or 621 amino 
acids are still active, but those missing 672 amino acids or more are no longer active.[87]  
 
Figure 1.5: Structural overview of mDnmt1(650–1602)–DNA 19-nucleotide oligomer complex with 
bound AdoHcy. (A) Color-coded domain architecture and numbering of mDnmt1 sequence. The 
thin vertical light blue bars indicate binding positions of zinc ions. (B) Ribbon representation of the 
complex in two orthogonal views. The CXXC, BAH1, BAH2, and methyltransferase domain are 
colored in red, light purple, orange and light blue, and DNA and zinc ions are colored in light 
brown and dark purple, respectively; CXXC-BAH1 linker in dark blue, BAH1-BAH2 linker in 
silver, (GK)n-containing BAH2-methyltransferase linker in black, and bound AdoHcy as in space-
filling representation.[84]  Permission requested  
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Valuable insights of the catalytic activity and mechanism of reaction at this site have come from 
enzymatic kinetics, computational studies and the crystal structure of the bacterial enzyme 
M.HhaI bound to substrates and cofactor. In brief, the mechanism involves DNA binding, 
AdoMet (cofactor) binding, base flipping and the transfer of methyl group from AdoMet to the 
C5 position of Cytosine in the DNA.[85, 88]  It is assumed that M.HhaI and Dnmt1 share a similar 
mechanism of reaction at the active site based on the conserved nature of the sequence motifs[86, 
89] , the results of 3H exchange reaction[90] and their inhibition by 5-fluorocytosine.[91]                                                                                                        
 
 
Figure 1.6: Sequence alignment of the C-terminal segments of hDnmt1 and mDnmt1[84]  
Permission requested  
 
 
Furthermore, similar studies also suggest that the M.HaI and Dnmt1 share very similar catalytic 
processes at the C5 of the activated target base and including the methyl transfer step.[90b, 91] The 
methyl transfer step has been labeled the rate-limiting step for both enzymes [90b, 91], however, 
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 A B C 
M.HhaI has ~100-fold faster catalytic rate than Dnmt1. It might be safe to speculate that the 
difference in catalytic rate might be due to the N-terminal in Dnmt1, which is absent in 
M.HhaI.[90b] Notwithstanding, some studies have attributed the difference in catalytic rate to be 
due to difference in rapid equilibrium between the  initial steps of target base attack, particularly, 
the target recognition step, base-flipping step and formation of the unstable covalent adduct 
intermediate.[90a]   
In addition, the allosteric regulation of Dnmt1 might lead to changes in the methylation rates as a 
result of changes in the rapid equilibrium during the early catalytic steps.[90b, 91]   Lastly,  the fact 
that Hhal flips the  target cytosine base into the catalytic pocket has been considered as possible 
reason for difference in methylation rates between Hhal and hDnmt1,  however, no base flipping 
experiments have been reported for Dnmt1, which if present might have a huge impact on 
hDnmt1 kinetics.[85] 
 
 
 
 
 
Figure 1.7: The catalytic core and TRD of the methyltransferase domain of the mDnmt1 (650-
1602)-DNA complex 19-mer with bound AdoHcy. (A) Ribbon representation of mDnmt1 catalytic 
core, with bound AdoHcy shown in space filling representation (B) Ribbon representation of 
mDnmt1 TRD. (C), Hydrophobic contacts between mDnmt1 catalytic core (residues Val1275, 
Leu1283 and Phe1299 in cyan), TRD (residues Val1346, Val1348 and Phe1353 in cyan) and BAH1 
(residues Val807 and Ala878 in magenta).[84] Permission requested  
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The Regulatory N-Terminal Domain 
The first three quarters of the hDnmt1 contain the regulatory domains: the DNA 
methyltransferase associated protein 1 (DMAP1)-binding domain, the Replication Foci Targeting 
Sequence (RFTS) domain, the CXXC zinc binding domain  and two Bromo-Adjacent Homology 
(BAH) domains[92] (Figure 1.5).  
All sequence specific contacts with DNA are made via the CXXC domain. The CXXC domain, 
also called zinc domain, targets both the major and minor groove of the DNA over a CpG- 
containing 4-bp segment.[84] The CXXC residues (Arg684-Ser685-Lys686-Gln687) penetrate 
into the major groove to form base-specific and phoshpodiester intermolecular interactions. Both 
guanine and cytosine bases in the CpG dinucleotide are recognized by side-chain interactions or 
the four CXXC residues mentioned above. Also, the DNA recognition is further strengthened by 
the salt bridges between arginine side chains of the CXXC domain and the phosphodiester 
backbone of the DNA. In summary, CXXC contributes to the catalytic action of Dnmt1 by 
recognizing and binding nonmethylated CpGs in the DNA.[84, 93]  
The BAH1 and BAH2 domains are separated by an α-helical linker; both domains are on the 
surface of the protein remote from the bound DNA. Moreover, they are connected to the CXXC 
domain and the catalytic site via flexible loops and BAH1 is connected to a Zn ion in Cys3-His-
coordination. This domain might contribute to the dynamic equilibrium required for Dnmt1 
activity, but its functional role in Dnmt1 is unknown. 
The function of the RFTS domain is also unclear but it is suspected to be involved in the proper 
targeting of Dnmt1 to the replicative foci during S phase of the cell cycle[94] and in the 
homodimerization of Dnmt1 which aids hemimethylated DNA binding.[95]  Lastly, the DMAP1 
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binding domain of Dnmt1 binds DMAP which act as co-repressor of transcription by interacting 
with histone deacetylase 2 (HDAC2).[92]  
N-Terminal Domain and Function                                                                                         
         The N-terminal domain has multiple regulatory mechanisms that control the activity and 
specificity of DNA methylation. Its many roles can be summarized into three key functions: (i) 
allosteric regulation of the catalytic activity (ii) multiple phoshorylation and methylation sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Intramolecular contacts between both BAH domains and the methyltransferase domain 
in the mDnmt1(650-1602)-DNA 19-mer structure. A, Close-up view of the methyltransferase 
domain (in cyan), highlighting its interactions with DNA and both BAH1 (in magenta) and BAH2 
(in orange) domains. B, Two views of anchoring of BAH2-TRD loop to the TRD of the 
methyltransferase domain. C, Two β-strands from the BAH1 domain (magenta) are paired with the 
central β-sheet (dark blue) of the catalytic core of the methyltransferase. The H-bonds are indicated 
by dashed lines. D, Residues around the C-terminus of the BAH2-TRD loop interact with the TRD 
of methyltransferase domain to further anchor the BAH2 domain to the TRD. The interactions of 
BAH1 and BAH2 with the methyltransferase domain lead to a buried surface area of 1148.7 Å2 and 
887.3 Å2, respectively.[84]  Permission requested  
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that regulate the catalytic activity of Dnmt1, and (iii) the many interactions between Dnmt1 and 
at least 31 other molecules that affect methylation.[96] The allosteric regulation of the catalytic 
pocket of Dnmt1 can be divided into two parts. One area of understanding was proposed by Song 
et al., who described an autoinhibition regulation of Dnmt1 at nonmethylated CpG sites on the 
DNA. Unmethylated DNA is excluded from the active site of mDnmt1 by binding with by 
CXXC domain; in addition, the presence of CXXC-BAH1 acidic linker prevents entrance of 
DNA into the catalytic pocket. The acidic linker is positioned between the DNA and the active 
site (Figure 1.11). Thus, the linker acts as a ‘gate keeper’ to the catalytic site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: The zinc finger clusters observed in the crystal structure of the mDnmt1(650-1602)-
DNA 19-mer complex. A, The Zn2+ ion is coordinated by cysteine residues from both the N-terminal 
and Cterminal segments of the CXXC domain. B, The Zn2+ ion is coordinated by cysteine residues 
from the middle segment of the CXXC domain. C, The Cys3His-coordinated Zn2+ ion connects the 
BAH1 domain to the linker helix between BAH domains. D, The Cys3His coordinated Zn2+ ion in 
the TRD. The Zn2+ ions are shown in purple. The nitrogen and sulfur atoms are dark blue and 
yellow, respectively.[84]  Permission requested  
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Figure 1.10: Intermolecular contacts between the catalytic domain of mDnmt1(650-1602) and 
bound DNA 19-mer. A, Ribbon representation of mDnmt1 catalytic domain bound to DNA 19-mer, 
with the side chains of DNA-interacting residues shown in stick representation. B, Surface 
electrostatic view of mDnmt1 catalytic domain bound to DNA. C, D, Intermolecular hydrogen 
bonding interactions between amino acid side chains and the DNA phosphodiester backbone. The 
nitrogen, oxygen and phosphate atoms are shown in dark blue, red and yellow, respectively. E, 
Schematic representation of intermolecular contacts in the mDnmt1(650-1602)-DNA 19-mer 
complex. The DNA region in contact with the catalytic domain is boxed by a red rectangle. The 
residue labels are colored according to their respective domains in Figure 1.11 [84] Permission 
requested 
 
 Furthermore, Song et al. proposed that nonmethylated CpG sites are protected from de novo 
methylation through binding with the CXXC domain[84]  and this binding increases the efficiency 
of maintenance methylation through inhibition of de novo methylation. Song’s proposal might 
support other studies that show Dnmt1’s catalytic preference for hemimethylated DNA 
compared to unmethylated DNA[97], however, Dnmt1 is also known to have a high kinetic 
preference for a poly(dI-dC) substrate[97a]. The other area of allosteric regulation of Dnmt1 is the 
activation of Dnmt1 with fully methylated DNA substrates. Fatemi et al. demonstrated that 
catalytic activity of murine Dnmt1 can be controlled by interaction of the N-terminal with fully 
methylated DNA.[98] Also, there are a number of other subtle pieces of evidence that have been 
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reported.[99]  Some of these results vary due to enzyme purification procedures, but there is a 
general agreement of increase catalytic activity of Dnmt1 in the presence of fully methylated 
DNA 
 
Figure 1.11:	  Comparison of mDnmt1 with M.HhaI in their DNA-bound complexes. (A) The crystal 
structure of the mDnmt1(650–1602)–DNA 19-nucleotide oligomer complex. The CXXC, BAH1, and 
BAH2 domains and CXXC-BAH1 linker of mDnmt1 have been removed for clarity. The bound 
DNA is in light brown, with the TRD and catalytic core in light and dark blue, respectively. (B) The 
crystal structure of the M.HhaI-DNA complex [PDB: 1MHT (8)]. The bound DNA is in light 
purple, with the TRD and catalytic core in pale and dark green, respectively. (C) Structural 
comparison of mDnmt1(650–1602)–DNA 19- nucleotide oligomer complex and M.HhaI-DNA 
complex in a stereo view looking down the DNA helix axis, after superposition of their 
methyltransferase domains. AdoHcy is shown in space-filling view. The everted cytosine in the 
M.HhaI complex is shown in ball-and-stick view in dark purple. (D) Electrostatic surface 
representation of mDnmt1 CXXC domain and the CXXC-BAH1 linker in the context of the 
structure of the mDnmt1(650–1602)–DNA 19- nucleotide oligomer complex. The BAH2-TRD loop 
is highlighted with thicker lines. (E) The proposed model for autoinhibitory mechanism in 
maintenance DNA methylation. In the autoinhibitory state, the CXXC domain and the 
autoinhibitory linker (in red) occlude the active site. In addition, the BAH2-TRD loop (in red) 
restrains the TRD in a retracted position so that it does not interact with CpG sites on the DNA.[84]  
Permission requested  
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Another important process of the N-terminal regulatory action of Dnmt1 is phosphorylation. 
Interestingly, the N-terminal has multiple phoshporylation sites that can control the catalytic 
activity of Dnmt1. [100] It is speculated that phosphorylation sites can cause conformational 
changes that affect the flexibility of the protein structure allowing different interaction between 
the DNA and Dnmt1. For example, phoshporylation of Ser515 can inhibit the activity of mouse 
Dnmt1 by altering the interactions between different domains.[100] Another report, suggest that 
phosphorylation appears to inhibit Dnmt1 as a result of destabilization of the Dnmt1-DNA 
complex.[101] Also interesting is the fact that Dnmt1 missing the 501 amino acids have been 
shown to have higher activity than the full-length enzyme [102] and the missing phosphorylation 
regions might be a partial reason for this. In summary, the importance of phosphorylation of 
certain serine residues of the first 580 amino acid for catalytic activity of Dnmt1 is not yet 
conclusive but current evidence points to its involvement in the catalytic action of Dnmt1. 
Lastly, we shall discuss the overwhelming number of interactions between the N-terminal of 
Dnmt1 and other molecules (Table 1.1). There have been some reports of interaction with the C-
terminal of Dnmt1; one of such interaction is with co-chaperone p23, which binds to the C-
terminal domain.[103]  So far, Svedruzic has grouped the interactions of N-terminal Dnmt1 with 
other molecules into four groups based on their physiological functions: (i) Dnmt1 dimerization; 
(ii) core chromatin replication complex; (iii) interaction with molecules involved in DNA repair, 
cell cycle control, and apoptosis; and (iv) interaction with RNA Polymerase II, RNA-binding 
proteins, and specific RNA molecules.[96]  We will discuss some examples from the four group 
mentioned above, in the coming paragraphs. 
 
30 
 
Core chromatin replication complex 
As part of the core chromatin replication complex, which preserves the existing epigenetic 
organization and chromatin structure, Dnmt1 interacts directly with proteins involved in 
Table 1.1 Summary of Molecules Currently Known to Interact Physically and/or Functional with 
Dnmt1[96]  
Core chromatin replication complex DNA repair, cell cycle control, and 
regulation of apoptosis 
RNA-directed DNA 
methylation 
   
_	  Dnmt3a	  and	  Dnmt3b	  
_	  SNF2h-­‐containing	  chromatin-­‐remodeling	  complex	  NoRC	  
_	  LSH	  protein	  (lymphoid-­‐specific	  helicases)	  protein	  related	  to	  the	  
SNF2	  family	  of	  chromatin-­‐remodeling	  ATPases	  
_	  PCNA,	  DNA	  clamp	  processivity-­‐promoting	  factor	  
_	  UHRF1	  
_	  HP1b,	  heterochromatin	  protein	  1b	  isoform	  (chromobox	  
protein)	  
_	  SUV39H1,	  histone-­‐lysine	  N-­‐methyltransferase	  
_	  G9a	  histone	  methyltransferase	  
_	  HDAC1	  and	  HDAC2,	  histone	  deacetylase	  1/2	  
_	  PML-­‐RAR	  promyelocytic	  leukemia-­‐retinoic	  acid	  receptor,	  
oncogene	  transcription	  factor	  
_	  RIP140,	  metabolic	  repressor,	  also	  known	  as	  NRIP1	  (nuclear	  
receptor	  interacting	  protein	  1)	  
_	  CFP1	  CXXC	  finger	  protein	  1	  (PHD	  domain)	  
_	  MBD2/MBD3,	  methyl-­‐CpG-­‐binding	  domain	  protein	  
_	  PcG-­‐EZH2	  Polycomb-­‐group	  proteins	  enhancer	  of	  Zeste	  
homolog	  2 
_	  PARP-­‐1	  (poly(ADP-­‐ribose)	  polymerase	  1)	  and	  	  
poly(ADPribose)	  
_	  pRb/E2F1,	  Retinoblastoma	  tumor	  suppressor	  
protein,	  control	  of	  G1/S	  transition	  and	  S-­‐phase	  
_	  p53,	  tumor	  suppressor,	  regulation	  of	  cell	  cycle	  
and	  apoptosis	  
_	  DMAP1,	  DNA	  methyltransferase	  1-­‐associated	  
protein	  1	  
_	  RGS6	  member	  of	  mammalian	  RGS	  (regulator	  
of	  G-­‐protein	  signaling)	  proteins	  
_	  CK1d/E	  kinase	  that	  phosphorylates	  Dnmt1	  
_	  Annexin	  V,	  scaffolding	  proteins	  that	  anchors	  
other	  proteins	  to	  the	  cell	  membrane	  and	  
participates	  in	  apoptosis	  
_	  Hsp90,	  chaperon	  
_	  p23,	  cochaperone	  
_	  SET	  7,	  protein	  lysine	  methyltransferase	  	  
_	  ATK1,	  serine/threonine	  protein	  kinase	  
 
_	  MeCP2,	  methyl-­‐CpG	  
binding	  
domain	  protein	  2	  (Rett	  
syndrome)	  
_	  RNA	  Pol	  II	  
_	  Specific	  tRNA	  and	  mRN 
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chromatin remodeling. Dnmt1 functionally associates with (sucrose nonfermenting) SNF2h-
containing chromatin-remodeling complex NoRC – chromatin remodelers machineries.[104] Also, 
the enzyme interacts with lymphoid-specific helicase (LSH) another chromatin remodeling 
enzyme of the SNF2 family. Interestingly, LSH function is so dependent on Dnmt1 that even 
inactive Dnmt1 is essential for it to function.[105] Such interactions with chromatin remodelers 
have been associated with possible interaction of Dnmt1with two histone deacetylase proteins, 
HDAC1 and HDAC2 since histone modification and DNA methylation share a common function 
– gene silencing. Studies have confirmed direct interaction of Dnmt1 with the two histone 
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deacetylase.[106]   Equally interesting, is the interaction of Dnmt1with Dnmt3a and Dnmt3b. the 
latter interaction is possible because many proteins involved in histone modification that interact 
with Dnmt1 also interact with Dnmt3a and Dnmt3b.[82, 107] This finding questions our current 
understanding of classifying Dnmt1 as a maintenance methyl transferase and the Dnmt3 family 
of enzymes as de novo methyl transferases. Cell-based and enzyme-based assay suggest that both 
Dnmt1 and Dnmt3 enzymes are involved in de novo methylation reactions through an unknown 
mechanism[82, 102b]; maybe there is some cooperativity between the methyl transferase enzymes. 
Furthermore, Dnmt1 can have more than ten times de novo activity than Dnmt3 enzymes[108],  
such finding compels researchers to suggest that the catalytic product of Dnmt3 can stimulate 
catalytic activity of Dnmt1.[109]  Also, it has been observed that Dnmt3 bind the regulatory 
domain of Dnmt1[110], which support the argument for possible stimulation of Dnmt1 by Dnmt3 
enzymes. 
The chromatin replication complex also houses an important enzyme ubiquitin-like PHD and 
ring finger domain1 (UHRF1), which recognizes a hemimethylated site on the DNA as Dnmt1 
does. UHRF1 is a large multidomain protein that is central in the epigenetic code complex.[111]  It 
can bind Dnmt1 and histone methyl transferase G9a through the SRA domain.[111-112]  Two 
studies mapped the interaction parts of Dnmt1 and UHRF1 to either the SRA[113] or the PHD[111] 
domain of UHRF1 and the N-terminal part of Dnmt1. Separate research have shown that UHRF1 
is highly important and it plays a central role in maintaining DNA methylation. UHRF1 knock-
out embryos die shortly after gastrulation, which implies a significant reduced level of DNA 
methylation.[112] Similarly, UHRF1 knockout ES cell are viable despite global demethylation but 
fail to differentiate properly.[112] The current model based on available data, describes a 
mechanism in which UHRF1 recruits Dnmt1 to hemimethylated DNA to facilitate its efficient 
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remethylation. However, it is also known that Dnmt1 is recruited to active DNA replication sites 
through its interaction with Proliferating Cell Nuclear Antigen (PCNA), a processivity factor for 
DNA polymerases δ and β[114], which then facilitates the methylation of hemimethylated DNA in 
S phase.[115]  
DNA repair, cell cycle control, and apoptosis                                                                 
 The N-terminal of Dnmt1 interacts with protein complex associated with DNA repair, cell cycle 
control and apoptosis. Experiments have shown that the molecules that are involved in  DNA 
damage response can stop DNA methylation at the level of Dnmt1 transcription[116]  or by direct 
interaction with Dnmt1[101a] or regulate apoptosis in complex with Dnmt1.[106]  For example, 
retinoblastoma protein (Rb) prevents excessive cell growth by inhibiting cell cycle progression 
until a cell is ready to divide. Interaction of Dnmt1 and Rb results in Dnmt1 inhibition and 
dissociation of Dnmt1-DNA complex.[117] The N-terminal of Dnmt1 binds to a specific pocket in 
Rb protein, and this interaction affects the allosteric regulation of Dnmt1.[87b] Another important 
interaction with the N-terminal of Dnmt1 is with p53, a tumor suppressor protein, which is 
important for DNA repair and apoptosis. Dnmt1 interaction with p53 affects the expression of 
the surviving gene, an inhibitor of apoptosis.[118] Also, Dnmt1 interaction with p53 might be 
involved in downregulation of protein phosphatases that regulate cell cycle.[119]   
Interaction with RNA polymerase  
Lastly, Dnmt1 interactions with RNA and there is evidence that RNA molecules are involved in 
control of DNA methylation in mammalian cells.[120] Several studies demonstrate the interaction 
of Dnmt1 and RNA Pol II; and RNA Pol II is involved in synthesis of non-coding miRNA.[121]  
There is support for the interaction of Dnmt3 with non-coding micro RNAs.[122] Some other 
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secondary interactions with Dnmt1 exist such as interaction with methyl-CpG-binding domain 
(MBD) family of proteins, which then bind several types of RNA molecules.[123]  One notable 
example is Dnmt1 interaction with MeCP2, which is functionally important in neuronal 
development[33a], as we discussed under Rett’s syndrome. Despite the number studies done, the 
interaction of Dnmt1 and RNAs remains the least understood, but there is a strong regulatory 
connection between RNA molecules and the allosteric site on Dnmt1. 
1.8 Regulation	  of	  Dnmt1	  
 
In the previous section we discussed various significant regulatory interactions of the N-terminal 
of Dnmt1 with a host of key proteins and complexes. We will discuss other specific examples of 
the N-terminal regulatory mechanism of mDnmt1, particularly the self-regulatory N-terminal of 
Dnmt1and other interactions with BRCA, SET7 and then pharmacological inhibitors of Dnmt1.  
Takeshita and colleagues solved the crystal structure of large fragment of Dnmt1 lacking only 
the first 290 residues of the N-terminal[124], this large structure gave the first insight into the 
molecular mechanism of Dnmt1 N-terminal regulation by the TS domain. In this structure, the 
TS domain (Figure 1.12) is found deeply buried inside the catalytic domain, where it forms 
several hydrogen bonds, which is thought to prevent Dnmt1 from binding the hemimethylated 
DNA substrate.[124] This arrangement of domain would imply that activation of Dnmt1 requires 
several conformational changes or actual displacement of TS from the catalytic pocket to allow 
substrate binding. As a consequence, O’Gara, Syeda and colleagues have shown that deletion of 
TS lowers the activation energy, thereby increasing methylation[125], and addition of purified TS 
domains inhibits Dnmt1 activity in vitro.[126]   These findings clearly support the model of a self-
regulatory N-terminal of Dnmt1, and corroborate the autoinhibitory function of TS domain 
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described by Takeshita et al.[124]  In addition, the crystal structure obtained by Song et al. show 
that the CXXC motif is in a position where the DNA binds (Figure 1.5)[84] , which is also an 
auto-regulatory device that prevents binding of nonmethylated DNA to the catalytic pocket. In 
summary, from the mDnmt1 crystal structures obtained by Song and Takeshita, there is a strong 
indication that multiple structural changes occur, especially, in the N-terminal and probably 
modest structural changes in the C- terminal before faithful DNA methylation is achieved. Thus, 
Dnmt1 has a self-regulatory mechanism located in the N-terminal that controls catalytic activity 
of the C-terminal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Ribbon model ofmouse Dnmt1(291–1620). Around the C-terminal catalytic domain 
(blue), the other domains including the RFTS (magenta), CXXC motif (cyan), and two BAH 
domains BAH1 (green) and BAH2 (orange) are shown. Four zinc ions are shown in red spheres. All 
of the zinc ions are in a motif similar to Zn-finger motif (Fig. S10). The KG-repeat (1112–1124) 
linker connecting the N-terminal region and the C-terminal catalytic domain is in a flexible 
structure as the density map showed disorder.[124]  Permission requested  
 
In addition to the auto-regulatory action of Dnmt1, there is evidence that reveals an important 
role BRCA1 plays in DNA methylation[116], as well as many other biological processes including 
cell cycle regulation, DNA damage repair, transcription regulation, and centrosome duplication. 
Shukla and colleagues discovered that the gene Dnmt1 is a transcriptional target of BRCA1.[116]  
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BRCA1 and OCT1 (another transcriptional factor) bind to the promoter region of Dnmt1 through 
a potential OCT1-binding site, AACGTTAA, which is found to be essential for maintaining a 
transcriptional active configuration of the promoter region in both mouse and human cells. Also, 
there is a positive correlation in the levels of global DNA methylation and expression levels of 
BRCA1 in human clinical samples (Figure 1.13)[116]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Expression of Dnmt1 and BRCA1 in human primary breast cancers. (A) BRCA1 and 
Dnmt1 protein levels in 31 human sporadic breast cancers. Immunohistochemical staining of 
BRCA1 and Dnmt1 protein levels were detected by using antibodies against BRCA1 and Dnmt1. 
Intensity of the staining was scored by division into 10 arbitrary units based on the graded 
intensities. The x axis and y axis are for Dnmt1 and BRCA1 levels, respectively. (B) Examples of 
immunohistochemical staining showing positive correlation between expression levels of BRCA1 
and Dnmt1 in human breast cancers. (C) Immuno-fluorescent images of varying methylation levels 
after 5-methyl cytosine staining, which was also proportional to levels 
of BRCA1 staining in all analyzed samples.[116] Permission requested 
Shukla further demonstrated that reduced function of BRCA1 leads to global DNA 
hypomethylation, loss of genomic imprinting, and an open chromatin configuration as observed 
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in many mutant mouse models. Their results indicate that BRCA1 is a positive regulator of 
Dnmt1 transcription through prevention of global hypomethylation – a hallmark of many 
cancers. Likewise, it supports the observation noticed in BRCA1 deficient cells, which show dire 
effects on cell viability and genomic stability, similar to effects noticed in Dnmt1 deficient 
cells[127]. Therefore, the outcome of the results of Shulka et al. further straightens the argument 
for a strong correlation between BRCA1 and Dnmt1 expression. 
Equally considered, apart from basic interactions of Dnmt1 with proteins and other complexes 
are certain regulators that covalently modify Dnmt1. Two good examples of such modifications 
are phosphorylation and methylation.[100-101] So far, we briefly looked at phosphorylation of 
Ser515[100] at the beginning of this chapter, however, the protein kinases responsible for the 
phosphorylation of Dnmt1 were not discussed. We will look at the kinases elucidated recently by 
Sugiyama and colleagues.[101a] In brief, using monoclonal antibodies, multi-PK antibodies, 
Sugiyama identified CDKL5 (cyclin-dependent kinase-like 5) as the kinase protein responsible 
for phosphorylation of Dnmt1. But, the phosphorylation action of CDKL5 is weak and the 
importance of this phosphorylation remained uncertain, which then prompted the search for 
another kinase, CK1δ/ε (casein kinase 1 δ/ε) with stronger phosphorylation activity.  Their 
results show that the casein kinase binds to and phosphorylates Dnmt1 at the N-terminal much 
more significantly than CDK15. Also, they identified the major phosphorylation site in the N-
terminal to be Ser 146. In addition, DNA-binding affinity of the N-terminal of Dnmt1 was 
greatly reduced by phosphorylation with CK1δ. In summary, the results from Sugiyama indicate 
that CK1 δ/ε bind to and phosphorylates the N-terminal of Dnmt1, thereby regulating the 
functions of Dnmt1 through a reduction of DNA-binding activity. 
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Interestingly, Dnmt1 is also suffers methylation from other methyl transferase enzymes. A 
histone methyltransferase enzyme SET7 is known to colocalize and directly interact with Dnmt1, 
and it is responsible for the monomethylation of Lys 142[128] on the N-terminal of Dnmt1. In 
support of this modification is the fact that over expression of SET7 led to reduced levels of 
Dnmt1 and siRNA-mediated knockdown of SET7 stabilized Dnmt1.[128] The consequence of 
methylation of Dnmt1 at Lys142 during S and G2 phases of the cell cycle is its susceptibility to 
proteasome-mediated degradation, as notice by Esteve et al.[128] Implying, there is a robust 
interaction between SET7 and Dnmt1, and that Dnmt1 stability is regulated by protein 
methylation couple to proteasome-mediated protein degradation. Although, more work still has 
to be done in vivo to confirm this association between Dnmt1 and SET7, it is evident that 
covalent modification such as methylation of Dnmt1 can affect its reactivity towards DNA –
binding. 
Dnmt1 is also inhibited by poly(ADP-ribose) and Poly(ADP-ribose) polymerase 1 (PARP1).[129]  
Though the mechanism of inhibition is not known, Dnmt1 is said to belongs to a class of proteins 
able to bind, in a noncovalent manner, long and branched ADP-ribose polymers. ADP-ribose 
polymer, either free or PARP1-bound are able to inhibit Dnmt1. The current study by Caiafa et 
al.[129a] show that poly(ADP-ribosyl)ated PARP1 and Dnmt1 form complexes in vivo which are 
catalytically inept in DNA methylation. Likewise, Dnmt1 can also be inhibited by 
poly(dA).poly(dT) and poly(dA-dT), but not by poly(A) or poly(dA)[130]. It seems that most of 
the inhibitory action of these polymers is competitive, since they bind to the enzyme which 
precludes the binding of DNA.[129a] 
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1.9	  Small	  Molecules	  
 
Given the importance of Dnmt1 in various diseases including cancer, a number of other 
inhibitors have been designed and currently being optimized to take advantage of the mechanism 
of methylation and the conserved residues in the catalytic pocket of Dnmt1. Cytosine analogues 
are the best known active inhibitors based on the mechanism of Dnmt1 methylation.[131] They 
include classical nucleoside inhibitors such as 5-azacytidine (AzaC)[132], 5-fluorocytosine, 
(FdC)[133], and zebularine[134] that show antiproliferative activity against cancer cells. These 
inhibitors cannot inhibit Dnmt1 directly, but have to be incorporated into the DNA, where they 
covalently trap Dnmt1 in the process of DNA methylation.[134] They are referred to as “suicide 
inhibitors” and their use is associated with excessive DNA damage and a high level of toxicity, 
which in turn limits their dosage to low concentrations during cancer therapy.[88e] However, there 
are continuing efforts to the improve pharmacology of cytosine analogues because of their 
features as lead compounds; particularly there are efforts to prevent the toxic incorporation into 
genomic DNA, but to still maintain the valuable suicide inhibitory property. 
The other main class of inhibitors are non-nucleoside covalent or non-covalent inhibitors, which 
include natural products such as the dietary polyphenols like (–)-epigallocatechin-3-gallate 
(EGCG)[135], curcumin [136], parthenolide[137], and mahanine[138]. Also, included in this class are 
small molecules and amino acid derivatives, for example the bisulfide bromotyrosine derivative 
psammaplins[139], L-tryptophan derivative RG108[140], hydralazine[141], and the 4-aminobenzoic 
acid derivatives procaine and procainamide.[142] The last members of this class are novel 
inhibitors identified from virtual screening (Figure 1.14); they include compounds from various 
databases that are virtually screened against the crystal structure of Dnmt1. We will revisit this 
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class of compounds in chapter two and discussed in detail the principle behind computational 
identification of lead compounds in drug discovery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: Compounds tested for inhibitory activity against Dnmt1 A. Promising nucleoside and 
approved drugs in clinical trials as Dnmt1 inhibitors B. Known natural product with great activity 
against various cancers C. New class of molecules from computation studies 
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Table 1.2 Summary of Available IC50 and Ki values of Known Dnmt1 Inhibitors and how these 
compounds affect M.SssI and MCF-7 Cells. 
 
Dnmt	  Inhibitors	   M.SssI	  
Dnmt1	  from	  
M.SssI	   	  MCF-­‐7	  
	  	  
Ki/	  
µM	  
IC50/	  
µM	   Ki/	  µM	  
IC50/	  
µM	  
Ki/	  
µM	  
IC50/	  
µM	  
Kazinol	  Q[143]	   	  -­‐	   -­‐	   -­‐	   7.0	   -­‐	  	   2.0	  
EGCG[143]	   	  -­‐	   -­‐	  	   	  -­‐	   3.0	   6.89	   2.0	  
	  EGCG[135]	   	  -­‐	   	  -­‐	   -­‐	  	   20.0	   	  -­‐	   -­‐	  	  
Clofarabin[144]	   -­‐	  	   	  -­‐	   	  -­‐	   -­‐	  	   	  -­‐	   640	  nM	  
5-­‐aza-­‐2ʹ′-­‐deoxycytidine[145]	   	  -­‐	   	  -­‐	   -­‐	  	   -­‐	  	   -­‐	  	   0.6	  
Fludarabine[145]	   -­‐	  	   	  -­‐	   -­‐	  	   -­‐	  	   	  -­‐	   15	  
2-­‐Chloro-­‐2ʹ′-­‐deoxyadenosine[145]	   -­‐	  	   	  -­‐	   -­‐	  	   -­‐	  	   -­‐	  	   0.2	  
Psammaplins	  A[139]	   	  -­‐	   -­‐	  	   -­‐	  	   18.6nM	   -­‐	  	   	  -­‐	  
Aurintricarboxylic	  acid[146]	   	  -­‐	   -­‐	  	   	  -­‐	   0.68	   -­‐	  	   	  -­‐	  
RG108[140a]	   -­‐	  	   -­‐	  	   	  -­‐	   115nM	   -­‐	  	   	  -­‐	  
Trimethylaurintricarboxylic	  acid	  (NSC97317)[146]	  	   -­‐	  	   -­‐	  	   	  -­‐	   4.79	   -­‐	  	   -­‐	  	  
5-­‐aza-­‐2ʹ′-­‐deoxycytidine[145]	   -­‐	  	   	  -­‐	   	  -­‐	   	  -­‐	   	  	   4.0	  
9-­‐beta-­‐D-­‐arabinofuanosyl-­‐2-­‐fluoroadenine	  
(Fludarabine)[145]	   -­‐	   	  -­‐	   -­‐	  	   	  -­‐	   	  -­‐	   4.0	  
Procainamide[147]	   -­‐	  	   5.0	   -­‐	  	   3.5	   -­‐	  	   	  	  
Curcumin[136,	  148]	   	  -­‐	   30nM	   	  -­‐	   	  -­‐	   -­‐	  	   <10.0	  
SGI-­‐1027[149]	   	  -­‐	   	  -­‐	   -­‐	  	   	  6-­‐12.5	  	   -­‐	  	   -­‐	  	  
methylenedisalicylic	  acid[146]	   	  -­‐	   	  -­‐	   	  -­‐	   92	   	  -­‐	   -­‐	  	  
Parthenolide[150]	   	  -­‐	   5.0	   -­‐	  	   3.5	   -­‐	  	   	  -­‐	  
	  Δ2-­‐isoxazoline[151]	   -­‐	  	   	  -­‐	   	  -­‐	   150	   	  -­‐	   	  -­‐	  
Antroquinonol	  D[152]	   	  -­‐	   -­‐	  	   	  -­‐	   5.0	   -­‐	  	   	  -­‐	  
Procainamide[147]	   	  -­‐	   -­‐	  	   7.2±0.6	   	  -­‐	   	  -­‐	   	  -­‐	  
 
 
 
 
1.10 	  Breast	  and	  	  Colon	  	  Cancer	  and	  DNA	  Methylation	  	  	  	  	  	  	  
 For this project we will narrow our focus to design and testing of Dnmt1 inhibitor in two cancer 
types: colorectal and breast cancer. Our discussion will be centered on key genes that are 
hypermethylated in both cancers and then center more on preliminary results involving breast 
cancer. 
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Breast Cancer  
Breast cancer is a common type of cancer occurring in both sexes, but it is a more common 
malignancy in women and it is greatly influenced by hormonal factors.[153]  So far, DNA 
methylation has been implicated in breast cancer progression as well as in a number other 
cancers including colorectal cancer.  Some important genes inactivated in breast cancer by 
aberrant DNA methylation are summarized in Table 1.3. For example, estrogen receptor (ER)-
negative breast cancer cells show widespread methylation and elevated DNA methyltransferase 
expression compared with (ER)-positive cells, indicating the importance of the hormonal factor 
but implicating Dnmt enzymes in breast cancers.[154]  Ottavia and colleagues found that the ER 
gene CpG island undergoes aberrant methylation, as noticed in established ER-negative breast 
cancer cell lines and primary tumors.[153] Also, an elaborate study by Parl et al. showed that the 
ER gene was unmethylated at the NotI site CpG island in all normal tissues such as thyroid, 
whole lung, bronchial epithelium, and cervix but are highly methylated and   showed a unique 
pattern in ER-negative cell lines and MCF-7/AdrR.  In addition, treatment of the ER-negative 
cell line MDA-MD231 with DNA methylation inhibitors led to demethylation of the ER CpG 
island and partial restoration of gene expression of the estrogen receptor[155]. Furthermore, 
detailed studies showed that expression of Dnmt1 at both RNA and protein level was high in ER-
negative breast cancer cell lines (BCC) compared with ER-positive. However, while Dnmt1 
expression was highly correlated with S-phase in ER-positive cells, ER-negative cells expressed 
Dnmt1 throughout the cell cycle; suggesting a dysregulation of Dnmt1 in ER-negative BCC.[154]  
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Table 1.3 Frequency of methylation of representative tumor suppressor and growth regulatory 
gene in breast cancer 
Gene Function Incidence (%) Reference 
    
P16INK4a Cyclin-dependent 
Kinase 
15 Herman et al. (1995) 
14-3-3σ G2 checkpoint 91 Ferguson et al. (2000) 
ERα Steroid receptor 50 Ottavaino et al (1994) 
PR  Steroid receptor  40  Lapidus et al. (1996) 
RARβ2 Steroid receptor 25  Sirchia et al. (2000) 
 
BRCA1 DNA damage repair 15 Dobrovic & 
Simfendorfer (1997) 
GSTP1 Carcinogen 
detoxification  
30 Esteller et al. (1998) 
E-cadherin Epithelial cell-cell 
adhesion 
50 Graff et al. (1995) 
TIMP-3  Inhibition of MMPs 25  Bachman et al. (199) 
    
Permission requested  
Moving down the list in Table 1.3, we come across GSPT1, another important gene in BCC, 
which, however, shows an inverse relationship with ER. This is because glutathione (GSH) and 
other cytosolic GSTs are involved in detoxification of xenobiotic and chemotherapeutic 
agents[156] , basically, they catalyze intracellular detoxification reactions by conjugating 
chemically reactive electrophiles to GISH, and thus inactivating the electrophilic carcinogen.[157]  
Experiments showed that GSTP1 was expressed in ER-negative but not in ER-positive lines.[158] 
GSPT1–negative cell line MCF-7 treated with 5-aza-dC could induce mRNA expression and de 
novo synthesis of π – class GSP. Also, Esteller et al., demonstrated that GSTP1 promoter 
methylation is associated with gene silencing in ~ 30% of primary breast carcinomas.[49a]  Lastly, 
Cavalieri and colleagues proposed that methylation-assoaciated inactivation of GSTP1 can result 
in A or G base mutation by estrogen metabolites-DNA adduct formation that results in genetic 
instability.[159]  
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From Table 1.3, the BRCA1 gene is a well-known breast cancer susceptibility gene and inherited 
mutations in this gene account for one-half of inherited carcinomas.[160]  Methylation of BRCA1 
has been proposed to silence the gene and cause reduced expression of BRCA1 protein in 
sporadic breast cancer.[161] A study with 194 primary breast carcinomas showed that the BRCA1 
promoter is methylated in 13% of unselected primary breast tumors[50] and as expected the 
BRCA1 of normal cells remain unmethylated. So far, BRCA1 hypermethylation has been 
detected exclusively in sporadic breast and ovarian cancers but not in tumors or colon or liver or 
leukemia; however there are isolated sporadic lung cancer cases.[41] 
An equally notable gene like BRCA1 is TIMP-3, which codes for a family of molecules that 
inhibit the proteolytic activity of matrix metalloproteins (MMPs).[162]  These proteins can 
suppress primary tumor growth by effects on tumor development, angiogenesis, invasion and 
metastasis.[163]  Bechman et al., showed methylation of the promoter region of TIMP-3 in ~ 30% 
of human BCC lines and also in ~ 30% of primary breast tumors.[39, 163]  Lastly, the loss of 
expression of TIMP-3 was restored by treating affected cells with 5-aza-dC, demonstrating the 
tight correlation between epigenetic gene silencing and cancer. 
Colorectal Cancer 
Normally, colorectal cancer (CRC) develops through a multistage process as a result of the 
continuous accumulation of mutations and frequently in the Wnt pathway – a signal transduction 
pathway that pass signals from outside a cell to inside the cell. Recent studies are mounting 
evidence of the involvement of epigenetic alterations of the chromatin structure in CRC 
development; particularly, modifications that lead to tumor suppressor gene silencing and 
activation of oncogenes.[164] CRCs can be grouped according to genomic instability; for example, 
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one group is chromosomal instability (CIN) which is characterized by aneuploidy and 
chromosomal gains and loss; while microsatellite instable (MSI) is another and its  identified by 
frequent insertion  and deletion mutations in the repetitive DNA sequence.[165] Polyp progression 
starts initially with  a mutation or inactivation of  the adonomatous polyposis coli, APC,  gene 
that results in activation of Wnt pathway, which leads to the progression of polyps to cancer by 
further mutations in other genes like KRAS and TP53[166] which unfortunately grapples apoptosis 
in the presence of DNA damage. However, apart from mutations, epigenetic modifications like 
DNA methylation and histone modification play key role in CRC. For example,  methylation in 
the promoter region of mismatch repair gene like MLH1 has been shown to be associated with 
MSI – high sporadic CRC[167] and DNA methylation-related deficiencies in the mismatch repair 
system can lead  to  mutation rates that are 100-fold greater than normal cells. Also, defects in 
mismatch repair system can lead to germ line mutations in human’s genes such as MHL1 and 
MSH2  and sometimes, MSH6, PMS1 and PMS2 as noticed in hereditary nonpolypsis colorectal 
cancer (HNPCC), which ensures an increase rate of progression in adenomatous polyps.[168]  
As a corollary, a distinct group of CRC called CpG island “methylator” phenotype (CIMP) has 
been introduced to differentiate it from “mutator” phenotype that was known before.[169]  The 
most commonly used gene markers for this subgroup include MLH1, p16, MINT1, MINT2, 
MINT31 CACNA1G, CRABP1, IGF2, NEUROG1, RUNX3, SOCS1, HIC1, IGFBP3, or WRN, 
with no consensus on how many  genes are required to be defined as CIMP positive.[170]  
However, CRC group can be classified as CIMP-high, CIMP-low and non-CIMP depending on 
the cancer-specific hypermethylation involved and the mutation rate of certain genes.[171] 
In summary, from various studies involving CRCs, it is obvious that CRC-specific 
hypermethylation affects a number of genes and pathways including TP53, P13K, WNT, IGF 
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signaling DNA repair/stability, apoptosis, angiogenesis, invasion and metastasis.[170a, 172] 
Similarly, DNA methylation-mediated gene silencing, also targets and affects many of the 
signaling pathways involved in CRC just as genetic mutation. Thus, the biomarkers can be used 
to develop test for CRC diagnosis and epigenetic drugs for CRC therapy. 
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CHAPTER	  2	  
DRUG	  DISCOVERY	  AND	  DESIGN	  OF	  Dnmt1	  INHIBITORS	  
 
2.0	  	   Introduction	  
 
Modern drug discovery, especially at the early stage, involves finding new compounds for 
identified biological targets such as enzymes, receptors, ion channels, transporters and DNA 
targets.[173] Usually, the target is druggable – that is, the target can potentially bind with high 
affinity to the drug and elicit therapeutic response both in vitro and in vivo – and can pass a 
target validation screen, which implies the target is involved in the disease and can be acted upon 
by the drug. Target validation can be done in vitro such as finding drugs that modulate the target 
via enzyme-based assay or by using model interactions – that is using computational methods. 
Also, in vivo validation methods such as animal model testing and gene knockout methods.[174]  
Usually, a multi-validation approach increases the confidence in the observed outcome for 
validating a target. Following the target validation, the search for ‘hit’ molecules and the process 
of drug design begins. A hit molecule has been defined as a molecule that shows desired activity 
during screening and the activity is reproducible upon retesting.[175] A number of screening 
methods are used to identify hit molecules during drug discovery and we shall discuss a few of 
them.  High throughput screening (HTS) is one method of hit identification which involves 
screening an entire diverse library of compounds directly, typically by cell-based assay, against a 
drug target. Usually, the conventional 96-well plates are replaced with 384-well microplates[176], 
novel fluorescence-based detection system are used[176] and screening robots used are fully 
adapted to desktop environment.[177] The HTS method is made possible by the use of laboratory 
automation and robot technology to screen hundreds of thousands of compounds to discover a 
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small group of hits that will be later confirmed with a secondary assay for further development 
into leads.[178] On the other hand, focused or knowledge based screen involves testing a small 
class of compounds that are known to hit specific class of targets (e.g. kinases) and compounds 
with similar structure.  The focus based approach is based on knowledge of protein target and 
literature studies that point to a chemical class of compounds likely to have chemical activity for 
the target protein.[179] There are other methods such as fragment screen[180], physiological screens 
and NMR screens[181] which are equally important in drug discovery.  As a complement to 
functional screening we have virtual screening, which are current rational drug design methods 
used in drug discovery and for the identification of Dnmt1 inhibitors. In general, rational drug 
design has been greatly accelerated by advances in genomics and proteomics[182] and 
bioinformatics[183], which in turn has made the isolation of targets and determination of  X-ray 
crystal structures possible. Also of great importance in rational drug design is the advancement 
in cheminformatics, computing power and molecular modeling[184], which couple nicely to the 
structural data of the crystal structure and are immensely useful in drug discovery. 
2.1	  Structure	  Aided	  Drug	  design	  (SADD)	  
 
 Structure aided drug design or structure-based drug design is an alternative to high throughput 
screening (HTS), and by contrast it is a knowledge-driven approach compared to HTS, which is 
a trial and error (experimental) based approach. The quality and amount of information regarding 
the target receptor and ligand is critical to SADD as well as in other computer-assisted drug 
design methods.[185] Structural information of the drug target can be resolved by X-ray 
crystallography or obtained from NMR spectroscopy. Also, homology model generated 
structures can be deduced from relevant structural data of target receptor family member(s), 
however, it is important that homology models are validated before use to reduce false positives 
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during screening for hits and lead optimization. SADD works best when the crystal structural 
data of the target receptor, and preferably to which the ligand is bound, is available. Such data 
would provide a starting point for structure activity relationship (SAR) since it gives insight into 
the geometric fit of the active ligand inside receptor and maybe information of a bound cofactor 
if present. Other important information from structure of the receptor include low-energy ligand 
conformation, molecular electrostatic potential[186], types of hydrogen donor or acceptors, 
functional groups and hydrophobic interactions between lipophilic groups.[187]  During drug 
design, the structural information gleaned from the ligand bound conformation can help guide 
rational subtle functional group alterations of new ligands either by visualization or the use of 
molecular modeling software. A good example is the rational design based substantially on 
molecular visualization and modeling is the identification of potent, bio-available, nonpeptide 
cyclic ureas as HIV protease inhibitor.[188]  The success of the design was a single act of 
replacing and mimicking a structural water molecule by adding to the ligand carbonyl oxygen 
that mimics the hydrogen-bonding feature of the structural water, which was first hypothesized 
by careful molecular visualization. In generally, computer-aided drug design methods are used to 
model ligands in silico inside the active site of a receptor in order to achieve best theoretical fit 
between the defined binding sites on the ligand and the complementary molecular space in the 
target. More often than not, the original structural data of the ligand is removed from the binding 
site of the receptor and new molecular structures are computationally docked into the binding 
site.  A typical in silico drug design process involves iterative cycles of docking, scoring and 
ranking based on how well the ligand docks with the active site in terms of alignment, hydrogen 
bonding, van der Waals forces, and electrostatics and hydrophobic interactions[189] (Figure 2.1).  
Docking entails conformational and orientational sampling of the ligand within the constraints of 
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the receptor site. The scoring function for virtual screening selects the best pose such as ligand, 
orientation and translation for a given molecule and then ranks each ligand from top to 
bottom.[190] Notably, ranking involves a complex calculation that attempts to estimate the energy 
of the binding affinities (non-covalent interaction) of ligands to receptors. The estimated energies 
thus give an approximate representation of the underlying biochemical and biophysical 
phenomena, which is by no means perfect. So far, there are three main classes of scoring 
function which include force field-based, empirical or knowledge-based scoring function.[191] 
 
 
 
 
 
Figure  2.1: Modelling molecular recognition. a | Structure of p38 mitogen-activated protein kinase 
with bound inhibitor BIRB796 (PDB code: 1KV2). The inhibitor is shown with its electrostatic 
potential surface. b | Enlarged view of the active site. c | Closeup view of the interaction between 
residue Glu71 and BIRB796. Hydrogen bonding (H-bond) and van der Waals interactions are colour-
coded red and green, respectively. d | Schematic representation of functions used to model pair-wise 
interactions that contribute to binding. Interactions are calculated as a function of the distance (rij) 
between two atoms i and j. Left of part d: van der Waals interaction given by a 12–6 Lennard–Jones 
potential (note the smoother attractive part of the potential compared to hydrogen bond term). Middle 
of part d: hydrogen-bond potential given by a ‘harder’ 12–10 Lennard–Jones potential (see also BOX 
2). This term is angle-dependent (as indicated in c). Right of part d: electrostatic potential for two like 
(blue) or opposite (black) charges of same magnitude calculated using a distance-dependent dielectric 
constant of 4r. Permission requested   
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Theory of docking 
 
The free energy of binding for the complex (Dnmt1-RG108) above is related to the binding 
The free energy of bind (ΔG) is related to binding affinity by equation 2 and 3: 
 
Docking must predict accurately two things relative to experimentally available data: the pose of 
the ligand structure and the binding affinity. Prediction of the correct structure (posing) of the 
[E+I] complex does not require information about KA. However, prediction of biological activity 
(ranking) requires this information. Thus the scoring terms can also be divided in two: one that 
considers the term [EI], which takes certain factors into consideration such as steric, electrostatic 
hydrogen bonding, inhibitor strain (if flexible) and enzyme strain. The factors are considered as 
part of the contributing factors to a change in free energy that occurs during docking; this is 
because the scoring function predicts the ligand affinities by a free energy perturbation (FEB) 
method.[192] In the FEB method, the free energy change is calculated by changing one system 
into another (from the unbound state transition to a bound state) via a set of unphysical mixed 
Where: 
G is the Gibbs free energy        [E] is the concentration free enzyme 
R is the gas constant  [I] is the concentration of free ligand 
KA is the equilibrium constant of association  [EI] is the concentration of the complex 
[EI]aq[E]aq [I]aq       
ΔG = -RTlnKA KA = Ki-1 = 
[!"]
[!][!]   (2,3) 
The aim of docking is to correctly predict the structure of the protein-ligand complex [E + I] = [EI] 
under equilibrium conditions. For example, if sinefungin is docked in Dnmt1 (PDB: 3WSR) then: 
  [E]aq + [I]aq   [EI]aq   (1)  
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states using molecular dynamics (MD) or Monte Carlo simulations.  Unfortunately, the results do 
not cover all the changes that occur during docking and virtual screening and thus it gives 
relative binding affinities for similar drugs docked in the same protein.[192-193]  Undoubtedly, 
scoring functions for ligand affinities still remains a challenge for docking and drug design. On 
the other hand, from the equation 1 the scoring function of the ligand poses inside the target at 
equilibrium do not require knowledge of KA, however, a different set of  factors become 
important such as desolvation (posing is in water), rotational entropy and translational entropy 
(degrees of freedom of the ligand) and the calculation is not as complex.[192]  It is obvious that 
the final equation for the scoring functions would be a lot more complex than equation 2, 
however, we will not dwell much on it but a number of reviews are available[192, 194] for more in 
depth discussions.  
One alternative approach that complements structure-based drug design is ligand-based drug 
design (LBDD) (Figure 2.2); the method uses the information present in known active ligand for 
lead identification and optimization. Normally, LBDD is computation based and requires 
structural information of both the ligand and the target receptor, however, it can be used even 
when the three-dimensional (3-D) protein structure of the target receptor is not available, 
typically as in the case of most G-protein-coupled receptors (GPCRs) targets[195] or protein 
structure resolve in an apo form[196], that is a protein that is not ligand bound. In the presence of 
structural data of the ligand and maybe the target receptor, similar computational techniques such 
as virtual screening and molecular modeling can be applied in LBDD. By using the molecular 
fingerprint of known ligands, databases can be screened to find molecules with similar 
fingerprints.[197]   The docking processes for LBDD  can generally be divided into three classes 
(Figure 2.2): (i) quantitative structure activity relationship (QSAR) which is a method that 
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relates chemical structure to biological or chemical activity using mathematical models.[198] The 
quantitative part of QSAR is described by a set of properties, usually known as descriptors, 
which is computed from the structure and in turn used to describe the structure. In addition, by 
using structural descriptors as independent variables and activity as dependable variable, a model 
can be built to describe the relationship between the two.[199] Once the QSAR model is built and 
validated, then it can be used to screen the biological activity of novel molecules from their 
structural properties. Development of anti-allergic pyranen-amines by Cramer at Smith Kline and 
French Laboratories is one of the finest applications of QSAR methodology.[200] Also, in the area 
of cancer research QSAR has been used to develop a number of antitumor agents and inhibitors 
of cancer related enzymes[201]  (ii) pharmcophore models try to describe the interaction between 
the active site of the target receptor and a ligand. It involves taking the essential features 
responsible for a drug’s biological activity[202] and modeling them. Usually, types, position and 
direction of the active ligand are encoded into the pharmacophore model, along with possible 
steric constraints of the active compound.[203] The pharmacophore model has been applied to a 
number of drug design process, even as filters to reduce false positives during preprocessing of 
compounds before virtual screening; and for output processing after virtual screening 
protocols.[204] Lastly, pharmacophore model in addition with QSAR has been used to design a 
series of novel benzimidazole and imidazole inhibitors of histone deacetylase 2.[205]  (iii)  
Similarity searching method operates on the principle that structurally related molecules are 
likely to have similar properties.[206] In addition, similarity search can be based on other features 
such as physiochemical properties as well as two and three-dimensional [207] features selected 
from QSAR or pharmacophore model. The chemical fingerprints is appropriate if only 
compounds structurally similar to the active compounds are desired, but if new scaffold/chemical 
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structure [208] are desired then physiochemical properties may be useful, One other usefulness of 
similarity search is when the number of ligands for which biological activity is known are too 
few to build a QSAR mode, then similarity search is applied.  
 
 
 
 
 
 
 
 
 
 
 
 
Virtual Screening 
Drug discovery employs LBDD and SBDD approaches and both methods use virtual screening 
(VS) as a tool to search and optimize hits to potential leads; this makes VS an important 
Figure 2.2: Classification of various methods of Ligand based virtual 
screening 
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component in modern drug design and warrants further discussion. In general, the use of 
computer-assisted technique(s) to search through a large database of compounds for new 
biological active molecules is described as virtual screening.[206] The screening process is aimed 
at enriching a small subset of active compounds of pharmaceutical importance that can be 
developed into drug candidates.  
 
 
 
 
 
 
 
 
 
 
 
 
VS enrichment process in a way to complements HTS (Figure 2.3), and in some cases, serves as 
a good alternative to HTS, especially, when adequate knowledge of the three-dimensional 
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Figure 2.3:  Drug discovery and rational drug design 
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structure of the target receptor and small molecule binding modes are known. Given the 
structural data of receptor and ligand either ligand-based or structured-based virtual screening 
methods can be used to obtain potential hits using rapid docking algorithms to place available 
compounds into the active site of the receptor (as in the case of SBVS) or model the available 
compounds onto the  active ligand template ( as in the case of LBVS). For our discussion we are 
interested in VS, challenges, methodologies and the docking programs used in structure-based 
virtual screening. So far, only SBVS has been used for identification of Dnmt1 inhibitors, 
however, we believe that LBVS can also be utilized but we will save the proposal for future 
discussion. 
 
2.2	  Structure-­‐based	  virtual	  screening	  
 
Challenges 
Structure-based virtual screening plays an important role in hit identification and lead 
optimization both in industry and academia. Over the years so many docking algorithms and 
scoring functions have been developed and refined to mimic true solution binding affinities of 
ligands to proteins, however, there are still some challenges. We shall highlight a couple of them 
in this section. Since docking and scoring functions are mathematic approximations of physical 
ligand-protein interactions, it is crucial that certain factors and conditions be considered before 
and during docking in order to obtain accurate results. One of such condition is the quality of the 
crystal structure used for virtual screening. Ideally, the receptor target for SBVS is an enzyme for 
which the crystal structure has been solve to a resolution of at most 2.5Å (preferably: placement 
of residues in the electron density map should be unambiguous) and the active site has been 
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characterized with a variety of probable hydrogen bond donors and acceptors, hydrophobic 
interactions, defined interstitial and structure water molecules (ordered water), and with 
molecular adherence surfaces.[208b] Although, this is not always the case with most receptors, in 
any case, a high quality receptor structure is fundamental to the success of SBVS in lead 
discovery.  Also, apart from using a structure with high resolution, the algorithm of the docking 
programs should allow for receptor flexibility, which is one factor that was lacking previously in 
many docking programs until recently.[209] Most docking programs rely on the Lock-and-Key 
hypothesis for protein ligand binding instead of the induced fit model, however, it is now widely 
accepted that ligands and proteins are quite flexible in solution and may experience different 
assemblage of conformations compared to what is used during rigid in silico screening.[201c, 210] 
In addition to the flexibility of receptor structure, it is the important to consider the effect of 
solvent during docking. Solvent plays a crucial role in docking, for instance ordered water 
molecule can be incorporated into the design of the ligand or treated as a bound ligand to which 
interactions with ligand of interest are probable.[188, 211] The solvent effect can also be 
incorporated into the scoring function approximation for binding affinities, however, most 
docking algorithm make the assumption that the molecules are in a vacuum instead of in a 
solvent. Furthermore, water molecules on the interface of target protein may facilitate increase in 
specificity or binding affinity of ligands[212] and so it is important to that docking programs 
account for both bulk and specific water molecules. There is also the question of specific water 
molecules found it cavity of proteins. Thilagavethi and Mancera showed that inclusion of 
conserved water molecules during ligand-protein cross-docking led to a statistically significant 
improvement in the accuracy of predicted docking poses. The success rate of predicting correct 
pose went from 39% in the absence of water to 69% in presence of conserved water 
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molecules.[213] Also, Sotriffer and colleagues tested the structural prediction ability of two 
docking programs as a function of crystal water (ordered water) in the cavity of cytochrome c 
peroxidase W191G mutant and found very good results.[214] On the other hand, there is also the 
problem of sampling algorithm been, at least potentially, biased towards input ligand 
conformation.[190] Cross and colleagues compared the input conformation of ligands from 
CORINA (structure generation software) with known crystal ligands and, surprisingly, noticed 
that crystal structures, on average, had overall better docking results.[215] Kellenberger also noted 
that the input coordinates of ligands have an impact on docking poses.[216] Also, there is evidence 
that ligand speciation such as protonation, tautomerism and isomerism are important in docking. 
Ten et al. investigated the influence of protonated ligand state on docking and their result showed 
that different protomers and stereoisomers affected the scoring function; more so, docking 
programs are just learning how to deal with speciation  of ligand species.[215] The above 
discussed challenges are by no means all the problems experienced by current virtual screening 
algorithms and programs but it succinctly describes the present performance state of VS in lead 
discovery and drug design It is also important to remember that structure-based drug design 
methods directs the discovery of drug leads, which are not drug products, but are primarily active 
compounds enough with at least micromolar affinity to a target.[209a] 
Methodology and docking programs 
Despite the challenges facing virtual screening, it is still a widely used tool to screen large 
libraries of compounds for identification of hits in drug design. The primary objective of virtual 
screening is to dock and score large libraries of compounds and rank them into active and 
inactive compounds, and the degree to which active compounds can be ranked ahead of inactive 
compounds is referred to as “enrichment”.[217] The most promising structures retrieved from 
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virtual screening depend on the method of docking and scoring function used. In this section, we 
will focus on the methodologies – preparation steps – docking and docking programs used to 
position ligands inside single receptor structures. In general, the preparation process in docking 
involves ligand and protein preparation, while the docking process involves posing a flexible 
ligand inside a rigid, or a partially flexible, receptor.[191]   
Ligand Preparation 
Ligand preparation starts with the question of which variety of chemical structures should be 
included in the chemical library used to search the chemical space.  Normally, a wide range of 
filters are applied to remove compounds with unfavorable pharmacodynamics or 
pharmacokinectics[218] and to reduce computational demands during the docking step. The initial 
selection criteria for organic molecules are drug-likeness, which implies that compounds are 
considered based on Lipinski’s Rule of Five and the absorption, distribution, metabolism and 
excretion (ADME) restriction.[219] However, the rule does not predict if a compound would be 
active or not. Drug-likeness also includes filtering compounds based structure flexibility, most 
drugs show a balance between flexibility and rigidness. It is important to filter out toxic 
structural features but include important bio-recognizable groups in drug molecules.[220] An 
alternative or complementary filter method to drug-likeness is active-ligand similarity 
method.[221] Based on structural similarity search among small molecules, it is possible to 
retrieve privileged structures[221] containing identical substructures that share close binding 
affinity for the receptor. In addition, a three-dimensional descriptor of the active ligand can be 
included during similarity search.[222] The similarity search approach involves using appropriate 
molecular “fingerinprints” to compute searches; an example of such fingerprint is Tanimoto 
coefficient[223] which has been used to improve the efficiency of similarity searches. 
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Furthermore, Bender and Glen[222a] have classified fingerprints  according to their dimensionality 
ranging from one-dimension to three-dimension; Zhang and Muegge[224] have pointed out that 
two-dimensional fingerprint (most popular fingerprint) are more successful in retrieving active 
compounds. Another equally used similarity search method is the pharmacophore model, that is, 
geometric and topological constraints can applied to the active compound, which can then be 
used as a search or filter criteria to screen for compounds.[225] Given the variability of target 
receptors and ligands in drug discovery filtering criteria varies widely and sometimes it 
depending on the quality and amount of knowledge available of ligand and receptor, but in 
generally, it is advised to start with a vast and structurally diverse library of compounds and then 
follow the funnel strategy[226] to extract or achieve an enrichment of compounds for lead 
development. 
Once a reliable and dedicated filter process is utilized and a diverse library has been selected, 
three-dimensional coordinate structures of all the compounds are generated and prepared in the 
same way as the ligand template to be used for the screening. The ligand preparation process can 
be as simple as adding hydrogen(s), formal charges and number of rotatable bonds or as 
thorough as including ionization/tautomerism[217] protonation, and stereoisomerism to the 
ligands, which can be done using ligand preparative software such as LigPrep.[217, 227]  
Protein Preparation 
X-ray crystallography and NMR structures are obtained from the protein data bank (PDB)[228], 
while homology models are generated using computer programs or devoted web servers such as 
SWISS-MODEL[229] and MODELLER.[230] Wallner and Ellofson have reviewed homology 
modeling programs such as SegMod/ENCAD, 3D-JIGSAW, NEST and builder giving the 
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strength and weakness of each program.[231] Normally, the starting point for protein preparation 
involves downloading and evaluating the receptor structures, usually, with programs such as 
PROCHECK.[232] Equally, homology models can be evaluated by similar software such as 
PROCHECK, but in addition there are a number of servers such as PSVS, Evals123D and JCSG 
Structure Validation Central available for three-dimensional model evaluation.[233] Once the 
receptor structure has been validated, further preparatory steps such as adding of hydrogens, 
checking for correct formal charges and bond orders are carried out. Additional protein 
preparation would depend on the docking software available and methodology; for instance 
Maestro[234] goes ahead and does hydrogen-bond network optimization.  After which a protein 
minimization of the optimized structure is performed followed by the removal of water 
molecules, which is a similar step in the preparation protocol in AUTODOCK.[235] Most 
programs do not yet know how to treat water molecules in the target receptor, however the water 
molecule is removed because it is difficult to computationally determine which water molecule 
to retain; and primarily because the free energy of water molecule is not directly connect to 
crystallographic occupancy.[236] On the other hand, we had discussed earlier of the importance of 
structured water in drug design so; maybe future computation algorithms would be able to tackle 
the structure water problem. 
Docking 
After filtering, selecting and preparing the target receptor and ligand for screening, a docking 
software and method is chosen. Currently, there are several free and commercially available 
docking programs; and the program of choice depend on the receptor target and which programs 
gives dependable results. From various reviews in the literature, the general consensus is that 
they is no universal docking program, the success of each program varies widely with different 
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ligands and receptors types. The strength and weakness of docking programs based on the work 
of Kellenberger et al. [214] is summarized in Table 2.1. In addition, Yuriev and Ramsland review 
on latest developments in molecular docking gives a more detailed and current review of docking 
programs and the novel features of each.[212]  
The screening process involves docking of the prepared ligands into the catalytic site of the 
receptor crystallographic structure. Docking entails using computational programs to predict 
ligand conformation and orientation (or pose) that best matches the receptor’s active site. Most 
docking programs generate several conformations for each ligand based on the number of 
rotatable bonds on the ligand (flexibility) by sampling the degrees of their freedom.[191] Initially 
both the target and the ligand were treated as rigid bodies during generation of poses; this was 
because the imposed rigidity reduces the computation requirement and simplifies the docking 
process. But the rigid treatment approach did not produce accurate results that reflect 
experimental observation. Consequently, most docking programs now treat ligand as flexible 
entities and protein as rigid structures but with some measure of flexibility, especially certain 
residues in the catalytic pocket. The treatment of ligand flexibility and poses can be divided into 
three categories[237]: systematic (incremental construction, conformational search, databases); 
random or stochastic methods (Monte Carlos, genetic algorithms, tabu search); and simulation 
methods (molecular dynamics, energy minimization)  
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Table 2.1:  A list of widely used protein-ligand docking software. The main strengths and 
weaknesses are based on the work by Kellebeger et al., 2004[216][371], and the selection of target 
studied by high-throughput virtual screening is followed favorable experimental testing. GA stands 
for Genetic Algorithm, HF for Hierachial Filtering, IC for Incremental Construction, MA for 
Matching Algorithm and MC for Monte Carlo sampling (Moitessier et al., 2009) 
 
Program  
 and algorithm 
Strengths Weakness Examples of recent successful virtual screening 
experiments 
 
AutodDock 
and AutoDock Vina 
(Morris et al., 1998; 
Osterberg., 2002; 
Trott and Olson, 2010) 
-GA 
 
 
Small ligands 
Large binding sites 
Freely available 
 
 
accuracy in highly 
flexible ligands 
low speed 
 
Glutamate Transporter 1 (GLT1) inhibitors[238]  
  Cdc25 phosphatase inhibitors[239]  
  D-Ala:D-Ala ligase inhibitors[240]  
  Cyclodextrin-based receptors[241]  
DOCK 
(Ewing et al., 2001; 
Kuntz et al., 1982; 
Lang et al., 2009; 
Moustakas et al., 2006; 
Oshiro et al., 1995) 
-IC 
 
 
-FlexX 
(Rarey et al., 1996) 
-IC 
 
Small binding sites 
opened cavities small 
hydrophobic ligands 
freely available 
 
 
 
 
Small binding sites small 
hydrophobic ligands 
 
accuracy in highly 
flexible ligands 
highly polar ligands 
 
 
 
 
 
very flexible ligands 
Hepatitis C virus helicase inhibitors[242]  
S-CoV 3C-like proteinase inhibitors[243]  
Cyclooxygenase (COX-2) inhibitors[244] 
 
 
Bacterial NAD synthetase inhibitors[245]  
Lymphoid phosphatase inhibitors[246]  
RNA polymerase inhibitors[247]  
ATP phosphoribosyltransferase (HisG)  
inhibitors[248]  
Human histamine H4 receptor ligands[249] 
 
Glide 
(Friesher et al., 2004) 
-HF+MC 
 
flexible ligands 
small hydrophobic 
ligands 
 
ranking for very 
polar ligands low 
speed 
 
Liver X receptor modulators[250]  
HIV-1 reverse transcripts inhibitors[251] 
 
 
GOLD 
(Verdonk et al., 2003; 
Verdonk et al., 2005) 
 
-GA 
 
 
small binding sites 
small hydrophobic 
ligands 
buried binding pockets 
 
 
ranking for very 
polar ligands or 
large cavities 
 
HIV-1: CD4-gp 120 binding inhibitors[252]  
Serotonin 5-HT(7) antagonists[253]  
 Non-peptide β-secretase inhibitors[254]  
Sarco/endoplasmic reticulum calcium  
ATPase inhibitors[255]  
Trypanosoma cruzi trans-sialidase inhibitors[256] 
 
 
Surflex 
(Jain, 2003; Jain, 2007) 
- IC+MA 
 
 
large and opened cavities 
small binding sites very 
flexible ligands 
 
 
low speed 
for large ligands 
 
 
Triple helical DNA interacalators[257]  
ErmC methyltransferase inhibitors[258] 
Hepatitis C virus NS5B polymerase  
inhibitors[259] 
 
Systematic method (incremental) 
The incremental construction method involves building the ligand “on-the-fly” within the 
constraints of the binding site, while at the same time exploring the ligand flexibility. The 
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approach is accomplished in a number of ways: (i) E-Novo protocol (or de Novo Design)[260] 
which involves docking various molecular fragments into the active-site region and then linking 
favorable matches covalently. An alternative approach is generating a scaffold core within the 
binding site, using a ligand-bound protein structure.   
 
 
 
 
 
 
 
 
 
 
The scaffold core can then be used to construct ligand of interest by an R-group 
fragmentation/enumeration process. (ii) In the TrixX BMI method, the ligands are first split into 
fragments, which are then counted    using triangular descriptors and stored in a database. During 
screening, the target-based query descriptors are used to extract matches and then reconstructed 
incrementally [261] to build the ligands. By and large, most systematic searches methods explore 
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all degrees of freedom in a molecule and it is the only search method that thoroughly samples the 
conformational space of the ligand. However, the method ultimately faces the problem of 
combinatorial explosion[262]  – exhaustive search calculation– that is computationally prohibitive. 
Certain algorithms such as MOLSDOCK algorithm have been designed to deal with this 
problem[263] and some examples of docking programs (Figure 2.4) that utilize the search 
algorithm, though with a little modification, include DOCK4.0, FLOG[264] and FlexX.[265]  
Random search 
Random search is a local search method that involves making random changes to either a single 
ligand or a population of ligands and then evaluates new ligands based on a pre-defined 
probability function with the hope of finding an improved solution or a better conformation.  
There are three approaches used in this method to generate new ligand conformations: (i) Monte 
Carlo methods use a random modification to generate alternative ligand poses; (ii) Genetic 
algorithm (GA) uses an evolutionary selection method to evolve poses that are favorable, which 
are passed to the next generation, but unfavorable poses are eliminate. The inherited poses are 
then passed through an iterative process where random or biased mutations can be made to 
increase genetic diversity and prevent premature convergence, and then the selection and 
crossover stages are carried out until favorable poses are obtained. (iii) Tabu search algorithm is 
a search method that takes into consideration already explored areas of the conformation space. 
In effect, the algorithm is able to mark solutions and those poses that have been rejected before 
with a “tabu” (forbidden) tag so that the algorithm does not repeat that conformation again.  The 
algorithm uses root mean square deviation (RMSD) to differentiate between current molecular 
coordinates and previous recorded conformations, and  to determine if a new molecular 
formation should be accepted or not. PRO_LEADS[266] is good example of a docking program 
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that uses tabu search algorithms. While programs such as AUTODOCK[235, 267] uses a more 
highly effective search algorithm which combines Monte Carlo like perturbation with other 
search algorithms such as simulated annealing, but, DOCK and GOLD[268] are known to 
implement GA searches. 
Simulated Search Method  
Simulation search method use molecular dynamics (MD) and energy minimization approaches to 
pose ligands in the active site of the enzyme. The major drawback of MD simulation is that it 
cannot cross high-energy barriers and so it can get trapped in a local minima when the 
calculations hits a rough potential energy landscape.[237] One way the problem has been solved is 
to use search algorithm that couples different degrees of freedom of the ligand to different 
temperatures; and during simulation the two temperatures that determine flexibility of the ligand 
are varied.[269] Other possible solutions tried include an attempt to simulate different parts of a 
protein-ligand system at different temperature[269b] or to start simulation from different point on 
the ligand. Unlike MD, energy minimization approach is a complementary method used by other 
search algorithms but not a standalone method. Docking programs such as DOCK and Monte 
Carlo algorithm have energy minimization incorporate into the search algorithm[270], while other 
programs that use simulation based search either alone or in combination include Glide[271], 
MOE-Dock[272], AUTODUCK and Hammerhead.[273] 
Scoring Function 
Scoring Function 
Docking programs contain not only search algorithms but also complementary scoring and 
ranking functions. Even when the correct binding modes of the ligands are predicted, scoring 
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functions are still crucial in differentiating correct poses from incorrect ones. Scoring functions 
make it possible to determine the correct pose of the ligand in the receptor, predict the binding 
affinity and suggest other possible ligands that can bind to the active site. Usually, scoring 
functions score the poses by a rough estimate of how the ligand matches the active site, and then 
the poses are ranked and rescored for how tightly the ligands bind to the receptor using more 
rigorous parameters. Essentially, scoring functions play a key role in the success of many 
docking programs, particularly in the area of virtual screening and lead optimization. In this 
section we will review a number of scoring functions used by various docking programs and 
current challenges and possible improvements made to these functions. Basically, three types of 
scoring functions are been implemented most docking programs: Force fields, empirical and 
knowledge based scoring functions. 
Force Fields Scoring Function 
The Force field score is based on physical atomic interactions[274], it essentially sums atomic 
interactions such as van der Waals, electrostatic (using Lennard-Jones potential) and 
bond/stretching/binding/torsional forces. Usually in docking, the force field scoring functions 
attempts to predict binding affinities of ligands by adding individual contributions from different 
types of interactions.  The major protein-ligand interaction is contributed by van der Waals and 
the electrostatic term[191], which turns out to be first shortcoming of the scoring function. The 
Lennard-Jones potential is usually used to model van der Waals potential and as such the steep 
form at short interatomic distance on the potential well (Figure 2.1) can lead to strong repulsion, 
which might result in significant steric clashes that are unaccounted for during computation. 
Sometimes these clashes are noticeable in docking results, it is important to visually inspect each 
docking result to weed out such steric clashes during post processing of docked results. 
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Furthermore, the electrostatic term grossly over emphasizes the polar interaction which is due to 
the function not being able to deal with effect of solvent. Shoichet and Wei have established 
possible solution to ligand solvation problem but there is also the desolvation effect to compute, 
which deals with explicit water surrounding of the solute atoms, which influences ligand 
binding.[275]  A rigorous approach to deal with the problem is reviewed by Wang and Adcock[276] 
but the solutions are too computationally expensive to be used in large scale virtual screening. 
Further solutions to the problem have been successfully implemented in virtual screening by 
using Poisson-Boltzman/Surface are (PB/SA)[277] model and the general-Born/surface area 
(GB/SA) model.[278]  However, it is important to note that some of the force field scoring 
functions are based on different force field parameter sets and they differ from one docking 
program to another. For example, AUTODOCK uses the AMBER force field[279], while G-score 
uses the Tripos force field[280] for scoring binding affinities. 
Empirical Scoring Function 
An empirical scoring function binding affinities are estimated as a weighted sum of several 
parameterized functions such as explicit hydrogen bonding, ionic interaction and hydrophobic 
contact terms.[194d] The coefficients of the weighted terms are obtained from regression analysis 
determined experimentally by fitting the binding affinity data of a training set of protein-ligand 
complexes with known three-dimensional structures.[281] The terms used in empirical scoring 
functions, though similar to force field, are simpler and easy to evaluate. In fact, Tarasov and 
Tovbin developed an extremely simple empirical scoring function NScore in order to test how 
sophisticated a scoring function has to be for it to be successful in docking. Surprisingly, the 
results from using NScore were comparable to GOLD, DOCK and Glide with sophisticated 
scoring functions, if the scoring was based on fundamental physic principles only.[282] In general, 
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one shortcoming of these functions is their dependence on the molecular data set used to perform 
regression analysis and fitting. As a result, there is a different weighting coefficient for various 
terms, which makes it difficult to transfer or merge terms into new scoring functions. More so, 
each scoring function has to be calibrated with different dataset of protein-ligand complexes, but 
with the increase in the number of protein-ligand complexes with three-dimensional structures 
available in the database, it would be possible to develop a reasonable general empirical scoring 
function by training with thousands of known protein-ligand complexes. So far, well-known 
docking programs such as Surflex[283]FlexX[265],and Glide[271] use empirical scoring function by 
combing various energy terms and the list of empirical scoring function is constantly growing 
with different training sets: LigScore, LUDI, ChemScore, SCORE, X-Score, ICM,  
MedusaScore, AIScore PLP, and SFCscore.[194d]  
Knowledge-based Scoring Function 
Knowledge-based scoring functions are developed from a statistical analysis of information 
gleaned from protein-ligand experimentally determined structures.[191]  They are also known as 
statistical-potential based scoring function. The principle behind knowledge-based scoring 
function is that pair-wise potentials or interatomic distances occurring more often than some 
average value should represent a favorable contact and the same is true for unfavorable 
interaction.[284] In addition, the atom-type interactions are usually selected based on their 
molecular environment in different experimental structures. The main appeal of these functions 
is the simplicity of the estimation, limited computational requirement and in addition to its 
ability to deal with low-resolution protein model with compactable long-scale simulation.[285] 
Although, the function is simple, the actual derivation using inverse Boltzmann relation[285] 
contains a reference state term that still remains a longstanding hurdle in deriving pair-wise 
69 
 
potentials.[286] In practical terms, derivation of these functions is challenging since it is based on 
implicit information from a limited data set, which affects its accuracy and it is tough to improve 
on the function in a stepwise manner. Despite the limitation inherent in knowledge-based scoring 
function, these functions have been implemented in the design and use of successful functions 
such as potential of mean force (PMF)[287], DrugScore[288], SMoG[289] and the well-known 
ITScore/SE.[290] 
Consensus Scoring 
The ideal scoring function would score absolute binding affinities accurate binding poses and 
predict nanomolar hit compounds, but no one scoring function is perfect in terms of accuracy and 
general applicability. Consensus scoring function combines the information of multiple scoring 
functions to even out the errors and improve the probability of enriching the screening process 
with true hits.[191] Paramount to the success of these functions is the ability to design appropriate 
consensus strategies of individual scores so that true binding modes can be differentiated from 
non-binding modes.[291] Some of the strategies used include vote-by-number, rank-by-number, 
average rank etc[292] and reliable scores such as MultiScore[293] , X-Cscore[294], SeleX-CS[295], and 
SCS[296]  have been developed and used in docking. 
In summary, scoring function are typically part of a larger program such as DOCK, FlexX, Glide 
etc. and each performs specific implementation in these programs. The review by Zou et al.[194d] 
outlines certain general criteria used to evaluate the performance of a scoring function. One of 
such criteria is the ability of a scoring function to distinguish native binding modes from decoys. 
Root mean standard deviation (rmsd) values are commonly used by most scoring function to 
distinguish binders from non-binders; if the rmsd is ≤ 2.0Å for true ligands then prediction is 
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usually considered a success. A second criterion for a scoring function is its ability to predict the 
binding affinity of a complex, that is, how tightly does the ligand binds to the receptor. This is 
where most scoring functions find it challenging to achieve a score scale similar to experimental 
binding data. Lastly, the scoring function should be capable of selecting potential binders (hits) 
from a given library of compounds, which is in effect virtual screening in computer-based drug 
design. Equally notable in the implementation of scoring functions is that small changes during 
the preparatory process of the ligand or protein can make a big difference in binding affinity.[296] 
For example, changes in the number of rotatable bonds, protonation states, minimization etc. are 
very critical to obtaining reliable results during docking. Furthermore, scoring functions are not 
independent of docking algorithms that sample the chemical space, as a result scores are also 
greatly influenced by the binding site, method used to explore the conformational space, or 
methods used to sample and optimize the ligands. 
2.3	  Computation	  Based	  Drug	  Discovery	  of	  Dnmt1	  Inhibitors	  
 
The use of molecular modeling and virtual screening in drug discovery is a powerful tool in 
rational drug design and most techniques are geared towards understanding binding modes of 
potential drugs at the active site as well as identifying new leads with novel scaffold.[297]  
Understanding the binding modes will help fine-tune drug molecules to be more effective, 
selective, specific, and perhaps avoid preventable side effects, which currently plagues the 
known approved nucleoside Dnmt1 inhibitors. The cytosine based nucleosides approved by the 
FDA for myelodysplastic syndromes have low specificity and exert cellular and clinical 
toxicity.[298] Researchers are turning to computational methods to discover other potential Dnmt1 
inhibitors with minimal side effects or to computationally reengineer the current suicidal 
nucleoside inhibitors in an effort to reduce the well-known side effects to nominal acceptable 
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limits. So far, a number of different virtual screening studies with Dnmt1 have provided novel 
potential drug-like inhibitors with unique binding modes to the enzyme. Herein, we shall discuss 
the discovery of non-nucleoside inhibitors of Dnmt1 by virtual screening and binding mode of 
both known nucleoside and non-nucleoside inhibitors.  
Homology Model 
Initially, before the Song et al. solved the crystal structure for hDnmt1, Siedlecki and colleagues 
had used a homology model[299] to discover two novel inhibitors, NSC3033530 and 
NSC404077[140b] (Figure 2.5).  The model was accomplished by using MODELER module in 
INSIGHT2000 to convert the Dnmt1 sequence into a three dimensional structure based on the X-
ray diffraction data of M HhaI, M. HaeIII and Dnmt2. Validation of the structure was done with 
the Profile3D module of INSIGHT2000 and PROCHECK.[232] After a short energy minimization 
process and removal of water molecules, the homology model of the Dnmt1 catalytic domain 
was ready for docking. Virtual screening of a set (the Diversity Set of 1990 compounds) of small 
molecules available from the National Cancer Institute (NCI) database was performed on the 
hDnmt1 homology model using the novel docking and scoring methodology in DOCK5.    
Interestingly, the two top-ranked compounds from this docking study, especially NSC404077 
(RG108) still remain potent inhibitors of Dnmt1 despite the availability of the two 
crystallographic structures of hDnmt1 in the PDB database. 
Though the Food and Drug Administration (FDA) has approved demethylating agents such as 
Vidaza and Dacogen, there is still an unwavering drive for new inhibitors for Dnmt1 because of 
the inherent toxicity of these nucleoside inhibitors[298]:  5-azacytidine (Vidaza) is cytotoxic, non-
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specific and gets incorporate into RNA[300], while 5-aza-2’-deoxycytidine (Dacogen) is also 
cytotoxic and gets incorporated into DNA.[301]  
 
 
 
 
 
 
 
 
 
 
However, zebularine, a nucleoside analog, shows comparatively less toxicity and tumor specific 
but it follows similar inhibitory mechanism as other nucleosides[302] and as such gets 
incorporated into the DNA and covalently binds to Dnmt1. The above reason for cytoxicity has 
fueled the search for new Dnmt1 inhibitors that are less toxic and do not get incorporated into the 
DNA and can reversibly bind to Dnmt1. Cornacchia and colleagues had asked the question 
whether drugs like procainamide and hydralizine are capable of inducing a lupus-like syndrome 
in humans as observed when cloned T cells were treated with 5-azacytidine, since these drugs 
Figure 2.5: Identification of two novel candidate DNA methyltransferase inhibitors by 
computational screening. (A, B) Chemical structures of NSC303530 and NSC401077. (C, D) 
Superimposed conformations of cytidine (green) and NSC303530 (C) or NSC401077 (D) 
docked into the active site of Dnmt1. The covalent bond between cytosine and the catalytic 
cysteine of Dnmt1 is formed at the cytosine-6 position (magenta)  406 Permission requested 
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like 5-azacytidine bind to DNA too.[302] Their results led to the discovery of two new inhibitors 
of Dnmt1, procainamide and hydralazine a common anti-arrhythmias and a local 
antihypertensive respectively. Later, Villar-Garea and colleagues tested the potential of procaine 
(a local anesthetic) as an inhibitor of Dnmt1 based on its structural similarity to 
procainamide.[142b] Using the MCF-7 breast cancer cell line, they showed that procaine is an 
inhibitor of Dnmt1 and it produces a 40% reduction in 5-methylcytosine DNA. Furthermore, it 
was proposed that the main polyphenol component of green tea, (−)-epigallocatechin-3-gallate 
(EGCG) could also inhibit Dnmt1 since previous studies showed that EGCG inhibits catechol-O-
methyltranferase, which belongs a superfamily of S-adenosylmethionine-dependent 
methyltransferases the same as Dnmt1.[135]  EGCG inhibited Dnmt1 in a dose-dependent manner, 
showing competitive inhibition with a Ki of 6.89 µM.[135] The newly found inhibitors are 
interesting but the mechanisms of action are still debatable, also the binding modes of these 
molecules to Dnmt1 are unknown. In order to understand the binding modes of these new 
inhibitors, Singh et al[303] conducted molecular modeling with the homology model provided by 
Lyko et al.[299] Their study compared the relative binding modes of two tautomeric forms of 
hydralazine, procainamide and procaine to known nucleoside inhibitors, 2’-deoxycytidine, 5-
azacytidine and decitabine inside the homology model. Importantly, their docking results 
suggested that the new inhibitors shared similar binding modes as the nucleoside inhibitors, 
particularly, the interaction of all inhibitors with Glu128 and Arg174 (Figure 2.6). Also, 
superimposing the new inhibitors with known nucleoside inhibitors in the catalytic pocket 
showed they all shared similar position (Figure 2.7) 
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Figure 2.7: Optimized docking models of e) procainamide and f) procaine with the homology model of 
human Dnmt1. Arrows indicate hydrogen bonding. “Clouds” on ligand atoms indicate the solvent-exposed 
surface area of ligand atoms (darker and larger clouds mean more solvent exposure). “Halos” around 
residues indicate the degree of interaction with ligand atoms (larger, darker halos mean greater 
interaction). The dotted contour reflects steric room for methyl substitution. The contour line is broken if 
it is closest to an atom which is fully exposed410 Permission requested 
Figure 2.6: Optimized docking models of a) 2′-deoxycytidine and b) 5-aza-2′-deoxycytidine c) the hydrazone 
tautomer (imino form) and d) the hydrazine tautomer (amino form)  with the homology model of human Dnmt1. 
Arrows indicate hydrogen bonding. “Clouds” on ligand atoms indicate the solvent-exposed surface area of 
ligand atoms (darker and larger clouds mean more solvent exposure). “Halos” around residues indicate the 
degree of interaction with ligand atoms (larger, darker halos mean greater interaction). The dotted contour 
reflects steric room for methyl substitution. The contour line is broken if it is closest to an atom which is fully 
exposed. 410 Permission requested 
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In Figure 2.8, three of the nitrogen atoms of hydralazine in the hydralazone tautomer show a 
rough overlap with three of the heteroatoms of 2’-deoxycytidine. Also, the amino group occupies 
the same binding position as the amino group of cytosine, which is capable of binding with 
Glu128. Furthermore, the unprotonated nitrogen of the phthalazine ring in the hydrazone forms a 
rough overlap with the binding position of the carbonyl oxygen of cytosine and any of these 
atoms (N or O) can hydrogen bond with Arg174. Equally notable is the binding modes of 
  
Figure 2.8 Comparison of the optimized binding models of hydralazine with the binding model of 2’-
deoxycytidine (carbon atoms in dark gray): a) hydrazone tautomer, b) hydrazine tautomer c) 
procainamide and d) procaine (carbon atoms in light gray). Nonpolar hydrogen atoms are omitted for 
clarity. Note the similar positions of the amino groups and the very similar position of the carbonyl 
oxygen of procainamide and procaine with the ribose oxygen. These atoms form hydrogen bonds with 
Glu128 and Arg174, respectively. 410 Permission requested 
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procaine and procainamide compared with the nucleoside inhibitors. The amino group of 
procaine and procainamide and that of 2’-deoxycytidine share similar positions; the carbonyl 
oxygen of procaine and procainamide occupy similar positions as the oxygen of the ribose sugar 
of 2’-deoxycytidine and are capable of making hydrogen bond with Arg174. In summary, their 
results highlight the importance of the interaction of inhibitors with key residues in the enzyme 
such as arginine and glutamic acid since they might play a major role in the mechanism of DNA 
methylation. 
 
 
 
 
 
 
Notably, Kuck and colleagues used the homology model of Lyko and a multistep virtual  
Furthermore, still using homology model, Fang and colleagues suggested the binding mode of 
EGCG and proposed a possible mechanism of action.[135] . Using an in-house homology model 
created using Hhal Mtase as molecular template and docking with GOLD; they noticed certain 
interactions at the catalytic site (Figure 2.9). The gallate moiety of EGCG could form hydrogen 
bonds with Glu1265 and Pro1223. Also, the position of the D ring is oriented roughly at the 
same position as the pyrimidyl ring of cytosine. In addition, the hydroxyl groups in the A and B 
rings are positioned to form hydrogen bonds with Ser1229 and Cys1225 respectively. From these 
 
Figure 2.9: Molecular modeling of the interaction between EGCG and Dnmt. A, binding orientation of 
EGCG in Dnmt1. The close-up view of the consensus orientation for EGCG. The protein is depicted in 
ribbon representation and colored by secondary structures (i.e., helix, strand, and loop). Both EGCG and 
ligand contact residues are represented in stick form and colored by atom type with carbon in gray, oxygen 
in red, and sulfur in yellow. B, hydrogen-binding network of EGCG in Dnmt1. -- represents hydrogen bond. 
Figure depicts all potential H-bonding X-H. . . Y interactions for which the X. . . Y distance is  4.0 Å  199 
Permission requested 
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findings they hypothesized that EGCG exerts its inhibitory effect on Dnmt1 function by blocking 
the entry of key nucleotide cytosine into the active site.[135] 
 
 
 
 
 
 
Figure 2.10: Optimized docking model of NSC 14778 with human Dnmt1. (A) 3D representation 
showing selected amino acid residues. Hydrogen bonds are indicated with blue dashes. Hydrogen 
atoms are omitted for clarity; (B) 2Dinteraction map displaying amino acid residues within 4.5 Å of 
the ligand. Green and blue arrows indicate hydrogen bonding to side chain and backbone atoms, 
respectively. Blue ‘clouds’ on ligand atoms indicate the solvent exposed surface area of ligand atoms. 
Light-blue ‘halos’ around residues indicate the degree of interaction with ligand atoms. The dotted 
contour reflects steric room for methyl substitution.411 Permission requested 
Figure 2.11: Optimized binding model of virtual screening hit ZINC 00082754 with human Dnmt1. a 
Three-dimensional representation displaying selected amino acid residues. Hydrogen bonds are 
indicated with magenta dashes. b Two-dimensional interaction map displaying amino acid residues 
within 4.5 Å of the ligand. The ligand proximity contour is depicted with a dotted line. The ligand solvent 
exposure is represented with blue circles; larger and darker circles on ligand atoms indicate more 
solvent exposure. The receptor solvent exposure differences—in the presence and absence of the 
ligand—are represented by the size and intensity of the turquoise discs surrounding the residues; larger 
and darker discs indicate residues highly exposed to solvent in the active site when the ligand is absent414 
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Notably, Kuck and colleagues used the homology model of Lyko and a multistep virtual 
screening methodology to uncovered a diverse collection of novel and selective inhibitors of  
Dnmt1.[304] One of such hits was NSC14778 with an IC50 of 92 µM. In this study, more than 
65,000 lead-like compounds were obtained from the NCI Open Database[305]  and prepared for 
docking using LigPrep and docked sequentially through GLIDE 5.0, GOLD 4.0 and AutoDock 
3.0 to arrive at 24 consensus hits of which NSC14778 was most active after experimental testing. 
Optimized docking model of NSC14778 (Figure 2.10) showed a network of predictable 
hydrogen bonds with key residues in the catalytic pocket, most importantly Arg174 and Arg318, 
which corresponds with the binding modes of procaine, procainamide and hydralazine. Equally 
noteworthy is the discovery of a natural product inhibitor by Medina-Franco and colleagues.[306]  
After obtaining 89,425 natural product compounds from the ZINC database[307] [440] and 
passing them through a filter program and preparing them with LigPrep, Medina-Franco used a 
similar multistep docking protocol to uncover a coumarin based inhibitor, ZINC00082754. Also, 
optimized binding mode of this compound with Dnmt1 showed possible hydrogen bonds with 
the side chains of Arg174 and Arg318 in addition to interactions with His321 and His322 
(Figure 2.11) 
  
Crystal Structure Based Inhibitors 
Two crystallographic structures of hDnmt1 are available in the Protein Data Bank (PDB).[228] 
The first crystal structure was solved by Song et al.[84] depicting a hDnmt1 crystallographic 
structure with SAH and DNA containing unmethylated CpG sites solved at a resolution of 3.6Å 
(PDB:3PTA), which is not a very good resolution. A second structure was recently added to the 
PDB database by Hashimoto and Cheng (PDB: 3SWR); they published a structure hDnmt1 
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bound to the inhibitor, sinefungin (SFG) and with a resolution of 2.49Å. The two structures are 
similar with a root mean square deviation (RMSD) of 1.4Å.[308]  Despite the available structures 
of hDnmt1 no virtual screening has been done entirely with either structure, however, modified 
structure[309] of PDB: 3PTA has been used for most docking experiments, while in some case 
3SWR has been rebuilt for virtual screening studies.[308]  
 
 
 
 
 
 
 
 
Yoo and colleagues argue that the conformation of the crystal structure of human Dnmt1 by 
Song is in an inactive state (that is the target base from DNA is not flipped out) and so the 
geometry presented by Song does not necessarily reflect the catalytic mechanism of Dnmt1, he 
described the structure as being in an open configuration and thus, not optimal for docking 
computations. Yoo came to this conclusion by comparing model structures of Dnmts and other 
available crystal structure of Dnmts[310] and concluded that 3PTA was in an open configuration. 
Yoo and Medina-Franco have used the modified crystal structure to discover a potent inhibitor 
  
Figure 2.12: Comparison of the binding modes with pharmacophore hypothesis for (a) 
NSC97317 and (b) 5,5-methylenedisalicylic acid (deprotonated forms). Hydrogen bonds are 
depicted with dashes. Nonpolar hydrogen atoms are omitted for clarity. Selected residues are 
displayed for reference. Red sphere: negative ionizable; pink sphere with vectors: hydrogen 
bond acceptor; blue sphere with vector: hydrogen bond donors; and orange ring: aromatic 
ring. Matching features, considering a distance matching tolerance of 2.0 Å, are marked with 
asterisks. Permission requested 
Adapted from Yoo et al.411 
80 
 
trimethylaurintricarboxylic acid (NSC97317) of Dnmt1. NSC97317 showed an IC50 value of 
4.79 µM, which is better than previously reported NSC14778[304] even though both compounds 
share similar chemical structure. However, the optimized docked model of NSC97317 show 
similar hydrogen bond interaction with Ser1229 and Arg1379 in addition to key mechanistic 
interaction with Glu1265 and Arg1311 (Figure 2.12). Also, hydrogen bonding with Glu1265, 
Arg1311 and Arg1461 have been predicted for other inhibitors and these interactions might be 
pharmacophoric. 
 
Pharmacophore Model 
In an effort to understand the basic structural requirements of Dnmt1 inhibitors, Yoo and 
Madina-Franco[311]  docked a comprehensive list of 14 known Dnmt1 inhibitors (Figure 14) with 
the homology model of the catalytic domain of hDnmt1 and studied the key protein-ligand 
interactions. The docking results revealed that all known inhibitors have hydrogen bond 
interactions with specific glutamic and arginine residues,  and suggested that these interactions 
could be pharmacophoric. As a result a pharmacophore hypothesis was developed using energy 
optimized pharmocophore (e-pharmacophore) method based on the work by Salam et al.[312] 
Briefly, the method entails the use of Glide to refine ligand-protein crystal structure, then starting 
with the refined X-ray ligand (Figure 24), pharmacophore sites are generated automatically with  
Phase (Phase, v3.0, Schrodinger, LLC, New York) based on a default set of six chemical 
features: hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobe (H), negative 
ionizable (N), positive ionizable (P), and aromatic ring (R). Each pharmacophore feature is 
assigned an energetic value equal to the sum of the Glide XP contributions the atom 
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comprising the site. The sites are then quantified and ranked on the basis of these energetic terms 
and the most favorable sites are selected for the pharmacophore hypothesis[312]; and the 
pharmacophore model is then used as queries for virtual screening. Applying the same e-
pharmacophore model to the 14 known inhibitor of Dnmt1 Yoo and colleague developed a five-
feature pharmocophore model (Figure 2.13 & 2.14) for the known inhibitors. The top-ranked 
feature is the negative charge next to residues Ser1229, Gly1230, and Arg1311, and then 
followed by an acceptor site that is in proximity to Arg 1311 and Arg 1461 (Figure 2.14). The 
third ranked feature is the aromatic ring, which in this case stabilizes the binding formation 
between AdoHcy and Cys1225, and a donor site that is proximal to Gln 1396 pharmacophore 
model captures key interactions of the 14 known inhibitors especially the highly conserved 
glutamic and arginine residues present in the catalytic domain of most DNA 
methyltransferases.[313] 
 
 
 
 
 
 
 
Finally, the fifth-ranked feature is a donor site close to residue Glu1265. The proposed  
 
Figure 2.13: Example of energy-optimized hypothesis for Aricept, 14, in PDB 1eve. Arrow represents 
the evolution from the initial ligand (a,d) to the ligand with all sites (b,e) to the ligand with the most 
energetically favorable sites (c,f). Pink sphere/circle ) hydrogen bond acceptor, green sphere/circle ) 
hydrophobic group, orange ring ) aromatic ring, and blue sphere/circle ) positive ionizable.421 
Permission requested 
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Most of the inhibitors matched several of the pharmacophore features in the proposed model, 
particularly the nucleoside analogues 5-azacytidine, decitabine, and 5-fluoro-2’-deoxycytidine 
matched all five pharmocophoric features (Figure 2.15) excerpt zebularine with only four 
matches because of the absence of an amino group on the heterocyclic ring. Procaine, 
procainamide, curcumin and hydralazine match three features: the aromatic ring, donor and 
acceptor feature. While for EGCG, the B ring satisfied both the aromatic ring requirement and 
the donor feature near Glu1265. The D ring matched the donor close to Gln1396 and the 
acceptor. All other inhibitors matched at least two of the chemical features, except NSC14778 
and parthenolide that matched only one the pharmacophore feature. The carboxylate feature of 
NSC 14778 matches the negative feature, which is the highest-ranked feature of the model. 
Whereas, parthenolide matched the acceptor feature interacting with key arginine residues 
Figure 2.14:  Structure-based pharmacophore model for Dnmt inhibitors. Red sphere negative 
ionizable, pink sphere hydrogen bond acceptor, blue sphere hydrogen bond donors, and orange 
ring aromatic ring. Selected amino acid residues in the catalytic site are schematically depicted for 
reference. See the online version of the manuscript for colors. 420 Permission requested 
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Arg1311 and Arg 1461 and it is possible that parthenolide might also interact with Glu1265 if it 
undergoes keto-enol tautomerisation.[313] In summary, the e-pharmacophore model shows good 
agreement with docking studies of most Dnmt1 inhibitors and it a vital step towards 
understanding the ligand-protein interactions and optimization of leads. 
In addition to virtual screening and pharmacophore modeling, Jharma et al.[149] introduced a new 
class of quinoline-based Dnmt1 inhibitors. They reported a quinoline-based compound 
designated SGI-1027, which inhibits the activity of Dnmt1, Dnmt3A and Dnmt3B as well M. 
SssI with an IC50 (6-13 µM). Further studies revealed that the mechanism of inhibition of Dnmt1 
is competitive not with the nucleoside base target but with S-adenosylmethionine. Also, SGI-
1207 is effective at reducing Dnmt1 concentration in different cancer cell types: hepatocellular 
carcinoma, (HepG2), human cervical cancer (HeLa), prostate cancer (LNCap), and breast cancer 
(MCF7) cell lines. The results show that the effectiveness of SGI-1027 is comparable with 
decitabine (95-96%) at inhibiting the proliferation of these cancer cells; similar growth-
inhibitory effects were obtained when this compound was exposed to colon cancer cells 
(HCT116 and RKO). However, unlike decitabine, SGI-107 exerts growth-inhibitory effect with 
minimal toxicity, even its exposure to rat liver cells showed minimal toxicity.[149] Also notable is 
the fact that SGI-1027 is able to induce rapid proteasomal degradation of Dnmt1 in a variety of 
cancer cell types as observed for the nucleoside inhibitors[314]; in effect it can be classed as a 
suicidal inhibitor.  
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Other Inhibitors: SGI-1027, SID49645275 and Procainamide-RG108  
 
 
 
 
 
 
 
 
One more addition to the class of new structure-based non-nucleoside inhibitor is 
thioxodihydropyrimidine compound designated SID49645275 (Figure 2.16) obtained from a 
nonradioactive high-throughput activity assay for hDnmt1.[315]  The compound showed an IC50 
of 811 nM, and its structure has been used by Medina-Franco and Yoo in similarity search for 
other compounds within its class; also elucidating the binding modes for SID49645275 and SGI-
107.[308, 315b]  
 
Figure 2.15 Comparison between the binding mode and pharmacophore hypothesis for representative 
Dnmt inhibitors.    Red sphere negative ionizable, pink sphere hydrogen bond acceptor, blue sphere 
hydrogen bond donors, and orange ring aromatic ring. The asterisk denotes the matching site with the 
inhibitors. Selected amino acid residues in the catalytic site are shown for reference.420 Permission 
requested 
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Finally, a new synthetic inhibitor of Dnmt1 has been introduced by Champion et al.[316]; it is a 
hybrid compound based on the conjugation of procainamide to L-RG108 (Figure 2.16) via an 
alkyl linker. Six of these conjugates were obtained and tested for Dnmt1 activity and then 
validated with in-house tumor cell lines (DU145 and HCT116). The compounds (Figure 2.16: 
especially, n=12) showed substantial inhibitory activity over parent compounds; at least 50 times 
more active than parent compounds. In addition only mind toxicity was observed and they 
showed selectivity for Dnmt1 over Dnmt3A/3L. 
 
 
 
 
 
 
In summary, a number of new scaffolds and compounds have been introduced as potential 
inhibitors of Dnmt1 many from various studies using virtual screening, binding mode and 
pharmacophore modeling. Also, some of the new compounds do show remarkable inhibitory 
effect comparable to known nucleoside inhibitors but with lesser toxicity. It follows that 
computational approach to drug discovery does offer some strong potential and will be used in 
this project to uncover new probable inhibitors of Dnmt1. 
Figure 2.16: Chemical structure of other novel Dnmt1 inhibitor, compound SGI-107, 
Procainamide-RG108 and SID49645275 
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CHAPTER	  3	  
DESIGN	  AND	  SYNTHESIS	  OF	  SMALL	  INHIBITOR	  MOLECULES	  
 
3.0	  Introduction	  
 
In order to uncover and develop novel inhibitors for Dnmt1, we used virtual screening in two 
independent studies; one study screened a diverse library of compounds from the ZINC[307] 
database using AutoDock 4.2[317], while the second study docked ligands from the Promiliad (in-
house) library of compounds using AUTODOCK Vina[267]. Both docking studies used the same 
crystallographic structure of Dnmt1 (PDB: 3PTA) solved by song et al.[84]. The choice of the 
docking program was based not only on the fact that they are open source software but also 
because the scoring functions used by AutoDock 4 (semi-empirical free energy force field) and 
Autodock Vina (modified X-score) are different but give closely related results. For any given 
problem, either program may provide better results; however, Autodock Vina is approximately 
two orders of magnitude faster than AutoDock and is deemed to have an improved accurate 
scoring function[267].  In addition to virtual screening, quantitative structure activity relationship 
and pharmacophore modeling were investigated to evaluate possible Dnmt1 inhibitors. 
Furthermore, transition state inhibitors were also designed based on cytosine and thymidine the 
inhibitors were made by modifying the C5 position of cytosine and thymidine. Lastly, analogues 
of known inhibitors were also investigated for possible inhibition of MCF-7 breast cancer cell. 
3.1	  Zinc	  Database	  Screening	  
 
For this study we divided the approach into two, first we docked a diverse collection of 5,400 
small molecules into the catalytic site of Dnmt1 (PDB: 3PTA) from which we obtained five hits 
87 
 
(Table 1.1) with distinct structures (Figure 3.1). Three of these compounds ZINC09425787, 
ZINC02835213 and ZINC04710208 were tested for Dnmt1 inhibition using an in-house high-
throughput screening assay, which measures the direct incorporation of tritium (3H) from S-
adenosyl-L-[methyl-3H]methionine (AdoMet) to a synthetic oligonucleotide, poly 
(deoxyinosinic-deoxycytidylic) acid (poly(dI-dC). The results showed that ZINC04710208 
(88SC) inhibits Dnmt1 with an IC50 of 233 μM. After testing of 88SC, amides derivatives were 
synthesis to check the importance of the carboxylic acid group and also to explore important 
amines used in drug design and development. Similarly, the napthyl group was substituted with 
other flexible and rigid carbon scaffold.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Top ranked structures from screening ZINC database library using AutoDock 4.2 
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Table 3.1 Docking results using AutoDock4.2 
 
  
 
 
 
 
Synthesis 
A Plochl & Erlenmeyer type reaction [318] was used to synthesize analogues of (Z)-2-acetamido-
3-(naphthalene-2-yl) acrylic acid (88SC). The first step of the reaction involves the condensation 
of a protect glycine and an aldehyde to give an oxazolone ring 2, which then undergoes  ring 
opening with acetone:water under reflux to give the acid, or the oxazolone can  be recrystallized 
in methanol to give a ring opened methyl ester product 3 (Scheme 3.1). 
 
 
 
 
 
Ligand Binding Energy/ 
kcal/mol 
Intermol Energy Internal Energy Torsional Energy Unbound Energy 
 
ZINC02835213 
 
-8.70 
 
-10.79 
 
-1.23 
 
2.09 
 
-1.23 
 
ZINC04710208 
 
-7.51 
 
-8.40 
 
-0.67 
 
0.89 
 
-0.67 
 
ZINC01694996 
 
-6.98 
 
-7.28 
 
-0.08 
 
0.30 
 
-0.08 
 
ZINC09425787 
 
-7.34 
 
-9.13 
 
-1.30 
 
1.79 
 
-1.30 
 
ZINC18140189 
 
-7.00 
 
-7.89 
 
-0.32 
 
0.89 
 
-0.32 
 
 
Scheme 3.1: (a) 2-acetamidoacetic acid, acetic anhydride, NaOAc 29% (b) acetone:water, reflux  83%                            
(c) recrystallize in methanol 
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The oxazolone ring can also be opened with primary or secondary amines to give the 
corresponding amides (Scheme 3.2), this is done by heating the oxazolone at reflux with the 
corresponding amine. Based on the fact that piperazines, piperidine and non-cyclic amines  were  
shown to have  inhibitory activity against Dnmt1 (Figure 3.4) on their own, and because of their 
known bioactivity and frequent use in drug design  amide analogues of ethyl 4-amino-1-
piperidinecarboxylate (2,2,6,6-tetramethylpiperidin-1-yl)oxy (TEMPO) 7PL7C, 4-Amino-
2,2,6,6-tetramethylpiperidine 7PL8C and 1-(2-Aminoethyl) piperazine 7PL11C and  other non-
cyclic amine were used to build a library of amide derivatives of 88SC. Apart from piperazines, 
piperadine, and non-cyclic amines,  other sulfur based amine (thiomorpholine), straight chain 
and bulky amines were also used to expand the diversity of the amides library. On the other 
hand, the modification of the naphthyl group (West) (Scheme 3.1) was  carried out by  using a 
variety of  single and flexible aldehydes for the Plochl & Erlenmeyer type reaction.[318] The 
modification on the West side of the molecule might give us a sense of the π-π interaction of the 
napthyl ring and aromatic residues in Dnmt1. The π-π interaction could be perturbed by changing 
the naphthyl ring for biphenyl, diphenyl ether, and single phenyl groups while leaving the acidic 
group constant (Figure 3.3). 
 
 
 
 
 
 
Scheme 3.2: (a) 2-acetamidoacetic acid, acetic anhydride, NaOAc 29%  (b) CH2Cl2 80oC 
RNH2 
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3.2	  Promiliad	  Database	  Screening	  
 
Screening of Dnmt1 inhibitors using AutoDock Vina on the Promiliad database gave a group of 
isoindolinone compounds (Figure 3.4) with predicted Dnmt1 activity, from which analogues 
were further synthesized and docked to improve activity. A series of isoindolinone compounds 
(Figure 3.5) were synthesized from a sequential Ugi/intramolecular Diels Alder Furan (IMDAF) 
Figure 3.2: Amide analogues from (Z)-2-acetamido-3-(naphthalene-2-yl) acrylic acid (88SC) 
Figure 3.3: Naphthyl group analogues from (Z)-2-acetamido-3-(naphthalene-2-yl) acrylic acid 
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reaction using an acetylenic dienophile intermediate. The Ugi synthesis reaction involved the 
condensation of acetylenic acid, 2-furaldehyde, isocyanide, and primary amines (Scheme 3.3) 
and  isoindolinone compounds were later obtained from an IMDAF reaction upon exposure of 
the Ugi product to catalytic amount of Yb(OTf)3 in 1,4-dioxane at high temperature (Scheme 
3.4).   
 
 
 
 
 
 
 
 
 
  
The acetylenic acid 27 and fufural 26 used for the isoindolinone analogues were kept constant 
while varying the isocyanide 28 and primary amine 29 components. Acetylic acid  was obtained 
by  direct Heck coupling of aryl iodide 22 and ethyl propiolate 23 in the presence of potassium 
carbonate (Scheme 3.3)[319] followed by hydrolysis of the ethyl arylpropiolates 24 with 
Figure 3.4: Dnmt1 activities of Isoindolinone compounds from the Promiliad library, and the activity 
of selected piperazine and piperidine compounds. 
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potassium hydroxide in a water:tetrahydrofuran (1:1) mixture to give the acetylenic acid 25. The 
importance of varying the amine and isocyanides component used in the Ugi reactions was to 
probe the different binding interactions of isoindolinone with Dnmt1 as a result of change of 
structure and possibly electrostatic charge around the compound. Thus, in the design of these 
isoindolinones certain isocyanides and amines were chosen to create structural difference in the 
library. Also some of the isocyanide derivatives used were components of isoindonlinone with 
good Dnmt1 activity from previous assay (Figure 3.4), particularly cyclohexyl isocyanide, 
isopropyl isocyanide and tert-butyl isocynanide were used for the isoindolinone analogues. 
 
 
 
  
 
 
 
 
 
 
 
Scheme 3.3 (a) Pd(PPh3)Cl2, CuI/K2CO3, THF, 650C 82% ( b)LiOH.H2O, 
H2O:MeOH:THF (1:2:3), 78% 
Scheme 3.4 (a)1 M in MeOH, RT overnight   (b)Yb(OTf)3, dioxane 100oC, 12 h 
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Figure 3.5: Isoindolinone analogues from variation of isocyanides and primary amine 
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Figure 3.5: Isoindolinone analogues from variation of isocyanides and primary amine 
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In summary, isoindolinone offers useful scaffold for drug design and it is present in many 
bioactive molecules[320] including both natural and synthetic compounds, and from virtual 
screening. In this project in this project it has been shown to have activity against Dnmt1. 
Consequently, we have used a three step reaction; synthesis of the acetylenic acid Ugi and 
IMDAF reactions produced a diverse set of compound library by varying two of the components. 
These compounds were later tested both on Dnmt1 and on breast cancer MCF7 cells. 
3.3	  Pharmacophore	  Modeling	  
Pharmacophore modeling like virtual screening has been used  in drug discovery for many 
years[321] and the models generated are either based on relevant chemical features derived from 
protein complex, as in the case of structured-based design or derived from common chemical 
features of known ligands (ligand-based design).  Ligandscout[322] is a known software with tools 
that allow automatic generation of a 3D pharmacophore model either through structured-based or 
ligand-based design. The chemical features used by Ligandscout include lipophilic points (LIP), 
positive ionizable points (PI), negative ionizable points (NI), hydrogen bond acceptors vector 
(HBD), and finally hydrogen bond acceptor (HBA). In addition, the models generated by 
Ligandscout include inaccessible areas (steric restriction zones) to ligands based on defined 
interactions; these sterically forbidden regions are shown as excluded volume spheres and can be 
automatically generated and added to the pharmacophore model. For the design of a 
pharmacophore model for Dnmt1 inhibitors, two PDB entries (3PTA and 3SWR) containing S-
Adenosyl-L-homocysteine and sinefungin bound to the DNA methyltransferase were used to 
automatically create two pharmacophore model, from which a common pharmacophore (Figure 
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3.6) consisting of 1 positive ionization area, 7 H-bond donor, 1 H-bond acceptor and 22 excluded 
volume spheres is created. The model characterizes the protein environment surrounding the 
ligands in the structure. The performance metric used to assess the quality of a  pharmacophore 
model is  the Receiver Operating Characteristics (ROC) curves; this tells how good the model is 
able to discriminate between active and inactive ligand and the area under the curve (AUC) 
quantifies the ROC between 0 and 1, with values closer to 1 been favorable and vice versa. For 
this study, known inhibitors of Dnmt1 and inactive ligands were first docked into the model to 
determine the ROC and AUC value before screening of potential ligand was carried out.  A 3D 
in silico screening of natural product compounds from the ZINC database was then carried out 
using the generated structure-based pharmacophore model with the aim of identifying structural 
templates that are similar to S-Adenosyl-L-homocysteine. The resulting hit molecules were 
ranked automatically based on maximum matching chemical features of the screened ligands 
with the pharmacophore (Figure 3.7).  
 
 
 
 
 
 
 
  
Figure 3.6: Pharmacophore model using Ligandscout. Green arrows represent hydrogen bond 
donor, red are hydrogen bond acceptors, blue star is the positive ionization area. 
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Figure 3.7: Top scoring natural product structures predicted by the pharmacophore model using  
LigandScout 
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3.4	  Comparative	  Molecular	  Field	  Analysis	  (CoMFA)	  
 
There is a correlation between structure and function and traditional quantitative structure-
activity relationship (QSAR) correlates biological activities of active ligands with 
physiochemical or certain structural chemical features[323]. Also, ligand-receptor interactions 
depend on structural complementarity between the ligand and the binding site of the protein, the 
interactions are mostly described by 3-dimensional properties and the binding modes of ligands 
are determined by molecular structure[324]. Comparative Molecular Field Analysis (CoMFA) is a 
widely used 3D QSAR program that describes 3D structure-activity relationship in a quantitative 
manner, it involves calculating electrostatic and steric potentials energies of charged carbons 
atom located at each vertex of a rectangular grid and a series of other molecules. Certain atomic 
probes such as hydrogen bond donor or acceptor, or a lipophilic probe are then used to calculate 
fields values at each grid point, these values correspond to the energy values the probe would 
 
Figure 3.7: Top scoring natural product structures predicted by the pharmacophore model using 
Ligandscout 
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experience in a regular 3D lattice. The field values are correlated to binding affinity or biological 
activity through a partial least square (PLS) analysis. Usually, compounds with known biological 
activity are used to build a CoMFA model and test compounds can be screened using this model. 
For this work, in order to rationalize the structure activity relationship with natural product 
compounds from the ZINC database and compounds from ChEML database, CoMFA 
methodology was used to build a model from a training set of known Dnmt1 inhibitors with 
pIC50 values ranging from 3.3 to 7.7. The first step in building a model is usually structure 
preparation; structures of a set of nine Dnmt1 inhibitors was constructed using SYBYL sketcher 
and assigned Gasteiger-Huckel charges. The charged structures were later relaxed with Tripos 
force field. A CoMFA model (Table 3.2) was built after a substructure alignment of each 
compound and screening of a test set, (the same Dnmt1 inhibitors), revealed a squared 
correlation coefficient r2 of 0.9750, which is within the (> .60) value for a good model. The 
potential predictive power of the constructed model was tested by screening of natural product 
compounds form IBScreen NP compounds obtained from the ZINC database and the top ranked 
structures are shown in Figure 3.8. 
 
 
 
 
 
 
 
 
Dnmt1  Inhibitors 
 
PKD 
 
COMFA 
 
PREDICTION 
 
FUNCTIONAL_DATA 
ATA 5.3196 872 5.035 0.2849 
CURCUMIN 4.5228 1377 4.351 0.1723 
EGCG 4.1549 1108 4.121 0.0335 
NSC138419 3.3979 0996 4.432 1.0344 
NSC14778 4.0362 0840 3.959 0.0774 
NSC348926 3.3467 0760 3.202 0.1450 
NSC408488 3.3010 1070 3.190 0.1114 
NSC57278 3.3279 1130 3.799 0.4708 
PROCAINAMIDE 5.0000 1372 4.443 0.5566 
PSAMMAPLINS A 7.7447 1709 7.777 0.0322 
RG108 6.9393 0850 7.033 0.0939 
SGI-1027 5.2218 1861 5.073 0.1491 
SID49645275 6.0969 0879 5.996 0.1012 
 
Table 3.2: Dnmt1 inhibitors pIC50 and CoMFA values and predicted activities 
100 
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Figure 3.8: Structures of natural product predicted by CoMFA QSAR to have similar Dnmt1 inhibitory 
effect
Figure 3.8: Structures of natural product predicted by CoMFA QSAR to have similar Dnmt1 inhibitory 
effect 
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3.5	  Transition	  State	  Based	  Inhibitor	  Design	  
 
Initially, before applying computational methods to identify potential Dnmt1 inhibitors an 
investigation was carried out into the possibility of using transition state inhibitors. Since 
transition state theory suggest catalytic acceleration of enzymes is proportional to free energy 
released upon binding of transition state analogue, analogues that resemble the transition  should  
give very powerful inhibitors. As a result, we designed and synthesized cytosine analogue with 
similar geometry and electronic features as the transition state during the methyl-transfer step 
from SAM to C5 position of cytosine (Figure 3.9).  Cytosine with methylene-sulfur analogues at 
 
Figure 3.8: Structures of natural product predicted by CoMFA QSAR to have similar Dnmt1 inhibitory 
effect 
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Figure 3.9: Proposed schematic representation of the methylation reaction catalyzed by DMT.  
the C5 position of cytosine might be one such structure that resembles the transition state during 
DNA methyltransferase especially one analogue that resemble the product.  
 
 
 
 
 
 
 
 
Kinectic and binding studies for Dnmt1 have  not been well studied but steady-state studies of 
M.Hhal[325] and M.MspI[326] indicate an ordered binding of substrates, that is, DNA binds first 
before Adomet. In brief, the mechanism of the reaction shows that the key step is the formation 
of a Michael adduct between the sulfhydryl of a conserved cysteine (Cys-81 in M.HhaI) and C-6 
of cytosine (Figure 3.9). The carbon-5 becomes nucleophilic for the SN2-type attack onto the 
methyl sulfonium center of AdoMet, which results in the capture of the methyl sulfonium center 
of AdoMet resulting in the transfer of the methyl group to the ring. The resulting intermediate 
undergoes β-elimination at the C-5 position to give the methylated cytosine (Figure 3.9).  For 
the transition state inhibitor design in this study we considered cytosine structure resembling the 
first step in the mechanism (Figure 3.9) without the cysteine bound at the C-6 position. In 
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addition, we introduced a triazole ring with an attached benzyl group to mimic purine ring, that 
is, SAM at that position. The synthesis of the transition state inhibitor analogue was divided into 
two parts; one part involved the construction of the triazole moiety 65, and the other a 
brominated thymidine analogue 68, both parts were later coupled to give the final product. For 
the synthesis of the triazole, a simple SN2 reaction converts benzyl bromide 59 to benzyl 
azide[327] 60, which can then undergo 1.3-dipolar cycloadditon[328] reaction with an propagyl 
alcohol 61 to give the corresponding triazole 62. The reaction is catalyzed by copper (I) which is 
generated in-situ by the reduction of a less expensive copper (II) salt (CuSO4.5H2O) with 
ascorbic acid or sodium ascorbate. Subsequently, the resultant alcohol was easily converted to 
mesylate[329] 63 in high yield and then to the thioester[330] 64 using potassium thioethanoate.  This 
thioester can be reduced to the thiol[331] 68 with pyrrolidine and then coupled to the brominated 
thymidine 67 via an SN2 type reaction. The brominated thymidine derivative was obtained by 
first protecting the hydroxyl groups in thymidine with tert-butyldimethylsilyl (TBDMS) to give 
3’,5’-bis-O-(tert-butyl dimethylsilyl) protected thymidine derivative[332] 66 and then a radical 
bromination[333] 67 in the benzylic position  was achieved with N-bromo succinimide (NBS) and 
2,2’-azo-bis-isobutyronitrile (AIBN). In the final step of this reaction, the thymidine sulfide 
derivative was converted to cytosine derivative via a two-step reaction. The first step involve the 
conversion thymidine analogue to a triazolyl derivative with 1,2,4- triazole and phosphoryl 
chloride, then after the triazole group at the C-4 position is replaced with amino group with 
aqueous ammonia followed by deprotection of the silyl to give the cytosine derivative 71 
(Scheme 3.6).  
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Secondary and tertiary amine fuctionalization at the C5 position of nucleoside gives rise to a 
special class of 5-substituted pyrimidine nucleosides with  potent antiviral[334] and anticancer[335] 
properties and there is a continued interest for cyclic amines[336] at the C-5 position of 
pyrimidine. We evaluated the medicinal property of the amine derivatives of nucleoside using 
thymidine and several amines: cyclic amines, straight chain and aromatic amines were used and 
the synthetic steps involve an SN2 reaction of the amine with brominated thymidine. One 
Scheme 3.5: (a)NaN3, DMSO  91% (b) CuSO4.5H2O, Na.Ascorbate H2O:tButyl alcohol, 66% (c) 
MeSO2Cl,CH2Cl2 83% d) potassium thioacetate, DMF, 54% 
 
Scheme 3.6: (a)TBDMSCl, Imidazol, DMF, 91% (b) NBS, AIBN Benzene 80oC (c) Et3N, 
Pyrrolidine, DMF (d)1,2,4-triazole, POCl3, DMAP, MeCN then NH3, Dioxane 
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important amine used for this synthesis is bis(4-bromophenyl)amine 79 which showed good 
anticancer property and would be a good amine to use as a template for other thymidine 
derivatives. 
 
 
 
 
 
 
 
3.6	  Procainamide	  Analogues	  
 
Unlike the transition state nucleoside analogues that bind to the enzyme, procainamide and it’s 
derivatives do not have a definitive mode of inhibition for Dnmt1. Procainamide is speculated to 
bind to CG-rich sequence, which then mediates demethylation, but they are widely accepted 
Dnmt1 inhibitors. In an effort to make other analogues of procainamide (Figure 3.10) we sort 
other amines that had the same 1,3-connection of nitrogen atoms as in procainamide, in addition, 
we  used other cyclic  and modified amines to test whether the inhibitory ability of procainamide 
could be improved.  The synthesis started with conversion of 4-nitrobenzoic acid 82 to the acid 
chloride 83 using oxalyl chloride and dimethyl formamide, and then amide formation with 
respective amine groups in methylene chloride with catalytic amounts of triethylamine. 
Scheme 3.7 (a) Ac2O, DMAP (b) NBS, AIBN Benzene  (c) DIPEA -THF 
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Subsequently, the nitro group was reduced with palladium on carbon at in methanol (Scheme 
3.8). 
 
 
 
 
 
 
 
 
 
 
Several important molecules have been proposed and tested as potential Dnmt1 inhibitors and in 
this study many more structures have been added. In particular, isoindolinones and transition 
state nucleosides have been uncovered as potent potential inhibitors of Dnmt1. Furthermore, a 
number of diverse natural products have been discovered that share structural and electronic 
similarity as S-adenyl-L-methionine and S-adenyl-homocystiene (SAH), which are known 
substrate and product of methylase reaction respective. Also, pharmacophore design agrees with 
Scheme 3.8 (a) Oxalyl chloride, DMF,CH2Cl2 (b) RNH2, Et3N, CH2Cl2 (c) Pd/C, H2 1atm MeOH 
 
Figure 3.10: Procainamide analogues using diverse amine groups. 
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most of the structures proposed by CoMFA QSAR study and the structural scaffold is in line 
with tryptophan structures of RG108. 
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CHAPTER	  4	  
RESULST	  AND	  DISCUSSIONS	  
4.1	  Transition	  State	  Inhibitors	  
 
Design and development of transition state analogs as competitive inhibitors of   Dnmt1 
was our initial approach for discovery of novel epigenetic modulators. We hypothesized that 
deoxycytidine analogs with structures similar to the methyl-transfer step from the SAM cofactor 
to cytosine would have a greater binding affinity for the catalytic site of Dnmt1 compared to 
either the cytosine substrate or the SAM cofactor alone. Thus, we designed substrate analogs of 
deoxycytidine modified at the C5 position and compound 71 was the primary compound 
proposed. The compound contains three structural features resembling the transition state: first 
the cytosine substrate, the methylene-sulfur linker, and lastly a benzyl-1H-1,2,3-triazol 
heterocyclic moiety to represent the adenosyl portion of the  cofactor SAM. At the time, we 
reasoned that these three features would represent a starting point for the molecular descriptors 
of the substrate and the cofactor. Also, Stefely et al.[337] had shown that aryl amides of  benzyl-
1H-1,2,3-triazole   inhibit  cancer cell growth of MCF-7 human breast tumor cells with IC50 of 
46 nM . In addition,   methylation studies by Stein and Fatemi revealed that Dnmt1 binds 
preferable to hemi-methylated DNA [97b, 98]. In essence, our proposed inhibitor 71 captured the 
important triazole pharmacophore needed for anticancer activity and a cytosine substrate 
recognized by Dnmt1 for selectivity 
To further expand our library and study of substrate analogs, we designed and 
synthesized C5-amino derivatives of cytosine and thymidine (compounds 75 and 76 – 81) to 
complement compound 71.  Formerly, Ward[338] and Prusoff[339] highlighted pharmacological 
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Figure 4.1: ELISA Assay:  screening of C5 pyrimidine analog 71 and 75 with an ELISA assay for 
activity. Data represent the average values of triplicate measurements. Error bars represent SD of 
the triplicate biological measurement  
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interest of 5-substituted pyrimidine nucleoside for their antiviral and anticancer properties. 
However, for our study, we were interested in the possible binding and transfer of the methyl 
group from SAM to the C-5 amino pyrimidine derivatives. Since N-methylation can occur both 
at sp2 and sp3-N-atom in the heterocyclic bases as well as the C(5) cytosine, we figured 
introduction of cyclic amines with sp3-N-atom at C(5) position of cytosine will have interesting 
nucleophilic properties for methyl transfer.  Also, we previously discussed how chromatin 
structure can be regulated through N-methylation of specific lysines in the N-terminal tails of 
histone H3 and H4. Mechanistically, we considered N-methylation of compounds 75 and 76 – 81 
would be a non-covalent event with respect to Dnmt1 compared to the known aza-nucleotide 
suicidal inhibitors and we believed this class of compounds would be better inhibitors. 
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To evaluate the inhibitory activity of C(5)-pyrimidine, we used an enzyme-linked 
immunosorbent assay (ELISA) to screen  the first set of compounds for Dnmt1 inhibition. The 
assay was performed by Dr. Brooke Martin using the EpiQuik Dnmt1 Assay Kit  and showed 
that neither the thio-analogs nor the amino analog displayed any inhibitory activity at micro 
molar concentration (Figure 4.1). However, the C5-amino derivative 75 at 1 mM reduced the 
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activity of the enzyme by 35.6%. Though not a spectacular inhibitor, it shows that the amino 
functionalized nucleoside hold possible ability to inhibit Dnmt1.  
A second evaluation method using radioactive methyl transfer assay developed by Jeremy 
Alverson of the Priestley group was used to test the ability of nucleoside inhibitors to influence 
human Dnmt1 activity. The method is a medium-throughput screening assay that measures the 
direct incorporation of tritium (3H) into the oligonucleotide poly-deoxyinosinic-deoxycytidylic 
acid (poly(dI-dC).  Once again the data reaffirms the inactivity of 71 against Dnmt1 even at 1 
mM (Figure 4.2), however, 75 showed slight activity at the same high concentration (1 mM) 
  
 
Though both 71 and 75 showed no measureable inhibitory activity at 100 µM, hepatotoxicity 
studies of HepG2 cell revealed that both compounds have minimal to undetectable liver toxicity 
at concentrations greater than 500 µM. Implying that further development of 75 with attention to 
electronic and steric might give rise to less toxic inhibitors.  
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Figure 4.2: Radioactive Assay I - In vitro radioacitive assay to evaluate the effect of nucleoside and 
amines on Dnmt1. Unless state, all compounds are assayed at 100 uM. Data represent the average 
values of triplicate measurements. Error bars represent SD of the triplicate biological measurement  
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Discussion 
In summary, nucleoside inhibitors such as 5-azacytidine, 5-aza-2’-deoxycytidine and  zebularine 
are well established inhibitors of Dnmt1 and have been approved for the treatment of high-risk 
myelodyplastic syndrome (MDS) – a condition of ineffective production of myeloid in the blood. 
These drugs function as suicide inhibitors of Dnmt1 through irreversible covalent interaction 
with the enzyme and are incorporated into the DNA after phosphorylation. As such, we initiated 
an attempt to reengineer cytidine and thymidine at the C5 position to create compounds with 
similar activity but less toxic and more selective compared to the azanucleotides. Compound 75 
showed minor activity against Dnmt1 however this compound displayed a remarkable lack of 
toxicity at high concentration (>500) better than the azanucleotides, which are cytotoxic at high 
concentration and thus limit their pharmaceutical use. 
4.2	  Virtual	  Screening	  
 
Our second approach towards discovering novel competitive inhibitors of Dnmt1 
involved computational modeling. We obtained four unique organic structures (Figure 28) from 
docking over 5000 compounds in the catalytic pocket of Dnmt1 (PDB:3PTA) with  the 
AutoDock virtual screening program and to validate the result, two of these compounds were 
tested for inhibition of enzymatic activity. The radioactive assay showed that ZINC04710208 
(88SC) inhibits Dnmt1 with an IC50 of 233 µM, while, ZINC02835213 exhibited only slight 
inhibition even at 250 µM (Table 4.1).  Though ZINC01694996 and ZINC18140189 were not 
tested at the time, they are worth discussing a little further because of their peculiar steric and 
electronic features, which could interact with specific residues in an enzyme. Plus 
114 
 
ZINC18140189 has remarkable pharmaceutical importance and it is a known drug, phenytoin – 
a major first line antiepileptic drug (AED). 
Table 4.1: Radioactive assay of hit compounds from ZINC database. %Dnmt1 inhibition is based 
on [340]radioactive SAM  and CPM implies count per minute. 
Average CPM
2325.92 0.00 ± 125.46
8632.55 6306.64 ± 988.67 100.00 ± 15.68
3446.08 1120.17 ± 363.43 17.76 ± 32.44
2071.88 -­‐254.04 ± 225.0226 -­‐4.03 ± -­‐88.58
4890.06 2564.14 ± 270.5037 40.66 ± 10.55
8309.89 5983.97 ± 389.7078 94.88 ± 6.51
9396.28 7070.36 ± 1016.382 112.11 ± 14.38
Sample Corrected CPM % DNMT1 Activity
Blank NA
ZINC02835213	  (250	  µM)
Neg.	  Control	  (No	  inhibition)
Pos.	  Control	  (10	  µM	  SAH)
ZINC04710208-­‐	  88SC	  (500	  µM)
ZINC04710208	  88SC	  (250	  µM)
ZINC04710208	  (125	  µM)
 
 
Our interest in phenytoin is not for its antiepileptic properties but for one of its side reactions 
noticed with patients taking the drug. Phenytoin like procainamide, hydralazine, is known to cause 
drug induced-lupus[340], a condition that is reversible.  This observation aligns with  our discussion in 
chapter 2 where Cornacchia and colleagues observed that procainamide and hydralazine are 
capable of inducing a lupus-like syndrome in humans similar to  5-azacytidine when treated with 
cloned T cells.[302] Also  Rubin[340] has characterized 40 known drugs into three categories: high, 
low and very low risk of inducing lupus. His classification is based solely on the number of times 
these drugs appear in the literature in connection with drug-induced lupus, and this classification 
puts phenytoin in low risk category compared to procainamide and hydralazine. It is also worth 
adding that Eldredge[341] and colleagues had experimentally place phenytoin in the same low risk 
category based the interaction of  phenytoin and other lupus-inducing drugs with DNA. Again 
procainamide and hydralazine remained top on the list because they altered the optical rotation of 
native DNA in addition to lowering the melting temperature or native DNA. A clear indication 
that lupus-inducing drug mode of action might involve DNA interaction. 
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Finally, though Singh et al modeled procainamide and hydralazine interaction in the catalytic 
pocket of Dnmt1 as the main mode of inhibition, we cannot rule out DNA interaction with these 
molecules as another possible mode of action. However, for our current study, phenytoin will be 
a good starting molecule since it is a low drug-induced lupus compound, plus it has structural 
features and handles for lead development. Also, given that Singh et al computational studies 
implied that procaine and procainamide interact with similar residues as 5-azacytidine and it is 
possible that this group of drug-induced lupus might be competitive inhibitors of Dnmt1 as well. 
4.3	  Analogs	  of	  ZINC04710208	  (88SC) 
 
The next step of development for 88SC was to make analogs using the inherent synthetic 
handles: the carboxylic acid group and the naphthalene ring. First we decided to increase the 
polarity of the carboxylic acid pharmacophore functionality by converting them to amides, 
particularly because two cyclic amines (piperidine and piperazine) showed reasonable Dnmt1 
inhibition at a 100 µM by 78% and 59% respectively. Thus using the Plochl and Erlenmeyer 
reaction we constructed the oxazolone ring which was later opened with different primary and 
secondary amines to give compounds 4 – 14. Furthermore, to ascertain the importance of the 
interaction of the naphthalene ring to the activity of 88SC, we replaced the naphthalene groups 
with a number of free rotating and smaller aromatic rings and groups, compounds 15 – 21. 
Compared to SS8C, the amide and naphthalene modification showed no activity (Figure 
4.3). In fact, the amines or the carboxylic acid of 88SC showed more inhibitory activity alone 
than the amide. This implies that the sterics and conformation inflexibility of the naphthalene 
group locks it inside a hydrophobic pocket that allows the carboxylic acid to make polar 
interactions with important enzyme residues necessary for methylation. If this is the case, it 
116 
 
means the structure 88SC can be optimized with functional groups that either contributes to the 
hydrophobicity or polarity on either ends of the molecule. However, the synthetic handles on the 
molecule are few and if the hydrogen bonding interactions of the carboxylic acid are already 
optimal changing this group with classical (sulphonic acid or N-hydroxyamide)  or non-classical 
bioisoteres (sulfonamide or tetrazole)  of –COOH might not significantly increase activity. 
 
 
 
As a step forward towards discovery of anticancer agents through inhibition of Dnmt1, 
we exposed our amide 88SC analogs to human breast cancer cells MCF7 and normal breast cells 
MCF10.  After treatment of compounds 4 – 14 for 72h, none of the analogs, even compound 6 
(phenylpiperazine derivative), inhibited the growth of MCF-7 at 100 µM (Figure 4.4) 
Unfortunately, 88SC did not induce any inhibition of MCF7 and neither did 13, a 
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Figure 4.3: Radioactive Assay II: In vitro radioactive inhibition assay of 88SC analogs on 
Dnmt1 activity. All compounds are assayed at 100 µM. Data represent the average values of 
triplicate measurements. Error bars represent SD of the triplicate biological measurement  
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methylpiperazine amide of 88SC. However, piperazine derivatives have been reported to have 
antiproliferative activity against human cancer cell lines. Kumar et al.[342] reported 
antiproliferation activity of 1-benzhydrylpiperazine derivatives against MCF-7, HeLa, HT-29 
carcinoma cell lines. Also, Cao and colleagues demonstrated that 4-substituted-piperazine-1-
carbodithioate derivatives of 2,4-diaminoquinazoline exhibit a broad spectrum of inhibitory 
effects on MCF-7, HeLa HCT 116 and A549 with an IC50 value in the range of 2.76 – 4.12 
µM[343]. According to Cao, the 4-substituted – piperazine derivatives act by two possible 
mechanism, either as antifolates or DNA damage-inducing agents. 
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Figure 41.  MCF7 Assay: Treatment of   88SC analogs on on human breast cancer cell MCF -7. 
All compounds are assayed at 100 µM. Data represent the average values of triplicate 
measurements. Error bars represent SD of the triplicate biological measurement 
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In summary, though compound 88SC and piperazine amines showed moderate activity 
on Dnmt1 using radioactive assay, they failed to show corresponding effect on MCF7.  Our 
result indicates that the targets for both 88SC and its derivatives might differ in MCF7 cells in 
addition to the fact that they were only moderately active against Dnmt1. Also, the structure of 
our piperazine derivatives did not match similar targets as those discussed, which explains the 
absence of activity for our molecules since structure determines activity in this case. 
4.4	  Isoindolinones	  Compounds	  
 
Another virtual screening study conducted by the Priestley group using AutoDock Vina 
docking software and the promiliad library of compounds uncovered isoindolinones, as a novel 
class of Dnmt1 inhibitors with promising biological activity. In an effort to study this class of 
compounds further, we synthesized analogs of isoindolinones using the Ugi type reaction 
followed by an IMDAF reaction. By varying the amine and the isocyanide component of the Ugi 
4-component reaction, we synthesized a diverse library of isoindolinones analogs for testing 
(Figure 3.5).The synthesis was in two separate sets. The first set of indolinones had a free 
phenol group while the second set of compounds the phenolic OH was converted to an acetate 
group. 
The first sets of compounds were tested for Dnmt1 inhibition using the radioactive based 
assay and in addition tested against MCF-7 and MCF10 cells. The results from the radioactive 
testing showed activity against Dnmt1 at 100 µM (Figure 4.5) for any of the compounds, 
however compounds 32, 38, 44, and 45 showed moderate inhibition of MCF7 cells with IC50 less 
than 100 µM. ( Figure 4.6). These results suggest that isoindolinones might be more active in the 
MCF-7 cells compared to enzymatic assay with Dnmt1 or this group of compounds might exhibit 
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multiple targets in MCF7 cancer cells. The literature indicates that Watson et al.[344] had 
investigated the use of a different class of isoindolinones as anticancer agents; particularly they 
studied the versatility of isoindolinones as MDM2-p53 protein-protein interaction inhibitor. 
Briefly, in normal cells the balance between active p53 and inactive MDM2 is maintained by a 
negative feedback mechanism: the activity of p53 is tightly regulated by the MDM2 protein and 
vice versa[345]. Thus MDM2 can tightly bind to the transcriptional domain of p53 and block 
transcriptional activity. As such the use of isoindolinones as protein-protein modulator has the 
possibility to release p53 and promote apoptosis[346], which justifies their use as anticancer 
agents.  Thus for our study, in comparing the results from both the radioactive assay and the cell 
based there is a possibility  that these class of isoindolinones might have two or more targets in 
the cell  compared to our proposed selective inhibition of Dnmt1. 
 
 
Figure 4.5:  Radioactive Assay III: In vitro radioactive inhibition assay of Isoindolinone analogs 
I on Dnmt1 activity.  All compounds are assayed at 100 µM. Data represent the average values 
of triplicate measurements. Error bars represent SD of the triplicate biological measurement  
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Apart from its target, another interesting property of isoindolinones deduced from the cell 
based assay is their minimal toxicity to healthy breast cell MCF10 (Table 4.2). Generally, most 
of the isoindolinones with moderate activity against MCF7 only displayed minimum lethality 
against MCF10 even at concentration > 500 µM. This property or behavior of isoindolinones 
might indicate a selectivity for certain biological target(s) ( e.g MDM2 or Dnmt1) that is up 
regulated in cancer cells compared to non-cancerous cells, which is another indicator that 
isoindolinones   can be considered as good leads for anticancer agents. Enhancing the binding 
interactions between isoindolinones with these biological target(s) would help increase the 
selectivity and activity of these compounds as anticancer therapeutics. 
 
Figure 8 
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Table 4.2: IC50 values of Isoindolinones obtained from MCF7 and MCF10   cell assay 
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The second set of isoindolinone involved the introduction of tryptamine in the R1 postion 
(Table 4.3) and the modification of the phenolic OH to an acetate group. The major goal was to 
ascertain the importance of the OH group on isoinolinone for lethal activity against MCF7 and to 
investigate the possibility of using the OH group to introduce important moieties to increase 
binding affinity. Similarly, the choice of tryptamine for R1 was due in part to its 
pharmacological importance and its current use in RG108. Lastly, given the electronics of 
isoindolinones Tamoxifen (an antagonist of the estrogen receptor) was introduced as a positive 
control for the MCF7 cell assay.  Our results indicate Tamoxifen is both toxic to MCF7 and 
MCF10 cells at our test concentration, which was 148 µM and we intend to redo the assay at 
much lower concentrations to obtain a selective toxicity concentration for MCF7 over MCF10.  
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Table 4.3: R1, R2 groups and IC50 values of Isoindolinones obtained from MCF7 and MCF10 cell 
assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compounds 34,41,49,50, 51, Compound 54 – 58 98 
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The activity of the second set of isoindolinones against MCF7 gave similar results to the 
first set of compounds. Compound 46 had the lowest IC50 value of 66 µM while the other active 
compounds were within 75 to 115 µM, an indication of similar biological targets but poor 
binding interactions which can be optimized if the target is known. However, one interesting 
observation from this class of compounds is that all isoindolinones with tryptamine at the R1 
position (the amine) seem to exhibit some form of activity. It is possible that tryptamine might be 
a good pharmacophore to retain in the molecule or it can be used to modulate the activity of this 
class of isoindolinones. On the other hand, changing the phenolic OH to acetate on 
insoindolinone did not show a marked effect or – improvement in activity. Perhaps other 
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modification at this position might increase activity and selectivity but acetate group at this 
position did not give the desired boost expected from our investigation. 
4.5	  Beta	  –	  Carbolines	  
 
In chapter 3 our study on pharmacophore modeling using LigandScout and CoMFA 
indicated that certain β- carboline natural product exhibit molecular descriptors similar to known 
Dnmt1 inhibitors (Figure 4.7). To test the results from this model, we designed and synthesized 
five simple β-carbolines intermediates (Figure 4.8) using the Pictet–Spengler condensation 
method and tested the products directly on MCF7 cancer cells. All β- carboline tested showed 
toxicity against MCF10 and MCF7 cells except for compound 95 (Table 4.4). One interesting 
compound in this group is 96, which showed full lethality against MCF7 cells at 53µM but only 
had an IC50 value of 47.2±1.3 µM on MCF10. Further development of 96 might reveal selective 
toxicity concentration for MCF7 cells. In addition 96 showed a 25% inhibition of Dnmt1 at 250 
µM, this is 5% over compound 46, which was the most active compound against MCF7. 
 
 
 
 
 
   
Figure 4.7: Potential β-carboline natural product for development as Dnmt1 
  inhibitors obtain from pharmacophore modeling using LigandScout.  
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Figure 4.8: First line of simple β-carboline to test pharmacophore model results of LigandScout.  
 
 
Table 4.4:  IC50 values of β – carbolines  and Tamoxifen obtained for  MCF7 and MCF10 cell assay 
 
 
β-Carboline 
 
MCF10 IC50(µM) 
 
MCF7 IC50(µM) 
95 348.7±23.3 288.3±3.9 
97 425±11.7 417.2±3.2 
94 335.0±54.5 306.4±11.5 
93 >500 >500 
96 
Tamoxifen 
47.2±1.3 
42.8±2.1 
53.8±1.1 
40±1.2 
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Figure4.9: Radioactive Assay IV: Testing of β-carbolines for Dnmt1 activity at 250 µM 
 
 
In summary, though we have only synthesized a few simple tetrahydro-β-carbolines, the results 
from the cell assay suggest this class of compounds are promising anticancer agents. It is obvious 
that the activity of these compounds can be modulated by altering the substitution around the 
tetrahydro-β-carboline moiety; in 96 cuminaldehyde gave the best results. The isopropyl group 
might be residing inside a hydrophobic pocket in the target and this position can be exploited or 
optimized with similar groups or using the Topliss scheme for aliphatic side chain substituents.  
Also, though we see toxicity with β-carbolines and the pharmacophore model suggest that these 
compounds share similar molecular descriptors with other Dnmt1 inhibitors; literature search 
indicates other targets exist.  Skouta et al[347] researched β-carbolines as compounds with 
oncogene-RAS lethality while Xiao and colleagues[348] studied the intercalating property of β-
carboline and Deveau et al[349] investigated the beta-carbolines as topoisomerase II inhibitors.  
This is a clear indication of the versatility of this class of compounds and why it will be too early 
to conclude our compounds only interact with Dnmt1 given the fact that beta-carbolines can be 
fine-tuned to induce desired effect for any one target. 
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Future Work: 
Given the minimal toxicity of isoindolinones it will be beneficially to harness this property 
further and synthesize analogues with greater potency. One approach would be to use the 
hydroxyl groups to added pharmacophore that can change bindin g of these molecules to their 
therapeutic targets. Also, given the structural rigidity of isoindolinones, the added 
pharmacophore would create more interactions with residues in the Dnmt1. 
Since β-carbolines are still in their early design and development stages, it will be important to 
use more steric or lipophilic aldehyde in for their synthesis in other to study the significance of 
these groups at that position. More so, the free amine can be optimized with different groups. It 
might be that the free amine is important for activity or that it can be utilize to improve activity. 
 
 
 
Isoindolinone         β-carboline 
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CHAPTER	  5	  
EXPERIMENTAL:	  CHEMISTRY	  AND	  BIOLOGY	  
 
5.1	  CHEMISTRY	  EXPERIMENTAL	  	  
 
General Methods 
All reagents were obtained from commercial sources: Sigma, Acros, Fisher, Alfa Aesar and were 
used without further purification unless otherwise stated.  Sensitive reaction solvents were 
purified by distillation over the drying agents indicated and kept under argon: anhydrous 
tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from Na/benzophenone. 
Anhydrous dimethylsulfoxide (DMSO) was distilled over calcium hydride (CaH2). Anhydrous 
methanol was distilled over magnesium wire and potassium permanganate. Anhydrous N,N-
dimethylformamide (DMF),  1,1-dichloromethane , pyridine, benzene, triethylamine (Et3N TEA) 
and dioxane were purchased from commercial suppliers. 
All air sensitive and non-aqueous reactions were carried out in oven-dried glassware or flamed 
dried and magnetic stir bar and under an atmosphere of argon unless otherwise stated.  All 
aqueous solutions (sodium chloride, ammonium chloride, calcium carbonate) were prepared with 
deionized water; brine, refers to a saturated aqueous solution of non-iodized salt; water refers to 
deionized water. For all reactions, the drying of the organic phase was with anhydrous salts 
(K2CO3, MgSO4, Na2SO4 or as indicated) and filtered through a filter paper (fluted or folded) or 
cotton plug. Also, all solvent evaporation or concentration of sample was done with a Buchi 
rotary evaporator under reduced pressure. Thin-layer chromatography (TLC) was performed 
with  aluminum-backed Sigma-Aldrich Silica gel matrix with fluorescent indicator 254 nm added 
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for TLC plates visualization under Ultra-Violet light (254 and 365 nm). Column chromatography 
was performed with Silicylce Silica gel 60 (230-400 mesh) and the solvent systems used are 
reported as percentages. 
Compounds were characterized using Varian Unity Plus 500 MHz and Bruker Avance 400MHz. 
Nuclear magnetic resonance (NMR) and Mass Spectra (MS) – electrospray ionization 
spectroscopy (ESI) The radioactive assay was performed by Jeremy Alverson; ELISA by Brooke 
Martins and the MCF7 Assay was by Adrienne Sochia. 
 
5.1 Chemistry Experimental 
 
5.1.1	  General	  procedure	  for	  the	  naphthalenyl	  acrylamide	  
 
A suspension of N-acetylglycine (585 mg, 5 mmol), sodium acetate (410 mg, 5 mmol) and acetic 
anhydride (31mmol, 3mL) was added and stirred at room temperature for 30minutes. To this 
white suspension was added 2-naphthaldehyde (780 mg, 5 mmol). The resultant suspension was 
stirred at room temperature for 1 h and then at 60 0C for 5h. 75 mL of water was added after 
cooling to room temperature and stirred vigorously for 30min. The undissolved yellow solid was 
filtered and washed with water (3 x 3 mL) to give (Z)-2-methyl-4-(naphthalene-2-
ylmethylene)oxazol-5(4H)-one (100 mg,  0.4 mmol) which was then  refluxed with individual 
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amine in a methylene chloride for 2h. The solvent was removed under low pressure and the 
crude product purified by column chromatography 
 
 
4: (Z)-2-acetamido-N-((1-ethylpyrrolidin-2-yl)methyl)-3-(naphthalen-2-yl)acrylamide: 
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  2-(Aminomethyl)-1-ethylpyrrolidine  (64 mg, 0.5 mmols)) were refluxed 
in a methylene chloride for 2h. The solvent was removed under low pressure and the 
crude  purified by column chromatography was purified on silica gel in Methanol–EtOAc  
to give an off white solid (33 mg,  22.5%) 1H NMR (500 MHz, DMSO-d6) δ 9.58 (br. s., 
1H), 8.03 (s, 1H), 7.88 (d, J = 7.83 Hz, 2H), 7.84 (br. s., 1H), 7.67 (d, J = 8.31 Hz, 1H), 
7.47 - 7.57 (m, 2H), 7.15 (s, 1H), 3.11 - 3.18 (m, 2H), 3.01 (m, J = 3.42 Hz, 1H), 2.96 (m, 
J = 5.38 Hz, 1H), 2.78 (dd, J = 7.34, 11.74 Hz, 1H), 2.21 (dd, J = 7.34, 11.74 Hz, 1H), 
2.08 (q, J = 8.48 Hz, 1H), 2.01 (s, 3H), 1.69 - 1.79 (m, 1H), 1.61 (m., 2H), 1.50 - 1.57 (m, 
1H), 1.03 (t, J = 7.34 Hz, 3H) 13C NMR (126 MHz, DMSO-d6) δ 169.8, 165.3, 133.2, 
133.1, 132.3, 131.1, 129.7, 128.7, 128.3, 127.9, 127.7, 127.2, 126.9, 126.8, 62.8, 53.7, 
48.5, 43.1, 28.9, 23.1, 14. MS ES+ (M+1) 366.1944 
 
5: (Z)-2-acetamido-3-(naphthalen-2-yl)-N-(pyridin-2-ylmethyl)acrylamide: Compound 2 
(Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  0.4 mmol) and  
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2-pyridinylmethanamine (54 mg, 0.5 mmols)) were refluxed in a methylene chloride for 
2h. The solvent was removed under low pressure and the crude  purified by column 
chromatography was purified on silica gel in Methanol –EtOAc  to give an off white 
solid (118mg,  81.1%) . 1H NMR (500 MHz, DMSO-d6) d 9.68 (s, 1H), 8.71 - 8.80 (m, 
1H), 8.49 (d, J = 4.40 Hz, 1H), 8.10 (s, 2H), 7.87 - 7.94 (m, 2H), 7.70 - 7.79 (m, 1H), 
7.53 (dd, J = 3.18, 6.11 Hz, 2H), 7.43 (d, J = 7.83 Hz, 1H), 7.29 (s, 1H), 7.21 - 7.26 (m, 
2H), 4.49 (d, J = 5.87 Hz, 2H), 2.08 (s, 3H) 13C NMR (126 MHz, DMSO-d6) d 170.3, 
165.8, 159.4, 149.1, 137.0, 133.3, 133.1, 132.3, 130.9, 129.8, 128.7, 128.3, 127.9, 127.3, 
126.9, 122.4, 121.2, 45.2, 45.9, 23.4 MS ES+(M+1) 346.1292 
 
 
 
6: (Z)-2-acetamido-3-(naphthalen-2-yl)-N-(2-(pyrrolidin-1-yl)ethyl)acrylamide: Compound 
2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  0.4 mmol) 
and  2-(1-pyrrolidinyl)ethanamine (57mg, 0.5mmols)) were refluxed in a methylene 
chloride for 2h. The solvent was removed under low pressure and the crude purified by 
column chromatography was purified on silica gel in Methanol–EtOAc  to give an off 
white solid (61mg,  42%)  1H NMR (500 MHz, DMSO-d6) d 9.50 (s, 1H), 8.03 (s, 1H), 
7.96 (t, J = 5.87 Hz, 1H), 7.85 - 7.92 (m, 3H), 7.67 (d, J = 8.31 Hz, 1H), 7.45 - 7.55 (m, 
2H), 7.16 (s, 1H), 3.25 (q, J = 6.68 Hz, 2H), 2.44 (t, 6H), 2.02 (s, 3H), 1.66 (t, 4H) 13C 
NMR (126 MHz, DMSO-d6) d 169.8, 165.3, 133.1, 132.4, 131.0, 129.6, 128.7, 128.2, 
127.8, 127.2, 126.9, 126.8, 55.1, 54.1, 39.0, 23.6, 23.5 MS ES+(M+1) 352.1792 
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7: (Z)-ethyl-4-(2-acetamido-3-(naphthalen-2-yl)acrylamido)piperidine-1-carboxylate:  
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  ethyl 4-amino-1-piperidinecarboxylate (86mg, 0.5mmols)) were refluxed 
in a methylene chloride for 2h. The solvent was removed under low pressure and the 
crude purified by column chromatography was purified on silica gel in Methanol–EtOAc  
to give an off white solid (158mg,  97%) 1H NMR (500 MHz, DMSO-d6) d 9.49 (s, 2H), 
8.03 (s, 2H), 7.94 (d, J = 7.83 Hz, 2H), 7.86 - 7.91 (m, 4H), 7.67 (d, J = 8.31 Hz, 2H), 
7.51 (dd, J = 3.18, 6.11 Hz, 3H), 7.03 (s, 2H), 4.02 (q, J = 7.34 Hz, 4H), 1.94 - 2.06 (m, 
5H), 1.59 - 1.75 (m, 4H), 1.32 - 1.49 (m, 4H), 1.06 - 1.23 (m, 6H) 13C NMR (126 MHz, 
DMSO-d6) δ 169.7, 165.0, 155.1, 133.3, 133.0, 132.5, 131.4, 129.5, 128.6, 128.2, 127.9, 
126.9, 61.1, 46.8, 43.0, 31.5, 23.4, 15.1 
 
8: (Z)-2-acetamido-3-(naphthalen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)acrylamide:  
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  2,2,6,6-tetramethyl-4-piperidinamine (94 mg, 0.5 mmols)) were refluxed 
in a methylene chloride for 2h. The solvent was removed under low pressure and the 
crude purified by column chromatography was purified on silica gel in Methanol–EtOAc  
to give an off white solid (128 mg,  81%) 1H NMR (500 MHz, DMSO-d6) d 9.47 (s, 1H), 
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8.02 (s, 1H), 7.88 (d, J = 8.31 Hz, 4H), 7.82 (d, J = 7.83 Hz, 1H), 7.67 (d, J = 8.31 Hz, 
1H), 7.51 (dd, J = 3.18, 6.11 Hz, 3H), 7.01 (s, 1H), 4.13 (d, J = 8.31 Hz, 1H), 2.01 (s, 
4H), 1.75 - 1.77 (m, 1H), 1.56 - 1.64 (m, 3H), 1.14 (s, 9H), 1.11 (br. s., 2H), 1.09 (br. s., 
1H), 1.02 (s, 9H) 13C NMR (126 MHz, DMSO-d6) d 169.7, 164.8, 133.3, 133.0, 132.6, 
131.7, 129.5, 128.6, 128.2, 127.9, 126.9, 126.5, 109.9, 50.9, 44.5, 35.1, 29.1, 23.4 MS 
ES+(M+1) 394.4022 
 
 
 
9: (Z)-2-acetamido-N-(2,2-diphenylethyl)-3-(naphthalen-2-yl)acrylamide: Compound 2 (Z)-
2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  0.4 mmol) and  2,2-
diphenylethylamine (99 mg, 0.5 mmols)) were refluxed in a methylene chloride for 2h. 
The solvent was removed under low pressure and the crude purified by column 
chromatography was purified on silica gel in Methanol–EtOAc  to give an off white solid 
(105 mg,  61%). 1H NMR (500 MHz, DMSO-d6) d 9.47 (br. s., 1H), 8.02 (br. s., 1H), 
7.96 (br. s., 1H), 7.87 (d, J = 8.31 Hz, 2H), 7.61 (d, J = 8.80 Hz, 1H), 7.46 - 7.54 (m, 2H), 
7.26 - 7.35 (m, 6H), 7.20 (d, J = 5.38 Hz, 4H), 6.90 (s, 1H), 4.37 (t, J = 7.34 Hz, 2H), 
3.81 (t, J = 6.11 Hz, 2H), 1.98 (s, 3H) 13C NMR (126 MHz, DMSO-d6) d 169.8, 165.7, 
143.4, 133.1, 132.3, 131.2, 129.5, 128.9, 128.7, 128.5, 128.3, 127.9, 127.1, 126.8, 50.3, 
44.3, 23.3 MS ES+(M+1) 435.2386 
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10: (Z)-N-(3-(1H-imidazol-1-yl)propyl)-2-acetamido-3-(naphthalen-2-yl)acrylamide:  
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  3-(1H-imidazol-1-yl)-1-propanamine (63 mg, 0.5 mmols)) were refluxed 
in a methylene chloride for 2h. The solvent was removed under low pressure and the 
crude purified by column chromatography was purified on silica gel in Methanol–EtOAc  
to give an off yellow solid (140mg,  97%)  1H NMR (500 MHz, DMSO-d6) d 9.62 (s, 
1H), 8.19 (br. s., 1H), 8.05 (s, 1H), 7.89 (d, J = 7.83 Hz, 3H), 7.69 (d, J = 8.80 Hz, 1H), 
7.63 (s, 1H), 7.51 (dd, J = 3.18, 6.11 Hz, 2H), 7.19 (s, 1H), 7.07 (s, 1H), 6.87 (s, 1H), 
3.99 (t, J = 6.85 Hz, 2H), 3.06 - 3.20 (m, 2H), 2.04 (s, 3H), 1.77 - 1.93 (m, 2H) 13C NMR 
(126 MHz, DMSO-d6) d 170.1, 165.8, 137.8, 133.3, 133.0, 132.4, 131.5, 129.6, 128.7, 
128.7, 128.3, 127.9, 127.1, 126.9, 126.7, 119.8, 43.9, 36.6, 31.3, 23.4 MS ES+(M+1) 
363.1745 
 
11: (Z)-N-(1-(naphthalen-2-yl)-3-oxo-3-thiomorpholinoprop-1-en-2-yl)acetamide:  
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  thiomorpholine (51 mg, 0.5 mmols)) were refluxed in a methylene 
chloride for 2h. The solvent was removed under low pressure and the crude purified by 
column chromatography was purified on silica gel in Methanol–EtOAc  to give an off 
136 
 
white solid (93.8 mg,  97%)  1H NMR (500 MHz, DMSO-d6) d 9.95 (s, 1H), 8.04 (s, 
1H), 7.83 - 7.93 (m, 3H), 7.59 - 7.70 (m, 1H), 7.45 - 7.56 (m, 2H), 6.24 (s, 1H), 3.65 - 
3.91 (m, 4H), 2.53 - 2.76 (m, 4H), 1.93 - 2.08 (m, 3H) 13C NMR (126 MHz, DMSO-d6) 
d 169.6, 167.9, 133.4, 132.7, 132.3, 130.7, 128.7, 128.5, 128.3, 127.9, 127.1, 126.8, 
119.4, 49.8, 26.3, 22.8 MS ES+(M+1) 341.1450 
 
12: (Z)-2-acetamido-3-(naphthalen-2-yl)-N-(1-phenylethyl)acrylamide:  Compound 2 (Z)-2-
methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  0.4 mmol) and  1-
phenylethanamine (60 mg, 0.5 mmols)) were refluxed in a methylene chloride for 2h. The 
solvent was removed under low pressure and the crude purified by column 
chromatography was purified on silica gel in Methanol–EtOAc  to give an yellowish 
solid (128 mg,  97%)  70% yield  1H NMR (500 MHz, DMSO-d6) d 9.51 (d, J = 1.96 Hz, 
1H), 8.46 (d, J = 5.38 Hz, 1H), 8.05 (br. s., 1H), 7.85 - 7.95 (m, 3H), 7.70 (d, J = 7.34 Hz, 
1H), 7.51 (td, J = 3.36, 6.48 Hz, 2H), 7.37 - 7.44 (m, 2H), 7.18 - 7.35 (m, 3H), 7.10 (d, J 
= 2.45 Hz, 1H), 5.06 (dd, J = 4.89, 6.85 Hz, 1H), 1.88 - 2.09 (m, 3H), 1.37 - 1.51 (m, 3H) 
13C NMR (126 MHz, DMSO-d6) d 169.8, 165.0, 145.1, 133.3, 133.0, 132.5, 131.3, 
129.6, 128.7, 128.5, 128.2, 127.9, 127.1, 127.0, 126.9, 126.6, 48.7, 23.4, 22.6 MS 
ES+(M+1) 359.1882 
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13: (Z)-N-(3-(4-methylpiperazin-1-yl)-1-(naphthalen-2-yl)-3-oxoprop-1-en-2-yl)acetamide: 
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  1-methylpiperazine (50 mg, 0.5 mmols)) were refluxed in a methylene 
chloride for 2h. The solvent was removed under low pressure and the crude purified by 
column chromatography was purified on silica gel in Methanol–EtOAc  to give an off 
white  solid (107.6mg,  80%) . 1H NMR (500 MHz, DMSO-d6) d 9.90 (br. s., 1H), 8.03 
(br. s., 1H), 7.83 - 7.95 (m, 3H), 7.66 (d, J = 8.80 Hz, 1H), 7.42 - 7.58 (m, 2H), 6.21 (d, J 
= 1.96 Hz, 1H), 3.37 - 3.71 (m, 4H), 2.36 (br. s., 3H), 2.20 (d, J = 2.93 Hz, 4H), 1.88 - 
2.03 (m, 3H) 13C NMR (126 MHz, DMSO-d6) d 169.4, 167.5, 133.4, 132.7, 132.3, 130.9, 
128.7, 128.5, 128.3, 127.9, 127.1, 126.8, 119.7, 54.4, 51.7, 46.1, 43.2, 22.8 MS 
ES+(M+1) 338.1873 
 
 
 
14: (Z)-2-acetamido-N-(5-(diethylamino)pentan-2-yl)-3-(naphthalen-2-yl)acrylamide: 
Compound 2 (Z)-2-methyl-4-(naphthalene-2-ylmethylene)oxazol-5(4H)-one (100 mg,  
0.4 mmol) and  N1,N1-diethylpentane-1, 4-diamine (80mg, 0.51mmols)) were refluxed in 
a methylene chloride for 2h. The solvent was removed under low pressure and the crude 
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purified by column chromatography was purified on silica gel in Methanol–EtOAc  to 
give an off white  solid (152 mg,  92%) 1H NMR (500 MHz, DMSO-d6) d 9.54 (br. s., 
1H), 8.03 (br. s., 1H), 7.82 - 7.92 (m, 3H), 7.69 (d, J = 8.31 Hz, 1H), 7.51 (dd, J = 3.18, 
6.11 Hz, 2H), 7.07 (s, 1H), 3.90 (m, 1H), 3.18 (s, 2H), 2.42 (q, J = 6.85 Hz, 4H), 2.04 (s, 
3H), 1.31 - 1.53 (m, 4H), 1.10 (d, J = 6.36 Hz, 3H), 0.93 (t, J = 7.09 Hz, 6H) 13C NMR 
(126 MHz, DMSO-d6) d 169.7, 164.9, 133.3, 133.0, 132.6, 131.7, 129.5, 128.6, 127.9, 
127.0, 126.9, 126.8, 126.6, 52.6, 46.7, 45.2, 34.4, 24.0, 23.4, 21.2, 12.2 MS ES+:( M+1) 
396.2309 
5.1.2	  General	  Procedure	  for	  α-­‐(N-­‐Acylamino)-­‐α,β-­‐unsaturated	  acids	  
 
 
A suspension of N-acetylglycine (585 mg, 5 mmol), sodium acetate (410 mg, 5 mmol) 
and acetic anhydride (3 mL, 31 mmol) was added and stirred at room temperature for 
30min to give a white suspension. phenyl-4-carboxaldehyde (911 mg, 5 mmol) was 
added  and the resultant suspension was stirred at room temperature for 1hr  and then at 
60 0C for 5h. After 5h and disappearance of the aldehyde as noted by TLC, 75mL of 
water was added after cooling to room temperature and stirred vigorously for 30min. The 
undissolved yellow solid was filtered and washed with water (3 x 3mL) and then refluxed 
in a solution of Acetone:water (3:1) 12 mL for 2h. Solvent was removed under low 
pressure and purified using column chromatography 20% MeOH/EtOAc to give the 
corresponding α-(N-Acylamino)-α,β-unsaturated acids. 
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15: (Z)-2-acetamido-3-(4-(methoxycarbonyl)phenyl)acrylic acid:  A  suspension of N-
acetylglycine (468mg, 4mmol), sodium acetate (328 mg, 4 mmol) and acetic anhydride 
(2450 mg, 24 mmol,) was added and stirred at room temperature for 30min to give a 
white methyl 4-formylbenzoate (755 mg, 5 mmol) was added  and the resultant 
suspension was stirred for 1hr at room temperature and then at 60o C for 12 h. After the 
disappearance of the aldehyde as noted by TLC, 75mL of water was added after cooling 
to room temperature and stirred vigorously for 30min. The undissolved yellow solid was 
filtered and washed with water (3 x 3mL) and then refluxed in a solution of 
Acetone:water (3:1) 12 mL for 2h. Solvent was removed under low pressure and purified 
using column chromatography 20% MeOH-EtOAc to give a yellow solid. (138mg, 13.2% 
- over two steps) 1H NMR (500 MHz, DMSO-d6) d 12.81 (br. s., 1H), 9.55 (br. s., 1H), 
8.19 (br. s., 1H), 7.73 - 7.98 (m, 2H), 7.53 (br. s., 1H), 7.27 (br. s., 1H), 3.85 (br. s., 3H), 
1.98 (br. s., 3H) 13C NMR (126 MHz, DMSO-d6) d 169.5, 166.6, 166.4, 134.8, 130.4, 
130.3, 130.1, 129.8, 129.5, 128.7, 52.7, 22.9 
 
16: (Z)-2-acetamido-3-(quinolin-4-yl)acrylic acid:  A suspension of N-acetylglycine (585 
mg, 5mmol), sodium acetate (410 mg, 5 mmol) and acetic anhydride (31 mmol, 3mL) 
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was added and stirred at room temperature for 30minutes to give a white suspension 4-
quinolinecarbaldehyde (785 mg, 5 mmol) was added  and the resultant suspension was 
stirred for 1hr at room temperature and then at 60o C for 5h. After 5h and disappearance 
of the aldehyde as noted by TLC, 75mL of water was added after cooling to room 
temperature and stirred vigorously for 30min. The undissolved yellow solid was filtered 
and washed with water (3 x 3mL) and then refluxed in a solution of Acetone:water (3:1) 
12 mL for 2h. Solvent was removed under low pressure and purified using column 
chromatography 20% MeOH-EtOAc to give yellow solid. (487 mg, 38% - over two 
steps).  1H NMR (500 MHz, DMSO-d6) δ 13.07 (br. s., 1H), 9.54 (br. s., 1H), 8.89 (d, J = 
4.40 Hz, 1H), 8.04 (d, J = 8.31 Hz, 1H), 7.97 (d, J = 8.31 Hz, 1H), 7.77 (t, J = 7.34 Hz, 
1H), 7.61 (t, J = 7.34 Hz, 1H), 7.52 (br. s., 1H), 7.50 (d, J = 3.91 Hz, 1H), 1.83 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 169.6, 166.2, 150.6, 148.4, 140.1, 132.7, 130.0, 127.3, 
126.1, 124.9, 120.6, 109.2, 60.3, 22.8 MS ES+: (M+1)257.0090 
 
 
 
17: (Z)-2-acetamido-3-(naphthalen-1-yl)acrylic acid: A suspension of N-acetylglycine (585 
mg, 5 mmol), sodium acetate (410 mg, 5 mmol) and acetic anhydride (31 mmol, 3mL) 
was added and stirred at room temperature for 30minutes to give a white suspension 2-
naphthaldehyde (785 mg, 5 mmol) was added  and the resultant suspension was stirred 
for 1hr at room temperature and then at 60o C for 5h. After 5h and disappearance of the 
aldehyde as noted by TLC, 75mL of water was added after cooling to room temperature 
and stirred vigorously for 30min. The undissolved yellow solid was filtered and washed 
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with water (3 x 3mL) and then refluxed in a solution of Acetone:water (3:1) 12 mL for 
2h. Solvent was removed under low pressure and purified using column chromatography 
20% MeOH-EtOAc to give yellow solid. (487 mg, 38% - over two steps).1H NMR (500 
MHz, DMSO-d6) Shift 12.72 (br. s., 1H), 9.57 (s, 1H), 8.11 (s, 1H), 7.90 (d, J = 7.83 Hz, 
3H), 7.74 (d, J = 8.80 Hz, 1H), 7.50 - 7.56 (m, 2H), 7.35 (s, 1H), 2.01 (s, 3H) 13C NMR 
(126 MHz, DMSO-d6) δ 169.7, 166.9, 133.3, 133.2, 131.9, 130.4, 128.8, 128.3, 128.0, 
127.9, 127.5, 127.0, 126.9, 23.1 
 
18: (Z)-2-acetamido-3-(3-(benzyloxy)phenyl)acrylic acid:  A  suspension of N-acetylglycine 
(585 mg, 5 mmol), sodium acetate (410 mg, 5 mmol) and acetic anhydride (31 mmol, 
3mL) was added and stirred at room temperature for 30minutes to give a white 
suspension 3-(benzyloxy)benzaldehyde (785 mg, 5 mmol) was added  and the resultant 
suspension was stirred for 1hr at room temperature and then at 60o C for 12 h. After the 
disappearance of the aldehyde as noted by TLC, 75mL of water was added after cooling 
to room temperature and stirred vigorously for 30min. The undissolved yellow solid was 
filtered and washed with water (3 x 3mL) and then refluxed in a solution of 
Acetone:water (3:1) 12 mL for 2h. Solvent was removed under low pressure and purified 
using column chromatography 20% MeOH-EtOAc to give yellow solid. (338.4mg, 25% - 
over two steps). 1H NMR (500 MHz, DMSO-d6) d 12.67 (br. s., 1H), 9.49 (s, 1H), 7.41 - 
7.45 (m, 2H), 7.38 (t, J = 7.34 Hz, 2H), 7.24 - 7.34 (m, 3H), 7.19 (d, J = 7.83 Hz, 1H), 
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7.15 (s, 1H), 7.00 (d, J = 6.85 Hz, 1H), 5.10 (s, 2H), 1.95 (s, 3H) 13C NMR (126 MHz, 
DMSO-d6) d 169.6, 166.8, 158.7, 137.4, 135.4, 131.1, 130.1, 128.9, 128.3, 128.1, 122.7, 
116.2, 69.6, 22.9 
 
19:  (Z)-2-acetamido-3-(4-phenoxyphenyl)acrylic acid: A  suspension of N-acetylglycine (585 
mg, 5 mmol), sodium acetate (410 mg, 5 mmol) and acetic anhydride (31 mmol, 3mL) 
was added and stirred at room temperature for 30minutes to give a white suspension 4-
phenoxybenzaldehyde (991 mg, 5 mmol) was added  and the resultant suspension was 
stirred for 1hr at room temperature and then at 60o C for 12 h. After the disappearance of 
the aldehyde as noted by TLC, 75mL of water was added after cooling to room 
temperature and stirred vigorously for 30min. The undissolved yellow solid was filtered 
and washed with water (3 x 3mL) and then refluxed in a solution of Acetone:water (3:1) 
12 mL for 2h. Solvent was removed under low pressure and purified using column 
chromatography 20% MeOH-EtOAc to give a white solid. (460mg, 31% - over two 
steps). 1H NMR (500 MHz, DMSO-d6) d 12.71 (br. s., 1H), 9.41 (s, 1H), 7.39 (td, J = 
4.10, 7.95 Hz, 3H), 7.31 (d, J = 7.34 Hz, 1H), 7.23 (br. s., 1H), 7.12 - 7.19 (m, 2H), 6.96 - 
7.06 (m, 3H), 1.80 (s, 3H) 13C NMR (126 MHz, DMSO-d6) d 169.4, 166.9, 157.3, 156.6, 
136.0, 130.6, 128.4, 124.2, 119.7, 119.4, 118.9, 22. MS ES+: (M+1) 298.0468 
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20: (Z)-2-acetamido-3-(4-cyanophenyl)acrylic acid: A  suspension of N-acetylglycine (585 
mg, 5 mmol), sodium acetate (410 mg, 5 mmol) and acetic anhydride (31 mmol, 3mL) 
was added and stirred at room temperature for 30minutes to give a white suspension 4-
cyanobenzaldehyde (755 mg, 5 mmol) was added  and the resultant suspension was 
stirred for 1hr at room temperature and then at 60o C for 12 h. After the disappearance of 
the aldehyde as noted by TLC, 75mL of water was added after cooling to room 
temperature and stirred vigorously for 30min. The undissolved yellow solid was filtered 
and washed with water (3 x 3mL) and then refluxed in a solution of Acetone:water (3:1) 
12 mL for 2h. Solvent was removed under low pressure and purified using column 
chromatography 20% MeOH-EtOAc to give a yellow solid. (174 mg, 15.2% - over two 
steps).1H NMR (500 MHz, DMSO-d6) δ 12.96 (br. s., 1H), 9.65 (br. s., 1H), 7.84 (d, J = 
7.83 Hz, 2H), 7.75 (d, J = 7.83 Hz, 2H), 7.20 (br. s., 1H), 1.99 (br. s., 3H) 13C NMR (126 
MHz, DMSO-d6) d 169.7, 167.0, 133.4, 133.2, 132.0, 130.5, 128.9, 128.4, 128.1, 128.0, 
127.6, 127.1, 126.9, 40.5, 40.4, 40.2, 40.0, 39.8, 39.7, 39.5, 38.8, 23.1, 0.6 
 
21: (Z)-2-acetamido-3-(4-nitrophenyl)acrylic acid: A  suspension of N-acetylglycine (585 
mg, 5 mmol), sodium acetate (410 mg, 5 mmol) and acetic anhydride (31 mmol, 3mL) 
was added and stirred at room temperature for 30minutes to give a white suspension 4-
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nitrobenzaldehyde (755 mg, 5 mmol) was added  and the resultant suspension was stirred 
for 1hr at room temperature and then at 60o C for 12 h. After the disappearance of the 
aldehyde as noted by TLC, 75mL of water was added after cooling to room temperature 
and stirred vigorously for 30min. The undissolved yellow solid was filtered and washed 
with water (3 x 3mL) and then refluxed in a solution of Acetone:water (3:1) 12 mL for 
2h. Solvent was removed under low pressure and purified using column chromatography 
20% MeOH-EtOAc to give a yellow solid. (788mg, 63% - over two steps). 1H NMR (500 
MHz, DMSO-d6) δ 13.00 (br. s., 1H), 9.69 (br. s., 1H), 8.21 (d, J = 8.32 Hz, 2H), 7.80 (d, 
J = 8.31 Hz, 2H), 7.21 (br. s., 1H), 2.48 (br. s., 1H), 1.98 (br. s., 3H) 13C NMR (126 
MHz, DMSO-d6) d 169.1, 166.0, 146.8, 140.9, 130.5, 130.4, 127.1, 123.5, 22. 
 
5.1.3	  Isoindolinone	  Synthesis	  
 
 
24: ethyl 3-(4-(trifluoromethyl)phenyl)propiolate:  To  a solution of 1-iodo-4-
(trifluromethyl)benzene (554 mg, 2 mmol) and ethyl propiolate (784.8 mg, 4 mmol) in THF (3 
mL) were added bis(triphenylphosphine)palladium(II)chloride (28 mg, 0.02 mmol),  copper 
iodide(15 mg, 0.04 mmol) and potassium carbonate (552 mg, 2 mmol). The mixture was stirred 
at 60o C for 3 h then cooled and filtered through celite (7 g) rinsing with diethyl ether. 
Subsequently, the solvent was removed by rotavap. Product was purified using column 
chromatography (10% Ethyl Acetate/Hexanes). Yield (82%). 1H NMR (500 MHz, 
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CHLOROFORM-d) d 8.12 - 8.57 (m, 2H), 7.61 - 7.95 (m, 2H), 4.31 (br. s., 2H), 1.35 (br. s., 3H) 
13C NMR (126 MHz, CHLOROFORM-d) d 153.5, 133.1, 132.3, 132.0, 125.5, 124.6, 123.5, 
83.8, 82.3, 62.3, 14.0 
 
25: 3-(4-(trifluoromethyl)phenyl)propiolic acid: Potassium Hydroxide (70 mg, 1.5 mmol) 
was added in small portions to ethyl 3-(4-(trifluromethyl)phenyl) propiolate  (203 
mg, 0.84 mmol) in THF:H2O (5 mL) mix solvent at 0oC and warmed up to room 
temperature. The solution was stirred at room temperature for 6h. The solvent was 
removed by rotavap and the crude diluted with water (2 mL) and pH adjusted to 3. 
It was then filtered and dried to give a white powder (142 mg, 74%). 1H NMR (500 
MHz, DMSO-d6) δ 8.37 (br. s., 9H), 8.00 (br. s., 10H) 13C NMR (126 MHz, 
CHLOROFORM-d) δ 153.7, 148.5, 133.7, 126.2, 123.7, 83.8, 83.1 
 
General preparation of isoindolines 
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Step I: One molar solution of furfural (41 µL 0.5 mmol), benzylamine (54ul, 0.5mmol), 
3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and n-butylisocyanide 
(52 µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon 
for 12 h. The Ugi product was purified by flash chromatography (40% EtoAc: Hexane) to 
give a mixture of three products that was used in the next step.  
Step II: 0.02 M of the Ugi product (20 mg, 0.04mmol) was prepared in Dioxane (2 mL), 
ytterbium(III) trifluoromethanesulfonate  (5 mg, 0.008 mmol) was added and heated in a 
sealed tube at 100 oC  for 12 h. The solvent was removed by rotavap and product purified 
by flash chromatography (70% EtoAc : Hexane) to the corresponding isoindolinone as a 
white solid. 
 
 
32: N-(tert-butyl)-5-hydroxy-3-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide:  Step I: One molar solution of 
freshly distilled furfural (82 µL 1mmol), 1,2,3,4-tetrahydro-1-naphthalenamine (146 µL, 
1 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (214 mg, 1 mmol) and n-
butylisocyanide (104 µL, 1 mmol)  was made up  in MeOH (4 mL) and stirred in the dark 
under argon for 12 h. The Ugi product was purified by flash chromatography first with 
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CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a 
mixture of three Ugi products that was used in the next step.     Step II: 0.02 M of the Ugi 
product (350 mg, 0.67 mmol) was prepared in Dioxane 14 mL) ,  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (103 mg, 0.167 mmol) was added and the reaction heated at 
100o C  in a sealed tube for 12 h. The solvent was removed by rotavap and product 
purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white 
solid (308 mg, 59% over two steps). 1H NMR (500 MHz, DMSO-d6) Shift 9.95 (s, 1H), 
8.49 (br. s., 1H), 7.73 (d, J = 7.83 Hz, 1H), 7.59 (d, J = 7.83 Hz, 1H), 7.16 - 7.26 (m, 1H), 
7.12 (br. s., 1H), 7.04 - 7.09 (m, 1H), 6.70 (d, J = 7.34 Hz, 1H), 5.32 (d, J = 4.89 Hz, 1H), 
4.71 (s, 1H), 3.34 (s, 1H), 3.07 (d, J = 3.91 Hz, 1H), 2.72 (br. s., 1H), 1.87 - 2.07 (m, 1H), 
1.63 - 1.84 (m, 1H), 1.33 - 1.43 (m, 1H), 1.22 - 1.31 (m, 1H), 0.55 - 1.06 (m, 3H) 13C 
NMR (126 MHz, DMSO-d6) Shift 169.0, 168.7, 155.5, 138.3, 138.1, 135.7, 134.3, 132.1, 
129.7, 129.4, 127.3, 126.6, 124.5, 124.1, 122.9, 119.9, 60.5, 51.3, 31.3, 29.4, 28.2, 22.3, 
19.9, 14.0 
 
33: N-butyl-2-(2,2-diphenylethyl)-5-hydroxy-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindoline-
1-carboxamide: Step I: One molar solution of freshly distilled furfural (41 µL 0.5 mmol), 
2,2-diphenylethylamine (98 mg, 0.5 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid 
(107 mg, 0.5 mmol) and n-butylisocyanide (52 µL, 0.5 mmol)  was made up  in MeOH (2 
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mL) and stirred in the dark under argon for 12 h. The Ugi product was purified by flash 
chromatography first with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 
20% &40%)) to give a mixture of three Ugi products that was used in the next step.  Step 
II: 0.02M of the Ugi product (160 mg, 0.27 mmol) was prepared in Dioxane (6 mL).  
20mol% ytterbium(III) trifluoromethanesulfonate  (43 mg, 0.067 mmol) was added and 
the reaction heated at 100o C  in a sealed tube for 12 h. The solvent was removed by 
rotavap and product purified by flash chromatography twice (70% & 35% EtoAc-
Hexane) to give a white solid (130 mg, 11.4% over two steps). 1H NMR (500 MHz, 
DMSO-d6) Shift 9.87 (br. s., 1H), 8.54 (br. s., 1H), 7.67 (d, J = 7.34 Hz, 2H), 7.42 (d, J = 
7.34 Hz, 2H), 7.14 - 7.31 (m, 8H), 7.10 (dd, J = 7.58, 19.81 Hz, 2H), 4.66 (br. s., 1H), 
4.41 - 4.48 (m, 1H), 4.29 - 4.36 (m, 1H), 3.33 (dd, J = 6.85, 14.18 Hz, 1H), 3.07 - 3.15 
(m, 2H), 2.46 (br. s., 2H), 1.36 - 1.45 (m, 2H), 1.21 - 1.33 (m, 2H), 0.43 - 0.99 (m, 3H) 
13C NMR (126 MHz, DMSO-d6) Shift 167.7, 167.2, 155.4, 142.9, 141.9, 138.2, 133.2, 
132.1, 131.9, 129.2, 129.1, 128.2, 128.1, 127.9, 127.8, 127.6, 127.1, 126.1, 124.2, 124.1, 
123.9, 123.1, 119.5, 110.0, 62.0, 49.4, 45.4, 39.0, 31.5, 19.9, 14.0 
 
34: 2-benzyl-N-butyl-4-(4-(trifluoromethyl)phenyl)-5-hydroxy-3-oxoisoindoline-1-
carboxamide:  Step I: One molar solution of freshly distilled furfural (62 µL 0.75 mmol), 
benzylamine (81 µL, 0.75 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (160 mg, 
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0.75 mmol) and n-butylisocyanide (78 µL, 0.75 mmol)  was made up  in MeOH (2 mL) 
and stirred in the dark under argon for 12 h. The Ugi product was purified by flash 
chromatography first with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 
20% &40%)) to give a mixture of three Ugi products that was used in the next step. Step 
II: 0.02M of the Ugi product (270 mg, 0.27 mmol) was prepared in Dioxane (6 mL).  20 
mol% ytterbium(III) trifluoromethanesulfonate  (86 mg, 0.13 mmol) was added and the 
reaction heated at 100o C  in a sealed tube for 12 h. The solvent was removed by rotavap 
and product purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give 
a white solid (130mg, 34.4% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 9.95 (s, 
1H), 8.44 - 8.64 (m, 1H), 7.75 (d, J = 8.03 Hz, 2H), 7.58 (d, J = 8.03 Hz, 2H), 7.28 - 7.42 
(m, 4H), 7.20 (d, J = 8.03 Hz, 2H), 5.08 (d, J = 15.06 Hz, 1H), 4.79 (s, 1H), 3.91 (d, J = 
15.31 Hz, 1H), 3.35 (s, 1H), 3.00 - 3.25 (m, 2H), 1.28 - 1.48 (m, 4H), 0.91 (t, J = 7.15 
Hz, 3H) 13C NMR (101 MHz, DMSO-d6) δ 167.2, 166.8, 155.1, 137.9, 136.9, 132.9, 
131.6, 128.8, 128.7, 127.9, 127.5, 127.4, 124.1, 123.7, 123.2, 122.7, 119.3, 61.0, 44.3, 
38.5, 31.0, 19.5, 13.6 
 
35: 2-benzyl-5-hydroxy-N-isopropyl-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindoline-1-
carboxamide:  Step I: One molar solution of freshly distilled furfural (41 µL 0.5 mmol), 
benzylamine (54 µL, 0.5 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 
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0.5 mmol) and isopropyl isocyanide (47 µL, 0.5 mmol)  was made up  in MeOH (2 mL) 
and stirred in the dark under argon for 12 h. The Ugi product was purified by flash 
chromatography first with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 
20% &40%)) to give a mixture of three Ugi products that was used in the next step.  Step 
II: 0.02 M of the Ugi product (143 mg, 0.31 mmol) was prepared in Dioxane (6 mL).  
20mol% ytterbium(III) trifluoromethanesulfonate  (47 mg, 0.07 mmol) was added and the 
reaction heated at 100o C  in a sealed tube for 12 h. The solvent was removed by rotavap 
and product purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give 
a white solid (62 mg, 7.0% over two steps). 1H NMR (400 MHz, DMSO-d6) δ 9.95 (s, 
1H), 9.80 - 10.10 (m, 1H), 8.47 (d, J = 7.53 Hz, 1H), 8.31 - 8.63 (m, 1H), 7.75 (d, J = 
8.03 Hz, 1H), 7.58 (d, J = 8.03 Hz, 1H), 7.27 - 7.40 (m, 4H), 7.21 (d, J = 7.78 Hz, 3H), 
5.07 (d, J = 15.06 Hz, 1H), 4.77 (s, 1H), 3.87 - 3.97 (m, 2H), 1.12 (dd, J = 6.78, 8.78 Hz, 
6H) 13C NMR (101 MHz, DMSO-d6) δ 167.2, 165.8, 155.0, 137.9, 136.9, 132.9, 131.6, 
128.8, 128.7, 128.0, 127.5, 127.2, 125.9, 124.1, 123.7, 122.6, 119.3, 60.9, 44.3, 40.9, 22.2 
 
 
36: 5-hydroxy-N-isopropyl-3-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (62 µL 0.75mmol), 1,2,3,4-tetrahydro-1-naphthalenamine (110 
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µL, 0.75 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (160 mg, 0.75 mmol) and 
isopropyl isocyanide (70 µL, 0.75 mmol)  was made up  in MeOH (3 mL) and stirred in 
the dark under argon for 12fh. The Ugi product was purified by flash chromatography 
first with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to 
give a mixture of three Ugi products that was used in the next step. Step II: 0.02M of the 
Ugi product (96 mg, 0.18 mmol) was prepared in Dioxane (4 mL).  20mol% 
ytterbium(III) trifluoromethanesulfonate  (30 mg, 0.04 mmol) was added and the reaction 
heated at 100o C  in a sealed tube for 12 h. The solvent was removed by rotavap and 
product purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give a 
white solid (63 mg, 9.3% over two steps) 1H NMR (500 MHz, DMSO-d6) δ 9.93 (s, 1H), 
8.41 (d, J = 7.34 Hz, 1H), 7.71 (d, J = 7.83 Hz, 3H), 7.57 (d, J = 7.83 Hz, 1H), 7.14 - 
7.27 (m, 1H), 7.02 - 7.12 (m, 2H), 6.71 (d, J = 7.34 Hz, 1H), 5.28 (d, J = 5.38 Hz, 1H), 
4.68 (s, 1H), 3.80 (d, J = 6.36 Hz, 1H), 3.34 - 3.34 (m, 1H), 3.33 (s, 1H), 2.71 (br. s., 3H), 
2.48 (br. s., 1H), 1.61 - 2.03 (m, 4H), 1.01 - 1.11 (m, 6H) 13C NMR (126 MHz, DMSO-
d6) δ 168.9, 167.7, 155.5, 138.3, 138.1, 135.8, 134.3, 132.1, 129.7, 129.4, 127.3, 126.6, 
126.5, 124.5, 124.1, 122.8, 119.9, 60.4, 51.2, 41.3, 29.4, 28.2, 22.6, 22.2 
 
37: 2-(2,2-diphenylethyl)-5-hydroxy-N-isopropyl-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide:  Step I: One molar solution of 
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freshly distilled furfural (41 µL 0.5 mmol), 2,2-diphenylethylamine (98 mg, 0.5 mmol), 
3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and isopropyl 
isocyanide (47 µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark 
under argon for 12 h. The Ugi product was purified by flash chromatography first with 
CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a 
mixture of three Ugi products that was used in the next step.  Step II: 0.02M of the Ugi 
product (210 mg, 0.37 mmol) was prepared in Dioxane (8 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (58  mg, 0.09  mmol) was added and the reaction heated at 
100o C  in a sealed tube for 12 h. The solvent was removed by rotavap and product 
purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white 
solid (190 mg, 25.5% over two steps). 1H NMR (500 MHz, DMSO-d6) Shift 9.90 (br. s., 
1H), 8.55 (d, J = 7.34 Hz, 1H), 7.70 (d, J = 7.34 Hz, 1H), 7.44 (d, J = 6.85 Hz, 2H), 7.09 - 
7.34 (m, 10H), 4.68 (br. s., 1H), 4.45 (d, J = 13.21 Hz, 1H), 4.35 (d, J = 6.36 Hz, 1H), 
3.90 (br. s., 1H), 3.34 (br. s., 2H), 1.08 - 1.18 (m, 6H) 13C NMR (126 MHz, DMSO-d6) δ 
167.7, 166.2, 155.4, 142.9, 142.0, 138.2, 133.3, 132.0, 129.3, 128.9, 127.8, 124.2, 61.9, 
49.5, 45.4, 41.5, 22.7 
	  
38: 2-benzyl-N-cyclohexyl-5-hydroxy-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindoline-1-
carboxamide carboxamide:  Step I: One molar solution of freshly distilled furfural (41 
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µL 0.5 mmol), benzylamine (54 µL, 0.5 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic 
acid (107 mg, 0.5 mmol) isocyanocyclohexane (62µL, 0.5 mmol)  was made up  in 
MeOH (2 mL) and stirred in the dark under argon for 12 h. The Ugi product was purified 
by flash chromatography first with CH2Cl2 and then gradient elution with EtoAc-Hexane 
(10%, 20% &40%)) to give a mixture of three Ugi products that was used in the next 
step.  Step II: 0.02 M of the Ugi product (121 mg, 0.23 mmol) was prepared in Dioxane 
(5 mL).  20mol% ytterbium(III) trifluoromethanesulfonate  (36 mg, 0.07 mmol) was 
added and the reaction heated at 100o C  in a sealed tube for 12 h. The solvent was 
removed by rotavap and product purified by flash chromatography twice (70% & 35% 
EtoAc-Hexane) to give a white solid (90 mg, 8.9% over two steps) 1H NMR (400 MHz, 
DMSO-d6) d 9.95 (s, 1H), 8.47 (d, J = 8.03 Hz, 1H), 7.75 (d, J = 8.28 Hz, 2H), 7.58 (d, J 
= 8.28 Hz, 2H), 7.31 - 7.39 (m, 4H), 7.20 (d, J = 8.03 Hz, 2H), 5.07 (d, J = 15.31 Hz, 
1H), 4.79 (s, 1H), 3.91 (d, J = 15.06 Hz, 1H), 3.60 (d, J = 7.78 Hz, 1H), 3.36 (s, 1H), 1.53 
- 1.87 (m, 5H), 1.13 - 1.38 (m, 5H) 13C NMR (101 MHz, DMSO-d6) d 167.2, 165.8, 
155.0, 138.3, 136.9, 133.0, 131.6, 128.8, 128.7, 128.0, 127.4, 125.9, 124.1, 123.7, 122.7, 
119.3, 60.8, 47.9, 44.3, 32.3, 32.3, 25.1, 24.4 
	  
39: N-cyclohexyl-5-hydroxy-3-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide P1: Step I: One molar solution of 
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freshly distilled furfural (82 µL 1 mmol), 1,2,3,4-tetrahydro-1-naphthalenamine (146 µL, 
1 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (214 mg, 1 mmol) and 
isocyanocyclohexane (124 µL, 1 mmol)  was made up  in MeOH (4 mL) and stirred in 
the dark under argon for 12 h. The Ugi product was purified by flash chromatography 
first with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to 
give a mixture of three Ugi products that was used in the next step.     Step II: 0.02 M of 
the Ugi product (236 mg, 0.43 mmol) was prepared in Dioxane 9mL) ,  20 mol% 
ytterbium(III) trifluoromethanesulfonate  (66 mg, 0.107 mmol) was added and the 
reaction heated at 100o C  in a sealed tube for 12 h. The solvent was removed by rotavap 
and product purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give 
a white solid (114 mg, 20% over two steps). 1H NMR (400 MHz, DMSO-d6) δ 9.95 (s, 
1H), 8.45 (d, J = 7.78 Hz, 1H), 7.75 (d, J = 8.03 Hz, 2H), 7.61 (d, J = 8.03 Hz, 2H), 7.17 
- 7.29 (m, 2H), 7.05 - 7.16 (m, 3H), 6.75 (d, J = 7.53 Hz, 1H), 5.33 (dd, J = 5.90, 9.66 
Hz, 1H), 4.76 (s, 1H), 3.54 (d, J = 7.28 Hz, 1H), 3.36 (s, 1H), 2.74 (br. s., 2H), 1.50 - 
2.09 (m, 8H), 1.08 - 1.35 (m, 5H) 13C NMR (101 MHz, DMSO-d6) δ 168.5, 167.3, 155.0, 
137.7, 135.4, 133.9, 131.7, 129.3, 129.0, 126.8, 126.1, 126.1, 124.0, 123.7, 122.3, 119.4, 
59.9, 50.7, 47.9, 32.1, 29.0, 27.7, 25.1, 24.4, 21.8 
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40: N-cyclohexyl-2-(2,2-diphenylethyl)-5-hydroxy-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide:  Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), ), 2,2-diphenylethylamine (98  mg, 0.5 
mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) 
isocyanocyclohexane (62 µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in 
the dark under argon for 12 h. The Ugi product was purified by flash chromatography 
first with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to 
give a mixture of three Ugi products that was used in the next step.  Step II: 0.02M of the 
Ugi product (227 mg, 0.37 mmol) was prepared in Dioxane (8 mL).  20mol% 
ytterbium(III) trifluoromethanesulfonate  (58 mg, 0.07 mmol) was added and the reaction 
heated at 100o C  in a sealed tube for 12 h. The solvent was removed by rotavap and 
product purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give a 
white solid (156 mg, 13.0% over two steps) 1H NMR (500 MHz, DMSO-d6) δ 9.90 (br. 
s., 1H), 8.55 (d, J = 6.85 Hz, 1H), 7.70 (d, J = 6.85 Hz, 2H), 7.45 (d, J = 6.85 Hz, 2H), 
7.18 - 7.32 (m,7H), 7.09 - 7.17 (m, 2H), 4.73 (br. s., 1H), 4.46 (d, J = 12.72 Hz, 2H), 4.34 
(t, J = 7.09 Hz, 2H), 3.59 (br. s., 2H), 3.32 - 3.39 (m, 2H), 1.47 - 1.87 (m, 4H), 1.11 - 
1.32 (m, 4H) 13C NMR (126 MHz, DMSO-d6) δ 167.7, 166.2, 155.4, 142.9, 142.0, 138.2, 
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133.3, 132.1, 131.9, 129.3, 128.2, 128.1, 127.6, 124.2, 119.7, 119.6, 61.9, 61.9, 49.6, 
48.5, 45.4, 32.9, 25.6, 24.9 
 
 
 
41: 5-hydroxy-2-(4-hydroxyphenethyl)-N-isopropyl-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), tyramine (68 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and isopropyl isocyanide (47 
µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 
h. The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02M of the Ugi product (132 mg, 0.26 
mmol) was prepared in Dioxane (6 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (41 mg, 0.06 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (98 mg, 
14.7% over two steps) 1H NMR (500 MHz, DMSO-d6) δ 9.88 (br. s., 1H), 9.20 (br. s., 
1H), 8.47 (d, J = 6.85 Hz, 2H), 7.69 (d, J = 6.85 Hz, 2H), 7.48 (d, J = 7.34 Hz, 2H), 7.33 
(d, J = 7.83 Hz, 2H), 7.15 (d, J = 7.34 Hz, 1H), 6.94 (d, J = 6.85 Hz, 1H), 6.64 (d, J = 
6.85 Hz, 1H), 4.91 (br. s., 1H), 3.80 - 3.90 (m, 2H), 3.34 (s, 1H), 2.96 - 3.04 (m, 2H), 
2.57 - 2.82 (m, 2H), 1.10 (t, J = 5.14 Hz, 6H) 13C NMR (126 MHz, DMSO-d6) δ 167.6, 
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166.6, 156.2, 155.3, 138.4, 133.4, 132.0, 129.7, 129.7, 129.3, 127.8, 127.6, 126.1, 124.2, 
124.0, 123.1, 119.6, 115.7, 115.6, 62.2, 62.0, 41.4, 33.1, 22.8 
 
42: N-(tert-butyl)-5-hydroxy-3-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (82 µL 1 mmol), 1,2,3,4-tetrahydro-1-naphthalenamine (146 µL, 
1 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (214 mg, 1 mmol) and tert-Butyl 
isocyanide (112 µL, 1 mmol)  was made up  in MeOH (4 mL) and stirred in the dark 
under argon for 12 h. The Ugi product was purified by flash chromatography first with 
CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a 
mixture of three Ugi products that was used in the next step.     Step II: 0.02 M of the Ugi 
product (154 mg, 0.43 mmol) was prepared in Dioxane 7 mL) ,  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (45 mg, 0.107 mmol) was added and the reaction heated at 
100o C  in a sealed tube for 12 h. The solvent was removed by rotavap and product 
purified by flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white 
solid (76 mg, 14% over two steps)1H NMR (400 MHz, DMSO-d6) δ 9.92 (br. s., 1H), 
8.23 (s, 1H), 7.75 (d, J = 8.28 Hz, 2H), 7.61 (d, J = 7.78 Hz, 2H), 7.28 - 7.32 (m, 1H), 
7.19 - 7.24 (m, 1H), 7.07 - 7.17 (m, 2H), 6.76 (d, J = 7.78 Hz, 1H), 5.32 (br. s., 1H), 4.82 
(s, 1H), 3.36 (br. s., 1H), 2.76 (br. s., 2H), 1.64 - 2.19 (m, 4H), 1.20 - 1.42 (m, 9H) 13C 
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NMR (101 MHz, DMSO-d6) δ 168.5, 167.4, 154.9, 138.0, 137.7, 135.6, 134.2, 131.6, 
129.2, 129.0, 126.8, 126.1, 124.0, 123.7, 123.7, 122.3, 119.4, 60.2, 50.7, 50.5, 29.0, 28.2, 
27.6, 21.8 
	  
 
 
 
43: N-(tert-butyl)-2-(2,2-diphenylethyl)-5-hydroxy-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide:   Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol),  2,2-diphenylethylamine (98 mg, 0.5 mmol), 
3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) tert-Butyl isocyanide 
(56 µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon 
for 12 h. The Ugi product was purified by flash chromatography first with CH2Cl2 and 
then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three 
Ugi products that was used in the next step.  Step II: 0.02M of the Ugi product (191 mg, 
0.33 mmol) was prepared in Dioxane (8 mL).  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (51 mg, 0.07 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (125 mg, 
10.0% over two steps)	  1H NMR (400 MHz, DMSO-d6) δ 9.88 (s, 1H), 8.44 (s, 1H), 7.74 
(d, J = 8.28 Hz, 2H), 7.50 (d, J = 8.28 Hz, 2H), 7.12 - 7.39 (m, 12 h), 4.89 (s, 1H), 4.52 
(d, J = 13.80 Hz, 1H), 4.42 (d, J = 6.27 Hz, 1H), 3.30 - 3.39 (m, 1H), 1.37 (s, 9H) 13C 
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NMR (101 MHz, DMSO-d6) δ 167.4, 166.0, 154.9, 142.6, 141.4, 133.2, 131.6, 128.9, 
128.8, 128.4, 127.8, 127.6, 126.7, 126.6, 123.7, 122.6, 119.2, 61.4, 50.9, 49.0, 44.7, 28.4 
 
46: 2-(2-(1H-indol-3-yl)ethyl)-5-hydroxy-N-isopropyl-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), tryptamine (80 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and isopropyl isocyanide (47 
µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 
h. The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02M of the Ugi product (135 mg, 0.25 
mmol) was prepared in Dioxane (5 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (40 mg, 0.06 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (98 mg, 
9.0% over two steps). 1H NMR (400 MHz, DMSO-d6) Shift 10.84 (br. s., 1H), 9.91 (s, 
1H), 8.56 (d, J = 7.28 Hz, 1H), 7.74 (d, J = 7.53 Hz, 2H), 7.50 - 7.57 (m, 3H), 7.37 (dd, J 
= 8.53, 11.29 Hz, 2H), 7.20 (d, J = 8.28 Hz, 1H), 7.14 (s, 1H), 7.08 (t, J = 7.53 Hz, 1H), 
6.94 - 7.02 (m, 1H), 5.10 (s, 1H), 3.89 - 4.03 (m, 2H), 2.85 - 3.25 (m, 3H), 1.16 (t, J = 
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5.77 Hz, 6H) 13C NMR (101 MHz, DMSO-d6) d 167.2, 166.3, 154.9, 138.0, 136.2, 133.1, 
131.6, 129.3, 127.0, 123.8, 123.7, 123.2, 122.6, 122.5, 121.0, 119.1, 118.2, 118.0, 111.5, 
111.1, 61.6, 41.6, 41.0, 23.5, 22.3 
 
98: methyl 3-(1-(tert-butylcarbamoyl)-5-hydroxy-4-methyl-3-oxoisoindolin-2-yl)-2-(1H-
indol-3-yl)propanoate: Step I: One molar solution of freshly distilled furfural (331 µL 4 
mmol), methyl 2-amino-4-(1H-indol-3-yl)butanoate (929 mg, 4 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and tert-Butyl isocyanide 
(452 µL, 4 mmol)  was made up  in MeOH (16 mL) and stirred in the dark under argon 
for 12 h. The Ugi product was purified by flash chromatography first with CH2Cl2 and 
then gradient elution with EtoAc-Hexane (10%, 20% &40%) to give a mixture of three 
Ugi products that was used in the next step.  Step II: 0.02 M of the Ugi product (185 mg, 
0.39 mmol) was prepared in Dioxane (5 mL).  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (61 mg, 0.09 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (164 mg, 
9.0% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 10.82 (s, 1H), 9.67 (s, 1H), 8.19 
(s, 1H), 7.63 (d, J = 7.78 Hz, 1H), 7.34 (d, J = 8.03 Hz, 1H), 7.17 (d, J = 8.28 Hz, 1H), 
6.99 - 7.13 (m, 5H), 5.19 (s, 1H), 5.05 (t, J = 7.65 Hz, 1H), 3.54 (s, 3H), 3.36 (s, 1H), 
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2.46 (s, 3H), 1.31 (s, 9H) 13C NMR (101 MHz, DMSO-d6) δ 170.3, 169.3, 166.6, 155.8, 
136.1, 133.3, 128.7, 127.0, 123.2, 122.4, 121.1, 119.6, 118.4, 118.2, 111.4, 109.4, 65.2, 
60.6, 54.0, 51.7, 50.6, 28.4, 9.4 
 
 
 
 
44: N-butyl-5-hydroxy-2-(4-hydroxyphenethyl)-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide45 Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), tyramine (68 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) n-butylisocyanide (52 µL, 
0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 h. 
The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02M of the Ugi product (139 mg, 0.27 
mmol) was prepared in Dioxane (6 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (42 mg, 0.07 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (84 mg, 
12.3% over two steps) 1H NMR (500 MHz, DMSO-d6) δ 9.87 (br. s., 1H), 9.18 (br. s., 
1H), 8.47 (br. s., 1H), 7.67 (d, J = 7.34 Hz, 2H), 7.46 (d, J = 7.34 Hz, 2H), 7.31 (d, J = 
8.31 Hz, 1H), 7.12 (d, J = 8.31 Hz, 1H), 6.91 (d, J = 7.34 Hz, 2H), 6.62 (d, J = 7.34 Hz, 
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2H), 4.91 (br. s., 1H), 3.82 (d, J = 4.89 Hz, 2H), 2.93 - 3.16 (m, 2H), 2.53 - 2.77 (m, 2H), 
1.39 (d, J = 6.36 Hz, 2H), 1.26 (d, J = 6.85 Hz, 2H), 0.84 (t, J = 6.60 Hz, 3H) 13C NMR 
(126 MHz, DMSO-d6) δ 167.6, 167.5, 156.2, 155.3, 138.3, 133.4, 132.1, 131.9, 129.7, 
129.6, 129.2, 124.1, 123.9, 119.5, 115.7, 115.6, 62.4, 43.1, 38.9, 33.0, 31.5, 19.9, 14.1 
      
      
45: N-(tert-butyl)-5-hydroxy-2-(4-hydroxyphenethyl)-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol),  tyramine (68 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) tert-Butyl isocyanide (56 µL, 
0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 h. 
The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02M of the Ugi product (264 mg, 0.51 
mmol) was prepared in Dioxane (10 mL).  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (79 mg, 0.12 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (191 mg, 
18.0% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 9.22 (s, 1H), 8.52 
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(t, J = 5.65 Hz, 1H), 7.73 (d, J = 8.28 Hz, 2H), 7.53 (d, J = 8.03 Hz, 2H), 7.38 (d, J = 
8.28 Hz, 1H), 7.19 (d, J = 8.28 Hz, 1H), 6.98 (d, J = 8.53 Hz, 2H), 6.69 (d, J = 8.28 Hz, 
2H), 4.98 (s, 1H), 3.83 - 3.94 (m, 1H), 3.00 - 3.24 (m, 2H), 2.62 - 2.84 (m, 2H), 1.25 - 
1.51 (m, 5H), 0.91 (t, J = 7.28 Hz, 3H) 13C NMR (101 MHz, DMSO-d6) δ 167.2, 167.1, 
155.8, 154.9, 137.9, 133.0, 131.6, 129.3, 129.2, 128.8, 127.1, 123.8, 123.7, 123.6, 123.2, 
122.6, 119.1, 115.2, 61.9, 42.8, 38.5, 32.6, 31.1 
 
52: N-cyclohexyl-5-hydroxy-2-(4-hydroxyphenethyl)-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide carboxamide: Step I: One molar 
solution of freshly distilled furfural (41 µL 0.5 mmol), tyramine (68 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) isocyanocyclohexane (62 µL, 
0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 h. 
The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02 M of the Ugi product (159 mg, 0.29 
mmol) was prepared in Dioxane (6 mL).  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (46 mg, 0.07 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (119 mg, 
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11.4% over two steps) 1H NMR (500 MHz, DMSO-d6) δ 9.90 (br. s., 1H), 9.22 (br. s., 
1H), 8.50 (d, J = 7.34 Hz, 1H), 7.67 - 7.72 (m, 2H), 7.49 (d, J = 7.34 Hz, 2H), 7.31 - 7.36 
(m, 1H), 7.16 (d, J = 7.83 Hz, 1H), 6.91 - 6.97 (m, 2H), 6.66 (d, J = 8.31 Hz, 2H), 4.97 
(br. s., 1H), 3.83 (br. s., 1H), 3.57 (br. s., 2H), 3.36 (br. s., 2H), 3.01 (d, J = 5.87 Hz, 2H), 
2.73 (br. s., 2H), 2.64 (br. s., 2H), 1.52 - 1.81 (m, 4H), 1.14 - 1.31 (m, 4H) 13C NMR (126 
MHz, DMSO-d6) δ 167.5, 166.6, 156.2, 138.4, 133.5, 132.0, 130.3, 129.7, 129.2, 127.7, 
126.1, 124.2, 124.0, 123.9, 119.4, 115.7, 115.6, 62.2, 48.5, 43.1, 33.1, 32.7, 25.6, 24.9 
	  
	  
 
 
 
47: 5-hydroxy-2-(4-hydroxyphenethyl)-3-oxo-N-pentyl-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), tyramine (68 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol 1-isocyanopentane (62 µL, 
0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 h. 
The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02 M of the Ugi product (203 mg, 0.38 
mmol) was prepared in Dioxane (8 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (59 mg, 0.09 mmol) was added and the reaction heated at 100o 
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C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (125 mg, 
12.0% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 9.91 (br. s., 1H), 9.23 (s, 1H), 
8.52 (t, J = 5.40 Hz, 1H), 7.73 (d, J = 7.78 Hz, 2H), 7.53 (d, J = 8.03 Hz, 2H), 7.37 (d, J 
= 8.28 Hz, 1H), 7.19 (d, J = 8.28 Hz, 1H), 6.98 (d, J = 8.03 Hz, 2H), 6.68 (d, J = 7.53 Hz, 
2H), 4.98 (s, 1H), 3.85 - 3.94 (m, 1H), 3.38 (s, 1H), 3.00 - 3.23 (m, 3H), 2.62 - 2.84 (m, 
2H), 1.45 - 1.50 (m, 2H), 1.29 (d, J = 3.01 Hz, 4H), 0.88 (t, J = 6.65 Hz, 3H) 13C NMR 
(101 MHz, DMSO-d6) δ 155.8, 154.9, 137.9, 133.0, 131.6, 129.3, 129.2, 128.8, 127.4, 
127.1, 125.9, 123.8, 123.7, 123.2, 122.6, 119.1, 115.2, 61.9, 42.8, 38.8, 32.6, 28.6, 28.5, 
21.8, 13.9 
	  
48: 2-(2,2-diphenylethyl)-5-hydroxy-3-oxo-N-pentyl-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), 2,2-diphenylethylamine (98 mg, 0.5 mmol), 
3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and 1-isocyanopentane 
(62 µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon 
for 12 h. The Ugi product was purified by flash chromatography first with CH2Cl2 and 
then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three 
Ugi products that was used in the next step.  Step II: 0.02 M of the Ugi product (276 mg, 
0.47 mmol) was prepared in Dioxane (6 mL).  20mol% ytterbium(III) 
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trifluoromethanesulfonate  (73 mg, 0.11 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (116 mg, 
10.0% over two steps). 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.59 (t, J = 5.52 
Hz, 1H), 7.75 (d, J = 8.28 Hz, 2H), 7.50 (d, J = 8.03 Hz, 2H), 7.14 - 7.37 (m, 12 h), 4.74 
(s, 1H), 4.54 (dd, J = 9.29, 13.80 Hz, 1H), 4.38 - 4.47 (m, 1H), 3.37 - 3.46 (m, 1H), 3.13 - 
3.21 (m, 2H), 1.44 - 1.54 (m, 2H), 1.30 (td, J = 3.58, 6.90 Hz, 4H), 0.83 - 0.93 (m, 3H) 
13C NMR (101 MHz, DMSO-d6) δ 167.3, 166.8, 155.0, 142.5, 141.5, 132.9, 131.6, 128.7, 
128.7, 128.4, 127.7, 127.6, 126.8, 126.6, 123.8, 123.7, 122.7, 119.2, 64.9, 61.6, 49.0, 
45.0, 38.8, 28.7, 28.5, 21.8, 13.9 
	  
49: 5-hydroxy-3-oxo-N-pentyl-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide  P1: Step I: One molar solution of 
freshly distilled furfural (82 µL 1.0 mmol), 1,2,3,4-tetrahydro-1-naphthalenamine (146 
µL, 1 mmol), 3-(4-(trifluoromethyl)phenyl) propiolic acid (214 mg, 1.0 mmol) and 1-
isocyanopentane (125µL, 1.0 mmol)  was made up  in MeOH (4 mL) and stirred in the 
dark under argon for 12 h. The Ugi product was purified by flash chromatography first 
with CH2Cl2 and then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a 
mixture of three Ugi products that was used in the next step.  Step II: 0.02M of the Ugi 
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product (235 mg, 0.43 mmol) was prepared in Dioxane (9 mL).  20 mol% ytterbium(III) 
trifluoromethanesulfonate  (67 mg, 0.11 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (194 mg, 
36.2% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 9.83 - 10.14 (m, 1H), 8.49 - 
8.61 (m, 1H), 7.72 - 7.80 (m, 2H), 7.66 (d, J = 8.28 Hz, 1H), 7.28 - 7.34 (m, 1H), 7.20 - 
7.27 (m, 1H), 7.05 - 7.19 (m, 2H), 6.77 (d, J = 7.78 Hz, 1H), 5.39 (dd, J = 5.90, 9.91 Hz, 
1H), 4.78 (s, 1H), 3.45 (s, 1H), 3.05 - 3.20 (m, 2H), 2.76 (br. s., 2H), 1.63 - 2.17 (m, 4H), 
1.39 - 1.53 (m, 2H), 1.17 - 1.37 (m, 5H), 0.89 (t, J = 6.78 Hz, 3H) 13C NMR (101 MHz, 
DMSO-d6) δ 168.6, 168.3, 155.1, 137.6, 135.3, 133.9, 131.7, 129.3, 129.0, 126.8, 126.1, 
126.0, 124.1, 123.7, 123.2, 122.4, 119.5, 60.1, 50.9, 38.8, 28.9, 28.5, 28.5, 27.8, 21.8, 
13.8 
	  
50: 2-(2-(1H-indol-3-yl)ethyl)-N-butyl-4-(4-(trifluoromethyl)phenyl)-5-hydroxy-3-
oxoisoindoline-1-carboxamide: Step I: One molar solution of freshly distilled furfural 
(62 µL 0.75mmol), tryptamine (120 mg, 0.75 mmol), 3-(4-(trifluoromethyl)phenyl) 
propiolic acid (160 mg, 0.75 mmol) and n-butylisocyanide (78 µL, 0.75 mmol)  was 
made up  in MeOH (2 mL) and stirred in the dark under argon for 12 h. The Ugi product 
was purified by flash chromatography first with CH2Cl2 and then gradient elution with 
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EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi products that was used 
in the next step. Step II: 0.02M of the Ugi product (350 mg, 0.65 mmol) was prepared in 
Dioxane (13 mL).  20 mol% ytterbium(III) trifluoromethanesulfonate  (101 mg, 0.13 
mmol) was added and the reaction heated at 100o C  in a sealed tube for 12 h. The solvent 
was removed by rotavap and product purified by flash chromatography twice (70% & 
35% EtoAc-Hexane) to give a white solid (294 mg, 41.2% over two steps) 1H NMR (400 
MHz, DMSO-d6) δ 10.83 (s, 1H), 9.91 (s, 1H), 8.55 (t, J = 5.65 Hz, 1H), 7.73 (d, J = 8.03 
Hz, 2H), 7.49 - 7.56 (m, 2H), 7.36 (dd, J = 8.16, 10.42 Hz, 2H), 7.19 (d, J = 8.28 Hz, 
1H), 7.12 (d, J = 2.01 Hz, 1H), 7.08 (t, J = 7.15 Hz, 1H), 6.94 - 7.01 (m, 1H), 5.10 (s, 
1H), 3.94 - 4.04 (m, 1H), 3.35 (s, 2H), 3.09 - 3.24 (m, 2H), 2.84 - 3.07 (m, 2H), 1.24 - 
1.52 (m, 4H), 0.90 (t, J = 7.28 Hz, 3H13C NMR (101 MHz, DMSO-d6) δ 167.3, 167.2, 
154.9, 138.1, 136.2, 133.1, 131.6, 129.3, 127.0, 123.9, 123.7, 123.2, 122.6, 122.6, 121.0, 
119.1, 118.3, 118.0, 111.5, 111.1, 61.8, 41.6, 38.6, 31.1, 23.5, 21.0, 19.5, 13.6 
 
	  
51: 2-(2-(1H-indol-3-yl)ethyl)-5-hydroxy-3-oxo-N-pentyl-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide: Step I: One molar solution of 
freshly distilled furfural (41 µL 0.5 mmol), tryptamine (80 mg, 0.5 mmol), 3-(4-
(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and 1-isocyanopentane (62 
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µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon for 12 
h. The Ugi product was purified by flash chromatography first with CH2Cl2 and then 
gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three Ugi 
products that was used in the next step.  Step II: 0.02M of the Ugi product (168 mg, 0.31 
mmol) was prepared in Dioxane (6 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (47 mg, 0.07 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (74 mg, 
7.0% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 10.85 (br. s., 1H), 9.93 (s, 1H), 
8.51 - 8.63 (m, 1H), 7.75 (d, J = 8.03 Hz, 2H), 7.50 - 7.59 (m, 2H), 7.38 (dd, J = 8.16, 
13.43 Hz, 2H), 7.18 - 7.24 (m, 1H), 7.06 - 7.15 (m, 2H), 6.95 - 7.03 (m, 1H), 5.09 - 5.15 
(m, 1H), 3.96 - 4.20 (m, 1H), 3.36 - 3.43 (m, 2H), 2.87 - 3.28 (m, 4H), 1.48 (d, J = 6.27 
Hz, 2H), 1.30 (d, J = 3.26 Hz, 4H), 0.83 - 0.94 (m, 3H) 13C NMR (101 MHz, DMSO-d6) 
δ 167.3, 167.2, 155.0, 136.2, 133.1, 131.6, 129.3, 127.0, 123.9, 123.7, 123.7, 122.6, 
122.6, 121.0, 119.1, 118.3, 118.0, 111.5, 111.1, 61.8, 41.7, 38.8, 28.7, 28.5, 23.5, 21.8, 
13.9	  
	  
53: 5-hydroxy-2-(4-isopropylbenzyl)-3-oxo-N-pentyl-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamide:  Step I: One molar solution of 
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freshly distilled furfural (41 µL 0.5 mmol), 4-isopropylbenzylamine (80 µL, 0.5 mmol), 
3-(4-(trifluoromethyl)phenyl) propiolic acid (107 mg, 0.5 mmol) and 1-isocyanopentane 
(62 µL, 0.5 mmol)  was made up  in MeOH (2 mL) and stirred in the dark under argon 
for 12 h. The Ugi product was purified by flash chromatography first with CH2Cl2 and 
then gradient elution with EtoAc-Hexane (10%, 20% &40%)) to give a mixture of three 
Ugi products that was used in the next step.  Step II: 0.02M of the Ugi product (159 mg, 
0.29 mmol) was prepared in Dioxane (6 mL).  20mol% ytterbium(III) 
trifluoromethanesulfonate  (45 mg, 0.07 mmol) was added and the reaction heated at 100o 
C  in a sealed tube for 12 h. The solvent was removed by rotavap and product purified by 
flash chromatography twice (70% & 35% EtoAc-Hexane) to give a white solid (113 mg, 
10.5% over two steps) 1H NMR (400 MHz, DMSO-d6) δ 9.94 (s, 1H), 8.52 (t, J = 5.40 
Hz, 1H), 7.75 (d, J = 8.03 Hz, 2H), 7.58 (d, J = 8.03 Hz, 2H), 7.34 (d, J = 8.28 Hz, 1H), 
7.17 - 7.25 (m, 3H), 7.12 (d, J = 8.03 Hz, 2H), 4.79 (s, 1H), 3.36 (s, 2H), 3.07 - 3.19 (m, 
2H), 2.88 (td, J = 6.90, 13.80 Hz, 1H), 1.46 (quin, J = 6.78 Hz, 2H), 1.25 - 1.36 (m, 4H), 
1.19 (d, J = 7.03 Hz, 6H), 0.86 - 0.94 (m, 3H)13C NMR (101 MHz, DMSO-d6) δ 167.1, 
166.8, 155.1, 147.6, 137.9, 137.8, 134.3, 132.9, 131.6, 128.8, 128.0, 126.6, 125.9, 124.1, 
123.7, 123.7, 122.7, 119.2, 60.9, 44.0, 38.8, 33.1, 28.5, 23.8, 21.8, 13.9 
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54: 2-benzyl-1-(cyclohexylcarbamoyl)-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindolin-5-yl 
acetate: To a stirring solution of acetic anhydride (100 µL, 1.2mmol) in pyridine (2 mL) 
was added compound  38 (68 mg, 0.12 mmol) and stirred at room temperature overnight. 
After disappearance of starting material, the reaction mixture was diluted with ethyl 
acetate (3 mL) and anhydrous CuSO4 solution was added to remove the pyridine (3 x 3 
mL). The organic portions were combined, washed with brine and dried over Na2SO4. 
The crude product was purified by column chromatography (35% EtOAc-hexanes) to 
give a white solid (66mg, 90%)  1H NMR (400 MHz, DMSO-d6) δ 8.60 (d, J = 7.78 Hz, 
1H), 7.82 (d, J = 8.03 Hz, 2H), 7.47 - 7.62 (m, 4H), 7.29 - 7.41 (m, 3H), 7.24 (d, J = 6.78 
Hz, 2H), 5.10 (d, J = 15.06 Hz, 1H), 4.97 (s, 1H), 3.97 (d, J = 15.06 Hz, 1H), 3.58 - 3.69 
(m, 1H), 3.35 (s, 1H), 2.00 (s, 3H), 1.54 - 1.90 (m, 5H), 1.16 - 1.40 (m, 5H) 13C NMR 
(101 MHz, DMSO-d6) δ 169.1, 166.2, 165.0, 148.1, 140.2, 136.6, 136.2, 130.8, 129.2, 
128.7, 128.4, 128.1, 127.5, 126.6, 125.7, 124.2, 123.1, 61.2, 48.1, 44.4, 32.3, 32.2, 25.1, 
24.3, 20.2 
	  
55: 2-benzyl-1-(isopropylcarbamoyl)-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindolin-5-yl 
acetate: To a stirring solution of acetic anhydride (100 µL, 1.2 mmol) in pyridine (2 mL) 
was added compound  35 (86 mg, 0.18 mmol) and stirred at room temperature overnight. 
After disappearance of starting material, the reaction mixture was diluted with ethyl 
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acetate (3 mL) and anhydrous CuSO4 solution was added to remove the pyridine (3 x 3 
mL). The organic portions were combined, washed with brine and dried over Na2SO4. 
The crude product was purified by column chromatography (35% EtOAc-hexanes) to 
give a white solid (81mg, 86%) 1H NMR (400 MHz, DMSO-d6) δ 8.60 (d, J = 7.53 Hz, 
1H), 7.81 (d, J = 8.28 Hz, 2H), 7.57 - 7.62 (m, 1H), 7.52 (d, J = 8.03 Hz, 3H), 7.28 - 7.41 
(m, 3H), 7.24 (d, J = 7.03 Hz, 2H), 5.08 (d, J = 15.31 Hz, 1H), 4.93 (s, 1H), 3.86 - 4.01 
(m, 1H), 3.34 (s, 1H), 2.00 (s, 3H), 1.14 (dd, J = 6.65, 10.67 Hz, 6H) 13C NMR (101 
MHz, DMSO-d6) δ 169.1, 166.2, 165.0, 148.1, 140.1, 136.6, 130.8, 129.2, 128.7, 128.4, 
128.0, 127.5, 126.6, 125.7, 124.2, 124.2, 123.1, 61.2, 44.4, 41.1, 22.3, 22.2, 20.2 
 
56: 4-(2-(5-acetoxy-1-(tert-butylcarbamoyl)-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindolin-2-
yl)ethyl)phenyl acetate: To a stirring solution of acetic anhydride (100 µL, 1.2 mmol) in 
pyridine (2 mL) was added compound  45 (180 mg, 0.35 mmol) and stirred at room 
temperature overnight. After disappearance of starting material, the reaction mixture was 
diluted with ethyl acetate (3 mL) and anhydrous CuSO4 solution was added to remove the 
pyridine (3 x 3 mL). The organic portions were combined, washed with brine and dried 
over Na2SO4. The crude product was purified by column chromatography (35% EtOAc-
hexanes) to give a white solid (118 mg, 56%) 1H NMR (400 MHz, DMSO-d6) δ 8.69 (t, J 
= 5.27 Hz, 1H), 7.81 (d, J = 8.03 Hz, 2H), 7.68 (d, J = 8.03 Hz, 1H), 7.47 - 7.55 (m, 3H), 
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7.23 - 7.29 (m, 2H), 7.05 - 7.10 (m, 2H), 5.24 (s, 1H), 3.95 - 4.05 (m, 1H), 3.39 (s, 1H), 
3.12 - 3.30 (m, 2H), 2.80 - 3.01 (m, 2H), 2.27 (s, 3H), 2.01 (s, 3H), 1.29 - 1.55 (m, 4H), 
0.93 (t, J = 7.40 Hz, 3H) 13C NMR (101 MHz, DMSO-d6) δ 169.1, 169.0, 166.4, 166.2, 
149.0, 148.1, 140.2, 136.2, 130.7, 130.6, 129.4, 129.4, 126.5, 125.7, 124.1, 123.1, 121.8, 
62.2, 42.5, 38.7, 32.7, 31.0, 20.8, 20.2 
 
57: 2-(2,2-diphenylethyl)-3-oxo-1-(pentylcarbamoyl)-4-(4-
(trifluoromethyl)phenyl)isoindolin-5-yl acetate To a stirring solution of acetic anhydride 
(100 µL, 1.2mmol) in pyridine (2 mL) was added compound  48 (50 mg, 0.08 mmol) and 
stirred at room temperature overnight. After disappearance of starting material, the 
reaction mixture was diluted with ethyl acetate (3 mL) and anhydrous CuSO4 solution 
was added to wash the pyridine (3 x 3 mL). The organic portions were combined, washed 
with brine and dried over Na2SO4. The crude product was purified by column 
chromatography (35% EtOAc-hexanes) to give a white solid (44 mg, 82%) 1H NMR (400 
MHz, DMSO-d6) δ 8.75 (t, J = 5.27 Hz, 1H), 7.81 (d, J = 8.28 Hz, 2H), 7.60 (d, J = 8.28 
Hz, 1H), 7.46 (dd, J = 8.03, 16.81 Hz, 3H), 7.15 - 7.39 (m, 9H), 4.91 (s, 1H), 4.55 (dd, J 
= 9.41, 13.68 Hz, 1H), 4.38 - 4.49 (m, 1H), 3.48 (dd, J = 7.03, 13.80 Hz, 1H), 3.20 (q, J = 
6.11 Hz, 2H), 1.98 (s, 3H), 1.46 - 1.56 (m, 2H), 1.27 - 1.36 (m, 4H), 0.88 (t, J = 6.27 Hz, 
3H) 13C NMR (101 MHz, DMSO-d6) δ 169.0, 166.3, 166.0, 148.1, 142.4, 141.5, 140.0, 
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130.7, 129.0, 128.7, 128.5, 127.7, 127.6, 126.8, 126.6, 126.5, 124.2, 123.2, 61.9, 48.9, 
45.1, 38.9, 28.6, 28.6, 21.8, 20.2, 13.9 
 
 
58: 1-(tert-butylcarbamoyl)-2-(2,2-diphenylethyl)-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindolin-5-yl acetate 81C To a stirring solution of acetic 
anhydride (100 µL, 1.2mmol) in pyridine (2 mL) was added compound  43 (77 mg, 0.13 
mmol) and stirred at room temperature overnight. After disappearance of starting 
material, the reaction mixture was diluted with ethyl acetate (3 mL) and anhydrous 
CuSO4 solution was added to wash the pyridine (3 x 3 mL). The organic portions were 
combined, washed with brine and dried over Na2SO4. The crude product was purified by 
column chromatography (35% EtOAc-hexanes) to give a white solid (78mg, 94%) 1H 
NMR (400 MHz, DMSO-d6) d 8.61 (s, 1H), 7.82 (d, J = 8.53 Hz, 2H), 7.67 (d, J = 8.28 
Hz, 1H), 7.43 - 7.53 (m, 3H), 7.28 - 7.42 (m, 8H), 7.14 - 7.28 (m, 2H), 5.07 (s, 1H), 4.54 
- 4.66 (m, 1H), 4.41 - 4.52 (m, 1H), 3.42 (dd, J = 6.65, 14.43 Hz, 1H), 1.98 (s, 3H), 1.40 
(s, 9H) 13C NMR (101 MHz, DMSO-d6) d 169.0, 166.4, 165.2, 148.1, 142.5, 141.3, 
140.3, 136.1, 130.7, 130.5, 129.2, 128.8, 128.5, 127.8, 127.6, 126.8, 126.6, 126.5, 124.2, 
123.1, 61.8, 51.1, 49.0, 44.9, 28.3, 20.2 
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5.1.4	  Nucleoside	  Derivatives	  
 
 
62: (1-benzyl-1H-1,2,3-triazol-4-yl)methanol: To a solution of benzyl azide (2.66  g, 20 
mmol) and propargyl alcohol  (1.28  mL, 22 mmol) in tBuOH:H2O (1:1, 10mL) at room 
temperature, sodium ascorbate (1.5844 g, 8 mmol) and CuSO4.5H2O (1.0 g, 2 mmol) 
were added and the resulting yellow mixture was stirred vigorously overnight. The 
reaction mixture was diluted and extracted with EtOAc (10 mL). The organic layer was 
dried over MgSO4 and the solvents were evaporated under reduced pressure. The product 
was purified by column chromatography (2% MeOH-EtOAc) to give an amorphous solid 
(2.51 g, 66%). 1H NMR (500 MHz, CHLOROFORM-d) δ 7.44 (bs, J = 3.18 Hz, 1H), 
7.32 - 7.36 (m, 3H), 7.25 (dd, J = 1.10, 2.81, 4.89 Hz, 2H), 5.47 (bs, J = 3.18 Hz, 2H), 
4.72 (bs, J = 2.69 Hz, 2H), 3.59 (bs, J = 2.20 Hz, 1H) 13C NMR (126 MHz, 
CHLOROFORM-d) δ 148.2, 134.5, 129.1, 128.8, 128.1, 121.7, 56.2, 54.2 
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63: (1-benzyl-1H-1,2,3-triazol-4-yl)methyl methanesulfonate: Under argon, Et3N (0.55 mL, 
3.9 6mmol) and methanesulfonyl chloride (0.222 mL, 2.87 mmol) were added 
successively to a solution of 1-Benzyl-4-hydroxymethyl-1H-1,2,3-triazole 62 (500mg, 
2.64mmol) in dry CH2Cl2 (10 mL) at -30o C. After stirring for 30minutes TLC showed no 
more starting material.  The mixture was poured into a mixture of water and CH2Cl2 (and 
the  separated organic layer was washed with NaHCO3, dilute HCl and brine, dried over 
MgSO4 and rotavap to give a white solid (0.5873g, 83%) 1H NMR (500 MHz, 
CHLOROFORM-d) δ 7.63 (br. s., 1H), 7.35 (br. s., 3H), 7.26 (br. s., 2H), 5.52 (br. s., 
2H), 5.31 (br. s., 2H), 2.98 (br. s., 3H) 13C NMR (126 MHz, CHLOROFORM-d) δ 141.3, 
134.1, 129.1, 128.2, 124.2, 62.5, 54.3, 38.2, 31.1 
 
64: Ethanethioic acid, S-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl] ester: To a stirring solution of 
[1-(Benzyl)-4-[340]-methyl]-1H-1,2,3-triazole (400 mg, 1,49 mmol) in DMF (3 mL) under 
argon  was added potassium thioacetate (195.69 mg, 1.713 mmol) and allowed to stir for 
15minutes. The reaction mixture was dissolved in 20 mL CH2Cl2 and washed with water 
(15mL x 3), the organic layer was dried with MgSO4, rotavap and purified by column 
(70% EtOAc/Hexanes) chromatography to give a white solid  (133.3 mg, 54%); 1H NMR 
(500 MHz, CHLOROFORM-d) δ 7.38 (br. s., 1H), 7.34 (br. s., 3H), 7.23 (d, J = 3.91 Hz, 
2H), 5.45 (br. s., 2H), 4.13 (s, 2H), 2.30 (s, 3H)  13C NMR (126 MHz, CHLOROFORM-
d) δ 195.2, 144.7, 134.5, 129.1, 128.7, 128.0, 121.7, 54.1, 30.3, 24.0 
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66: 1-(4-((tert-butyldimethylsilyl)oxy)-5-(((tert-
butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-
dione: A solution of thymidine (5 g, 20.7 mmol), imidazole (5.6 g, 82.8 mmol) and 
TBDMSCl (6.85 g, 45.5 mmol) in DMF (30 mL) was stirred under an argon atmosphere 
for 2 h at 50oC. The resultant mixture was then diluted with ethyl acetate (80 mL) and 
washed with saturated ammonium chloride solution (3 x 50 mL) and brine (3x 50 mL). 
The combined organic fractions were then dried over Na2SO4 and solvent removed in 
vacuo to give 3’, 5’-bis (O-tert-butyldimethylsilyl)-2’-deoxyuridine as a white solid (8.98 
g, 92%). Rf = 0.64 (MeOH/EtOAc, 2%); 1H NMR (500 MHz, CHLOROFORM-d) δ 9.88 
(br. s., 1H), 7.43 (d, J = 1.47 Hz, 1H), 6.27 - 6.35 (m, 1H), 4.36 (dd, J = 2.69, 5.62 Hz, 
1H), 3.89 (d, J = 2.45 Hz, 1H), 3.67 - 3.85 (m, 2H), 1.92 - 2.28 (m, 2H), 1.87 (d, J = 0.98 
Hz, 3H), 0.81 - 0.93 (m, 18H), -0.29 - 0.34 (m, 12 h) 13C NMR (126 MHz, 
CHLOROFORM-d) δ 164.3, 150.6, 135.4, 110.8, 87.7, 84.7, 72.2, 62.9, 41.4, 25.8, 18.4, 
12.5, -5.1 
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67, 68 & 69: B) 3’, 5’-Bis (O-tert-butyldimethylsilyl)-2’-deoxyuridine (400 mg, 0.85mmol), N-
bromosuccinimide(211.79 mg, 1.19 mmol) and azoisobutyronitrile (12.56 mg, 
0.21 mmol) were dissolved in benzene (10 mL) under an inert atmosphere. This 
solution was then heated under reflux for 40 min at 80 oC. The particulates were 
removed by filtration (filter paper) while the reaction mixture was still hot. The 
filtrate was then evaporated in vacuo and the resulting crude oily product, 5-
Bromo-3’,5’-bis(O-tert-butyldimethylsilyl)-2’-deoxyuridine (B) was used without 
further purification 
C)5-((((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)thio)methyl)-1-(4-((tert-
butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione To a flame dried 10 mL three neck flask 
containing S-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl] ester (A) (100 mg, 0.40 
mmol)   dissolved in anhydrous DMF (2 mL) was added pyrrolidine (36 µL, 0.40 
mmol) via syringe under argon. After stirring and monitoring with TLC for the 
disappearance of starting material, triethylamaine (52 µL, 0.38 mmol) was added 
and the resultant solution cannulated to a solution of 5-Bromo-3’,5’-bis(O-tert-
butyldimethylsilyl)-2’-deoxyuridine (B) in DMF (2 mL). The resulting solution 
stirred at 75o C for 2 h. The mixture was then diluted with CH2Cl2, washed with 
water (3 x 100 mL), NaHCO3, and brine and dried with MgSO4. The crude 
product was purified by column chromatography to give an off white solid (302 
mg, 45% over two steps); 1H NMR (500 MHz, CHLOROFORM-d) δ 8.76 (br. s., 
1H), 7.80 (br. s., 1H), 7.53 (br. s., 1H), 7.35 (br. s., 3H), 7.23 - 7.30 (m, 2H), 6.32 
(br. s., 1H), 5.49 (br. s., 2H), 4.43 (br. s., 1H), 3.76 - 3.97 (m, 3H), 3.73 (br. s., 
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2H), 3.37 (d, J = 9.78 Hz, 2H), 2.25 (br. s., 2H), 0.77 - 1.06 (m, 18H), -0.18 - 0.17 
(m, 12 h) 13C NMR (126 MHz, CHLOROFORM-d) δ 162.7, 149.9, 145.7, 138.2, 
134.6, 129.1, 128.7, 128.1, 122.0, 111.1, 88.0, 85.1, 72.4, 63.3, 54.2, 40.7, 26.8, 
25.9, 25.7, 25.5, 18.2, -5.1 
 
70: 4-amino-5-((((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)thio)methyl)-1-(4-((tert-
butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-
yl)pyrimidin-2(1H)-one 1, 2, 4-triazole (2.229 g, 21.8mmol) was suspended in dry MeCN 
(25 mL), 5-((((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)thio)methyl)-1-(4-((tert-
butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione (1 g, 1.48 mmol) dissolved in MeCN (5 mL) and DMAP 
(3.97 g, 22.02 mmol) was added and stirred until dissolved. POCl3 (0.688 mL, 7.62 
mmol) was added drop wise and allowed to stir for 2 h. The reaction was diluted with 
EtOAc (50 mL) and quenched with NaHCO3, washed with brine and dried with Na2SO4. 
Solvent was removed under low pressure and used for the next step without further 
purification. The resultant mixture was dissolved in dioxane (20 mL) and NH4OH (25  
mL) was added and stirred overnight. Excess solvent was removed and resultant purified 
by column chromatography to give a while solid (336 mg, 50% over two steps); 1H NMR 
(500 MHz, CHLOROFORM-d) δ 8.18 (br. s., 2H), 7.81 (br. s., 1H), 7.35 (d, J = 3.91 Hz, 
2H), 7.26 (br. s., 2H), 6.32 (br. s., 1H), 5.48 (br. s., 2H), 4.37 (br. s., 1H), 3.95 (br. s., 
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1H), 3.77 - 3.87 (m, 4H), 3.68 (br. s., 2H), 3.59 (br. s., 2H), 2.40 (d, J = 12.23 Hz, 1H), 
1.97 - 2.07 (m, 1H), 0.87 (d, J = 13.21 Hz, 18H), 0.06 (d, J = 17.12 Hz, 12 h) 13C NMR 
(126 MHz, CHLOROFORM-d) δ 164.6, 155.7, 145.7, 140.8, 134.3, 129.2, 128.9, 128.1, 
121.4, 101.6, 87.9, 86.2, 72.1, 63.1, 54.3, 41.8, 30.9, 29.3, 26.0, 25.7, 17.9, -5.1 
 
 
 
 
71: 4-amino-5-((((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)thio)methyl)-1-((2R,4S,5R)-4-
hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one To a solution of 4-
amino-5-((((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)thio)methyl)-1-(4-((tert-
butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-
yl)pyrimidin-2(1H)-one  (235mg, 0.347mmol) in dry THF (3.5mL) was added TBAF 
(1M solution in THF, 0.875mL, 0.9022mmol). The mixture was stirred for 3 h at room 
temperature.  The resulting mixture was evaporated and purified by silica gel (20% 
MeOH/EtOAc) to give a white solid (89mg, 58%) 1H NMR (500 MHz, DMSO-d6) δ 8.03 
(s, 2H), 7.77 (s, 2H), 7.25 - 7.38 (m, 4H), 6.14 (t, J = 6.60 Hz, 1H), 5.54 (s, 2H), 5.18 (d, 
J = 4.40 Hz, 1H), 4.81 - 5.07 (m, 1H), 4.18 (br. s., 1H), 3.74 (d, J = 2.93 Hz, 2H), 3.63 (s, 
2H), 3.47 - 3.57 (m, 1H), 3.45 (d, J = 4.89 Hz, 2H), 3.33 (br. s., 1H), 2.05 - 2.13 (m, 1H), 
1.96 (td, J = 6.54, 12.84 Hz, 1H) 13C NMR (126 MHz, DMSO-d6) δ 164.4, 155.1, 145.1, 
140.5, 136.7, 129.2, 128.6, 128.3, 123.5, 101.8, 87.6, 85.3, 70.9, 62.0, 53.3, 40.6, 28.5, 
24.4 
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73: (3-acetoxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-
yl)methyl acetate: Thymidine (1.0 g, 4.10 mmol), DMAP (spatula tip) and Ac2O (5 mL) 
were stirred under nitrogen until all the solid disappeared. Excess Ac2O was evaporated 
in vacuo and the residue was dissolved in 100 mL of DCM. The organic layer was 
washed with 2 x 100 mL of water, 100 mL of NaHCO3, and brine. The organic layer was 
dried over MgSO4, filtered and evaporated. The acetate 73 was obtained as a white solid 
yield (1.07 g, 81%) 1H NMR (500 MHz, CHLOROFORM-d) Shift 9.55 (br. s., 1H), 6.32 
(dd, J = 5.75, 8.44 Hz, 1H), 5.16 - 5.22 (m, 1H), 4.28 - 4.39 (m, 2H), 4.18 - 4.25 (m, 1H), 
2.39 - 2.48 (m, 1H), 2.10 (dd, J = 0.61, 6.48 Hz, 7H), 1.92 (s, 3H) 13C NMR (126 MHz, 
CHLOROFORM-d) δ 170.7, 163.2, 149.8, 134.9, 111.6, 84.8, 82.1, 74.1, 63.9, 36.6, 
20.8, 11.0 
	  
74: (3-acetoxy-5-(5-(bromomethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl acetate: After addition of NBS (166 mg, 0.93 mmol) and 
AIBN (8.3 mg, 0.05 mmol) to the refluxing solution of 73 (250 mg, 0.765 mmol)  in 200 
mL of dry benzene stirring with refluxing was kept for 5 h with  monitoring the progress 
of bromination by tlc (EtOAc:Hexane 70%). Hot filtration of benzene solution to remove 
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solid particles through ordinary filter paper followed by evaporation of benzene gave 
crude monobromo- interemdiate which was used directly for the next step. 
 
76: (3-acetoxy-5-(2,4-dioxo-5-(thiomorpholinomethyl)-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl acetate: To a solution of crude monobromo-intermediate 
74 and thiomorpholine (0.45 mL, 4.5 mmol) in dry THF was added 
diisopropylethylamine (174 µL, 1 mmol) and refluxed for 3 h. The reaction was cool and 
solvent removed under reduced pressure. Purification was by column chromatography 
using  methanol-Ethyl acetate (20%) to give a white foam (275 mg, 85% over two steps). 
1H NMR (400 MHz, DMSO-d6) δ 11.44 (br. s., 1H), 7.53 (s, 1H), 6.19 (t, J = 7.03 Hz, 
1H), 5.22 (br. s., 1H), 4.18 - 4.33 (m, 3H), 3.12 - 3.29 (m, 2H), 2.62 (d, J = 9.54 Hz, 8H), 
2.28 - 2.36 (m, 2H), 2.09 (s, 6H) 13C NMR (101 MHz, DMSO-d6) δ 170.1, 163.2, 150.2, 
138.1, 109.8, 84.5, 81.3, 74.1, 63.8, 54.1, 53.3, 35.9, 27.1, 20.8 
	  
81: 5-(5-(((2-(1H-indol-3-yl)ethyl)(methyl)amino)methyl)-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-2-(acetoxymethyl)tetrahydrofuran-3-yl acetate: To a solution of crude 74 
monobromo-intermediate and N-methyltryptamine (786 mg, 4.5 mmol) in dry THF was 
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added diisopropylethylamine (174 µL, 1 mmol) and refluxed for 3 h. The reaction was 
cool and solvent removed under reduced pressure. Purification was by column 
chromatography using  methanol-Ethyl acetate (20%) to give a white foam (294 mg, 77% 
over two steps) 1H NMR (400 MHz, DMSO-d6) δ 11.46 (s, 1H), 10.78 (br. s., 1H), 7.56 
(s, 1H), 7.49 (d, J = 7.78 Hz, 1H), 7.34 (d, J = 8.03 Hz, 1H), 7.14 (d, J = 1.51 Hz, 1H), 
7.07 (t, J = 7.53 Hz, 1H), 6.94 - 7.01 (m, 1H), 6.21 (t, J = 7.28 Hz, 1H), 5.22 (d, J = 4.52 
Hz, 1H), 4.22 (s, 3H), 3.25 - 3.33 (m, 2H), 2.79 - 2.90 (m, 2H), 2.59 - 2.69 (m, 2H), 2.31 
- 2.39 (m, 2H), 2.23 - 2.29 (m, 3H), 2.08 (d, J = 10.04 Hz, 6H) 13C NMR (101 MHz, 
DMSO-d6) δ 170.1, 163.1, 150.2, 137.7, 136.2, 127.2, 122.4, 120.8, 118.1, 112.5, 111.3, 
111.1, 84.4, 81.3, 74.2, 63.8, 57.5, 52.1, 41.6, 35.9, 22.8, 20.8, 20.5 
 
80: (3-acetoxy-5-(5-(morpholinomethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl acetate: To a solution of crude monobromo-intermediate 
74 and morpholine (0.3 mL, 4.5 mmol) in dry THF was added diisopropylethylamine 
(174 µL, 1 mmol) and refluxed for 3h. The reaction was cool and solvent removed under 
reduced pressure. Purification was by column chromatography using  methanol-Ethyl 
acetate (20%) to give a white foam (203 mg, 64% over two steps) 1H NMR (400 MHz, 
DMSO-d6) δ 11.45 (s, 1H), 7.56 (s, 1H), 6.19 (t, J = 7.15 Hz, 1H), 5.23 (d, J = 6.27 Hz, 
1H), 4.12 - 4.47 (m, 4H), 3.56 (br. s., 5H), 3.14 - 3.23 (m, 2H), 2.34 - 2.42 (m, 4H), 2.09 
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(d, J = 1.25 Hz, 6H) 13C NMR (101 MHz, DMSO-d6) δ 172.0, 170.5, 163.1, 150.2, 138.3, 
109.6, 84.6, 81.3, 74.1, 66.1, 63.8, 53.0, 52.8, 35.9, 20.7, 20.6 
 
 
5.1.5	  Procainamide	  Derivatives	  
 
 
 
Synthesis of 3-nitrobenzamide derivatives.  
To an oven dried 25 mL round bottom flask was added p-nitrobenzoic acid (103 mg, 0.62mmol) 
and DCM (1.1 mL) under argon atmosphere. Oxalyl chloride (0.5 mL, 6.2mmol) was added drop 
wise followed by DMF (2 drops) resulting in vigorous bubbling. The mixture was stirred for 1 h 
after which no precipitate was remained and the stating material was not observed by TLC. The 
solvent was evaporated under reduced pressure to give a white solid, which was taken up in 
DCM (3 mL) without further purification and added immediately to the appropriate amine (1.2 
equivalents) and  triethylamine (2 equivalents) stirred overnight at room temperature. 
Synthesis of 3-aminobenzamide derivatives. A solution of 3-nitro-benzamide (1 equivalent) in 
methanol was treated with 5% Pd/C (5 % w/w). The reaction was subjected to hydrogenation 
under 1atm hydrogen gas pressure at room temperature, using a balloon, and the reaction mixture 
stirred overnight. After completion of the reaction, the mixture was filtered through Celite pad (4 
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g) and concentrated by removable of solvent under reduced pressure. The resulting residue was 
purified by silica gel column chromatography. 
 
84: 4-amino-N-(5-(diethylamino)pentan-2-yl)benzamide: Yellow solid (91%) 1H NMR (500 
MHz, CHLOROFORM-d) δ 7.47 - 7.60 (m, 2H), 6.55 (d, J = 7.83 Hz, 2H), 6.29 (d, J = 
7.83 Hz, 1H), 4.09 (br. s., 1H), 3.04 - 3.45 (m, 2H), 2.44 (q, J = 7.17 Hz, 4H), 2.35 (br. s., 
2H),  1.47 (br. s., 4H), 1.14 (d, J = 6.36 Hz, 3H), 0.93 (t, J = 7.09 Hz, 6H) 13C NMR (126 
MHz, CHLOROFORM-d) δ 166.8, 149.6, 128.4, 124.2, 113.9, 52.6, 46.7, 45.4, 34.9, 
23.5, 20.9, 11.2 
 
85: 4-amino-N-(2-(pyrrolidin-1-yl)ethyl)benzamide: White solid (90.4%) 1H NMR (500 
MHz, CHLOROFORM-d) δ 7.59 (d, J = 7.83 Hz, 2H), 6.70 (br. s., 1H), 6.62 (d, J = 8.31 
Hz, 2H), 4.04 (br. s., 2H), 3.50 (q, J = 5.54 Hz, 2H), 2.66 (t, J = 6.11 Hz, 2H), 2.52 (br. 
s., 4H), 1.76 (br. s., 4H) 13C NMR (126 MHz, CHLOROFORM-d) δ 165.4, 149.4, 140.3, 
128.2, 123.7, 54.3, 53.8, 38.7, 23.5 
 
86: 4-amino-N-(3-ethoxypropyl)benzamide: White solid (81%) 1H NMR (500 MHz, 
CHLOROFORM-d) δ 7.60 (d, J = 8.31 Hz, 1H), 6.91 (br. s., 2H), 6.65 (d, J = 8.31 Hz, 
2H), 3.94 (br. s., 2H), 3.47 - 3.63 (m, 6H), 1.82 - 1.90 (m, 2H), 1.24 (t, J = 6.85 Hz, 3H) 
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13C NMR (126 MHz, CHLOROFORM-d) δ 166.9, 149.3, 128.5, 124.5, 114.1, 70.6, 66.6, 
39.3, 28.9, 15.4 
 
87: N-(3-(1H-imidazol-1-yl)propyl)-4-aminobenzamide: White solid (85% over 2 steps) 1H 
NMR (500 MHz, DMSO-d6) δ 8.03 (br. s., 1H), 7.60 - 7.66 (m, 1H), 7.54 (d, J = 8.31 Hz, 
2H), 7.18 (s, 1H), 6.86 (s, 2H), 6.51 (d, J = 8.31 Hz, 1H), 5.59 (br. s., 2H), 3.96 (t, J = 
6.60 Hz, 2H), 3.15 (d, J = 5.87 Hz, 2H), 1.83 - 1.94 (m, 2H) 13C NMR (126 MHz, 
DMSO-d6) δ 166.8, 152.0, 137.8, 129.1, 128.8, 121.6, 119.8, 112.9, 44.3, 36.7, 31.5 
 
 
88: (R)-ethyl 2-(4-aminobenzamido)-3-(1H-indol-3-yl)propanoate White solid (81%) 1H 
NMR (500 MHz, DMSO-d6) δ 10.82 (br. s., 1H), 8.05 - 8.29 (m, 1H), 7.46 - 7.69 (m, 
3H), 7.30 (d, J = 7.83 Hz, 1H), 7.17 (d, J = 1.47 Hz, 1H), 6.89 - 7.07 (m, 2H), 6.50 (d, J 
= 8.31 Hz, 2H), 5.64 (s, 2H), 4.50 - 4.68 (m, 1H), 4.03 (q, J = 7.17 Hz, 2H), 3.59 (s, 1H), 
3.32 (s, 2H H2O), 3.06 - 3.22 (m, 1H), 1.08 (t, J = 7.09 Hz, 3H) 13C NMR (126 MHz, 
DMSO-d6) δ 173.3, 166.8, 152.3, 136.7, 129.5, 127.6, 124.1, 121.4, 120.7, 118.8, 118.5, 
112.8, 111.9, 110.5, 60.7, 54.1, 27.1, 14.4 
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89: (R)-methyl 2-(4-aminobenzamido)-3-(4-hydroxyphenyl)propanoate White solids (73%)  
1H NMR (500 MHz, DMSO-d6) δ 9.18 (s, 1H), 8.23 (d, J = 7.83 Hz, 1H), 7.44 - 7.59 (m, 
2H), 7.04 (d, J = 7.83 Hz, 2H), 6.62 (d, J = 8.31 Hz, 2H), 6.50 (d, J = 8.31 Hz, 2H), 5.57 
- 5.73 (m, 2H), 4.38 - 4.53 (m, 1H), 3.48 - 3.66 (m, 1H), 3.32 (s, 3H), 2.86 - 3.02 (m, 1H) 
13C NMR (126 MHz, DMSO-d6) δ 173.3, 166.8, 156.3, 152.3, 130.4, 129.5, 128.3, 120.6, 
115.4, 112.8, 55.0, 52.2, 36.0 
 
90: (R)-4-amino-N-(1-hydroxy-3-(1H-indol-2-yl)propan-2-yl)benzamide White solid (74%) 
1H NMR (500 MHz, DMSO-d6) δ 10.79 (br. s., 1H), 7.95 (d, J = 7.34 Hz, 1H), 7.60 (d, J 
= 4.89 Hz, 2H), 7.54 (d, J = 6.85 Hz, 1H), 7.30 (d, J = 7.34 Hz, 1H), 7.14 (br. s., 1H), 
6.90 - 7.07 (m, 2H), 6.50 (br. s., 2H), 5.94 (br. s., 2H), 5.58 (br. s., 1H), 4.53 (br. s., 1H), 
4.18 (br. s., 2H), 3.33 (br. s., 1H), 3.00 (br. s., 1H) 13C NMR (126 MHz, DMSO-d6) δ 
166.7, 153.9, 152.0, 136.6, 131.6, 129.2, 127.8, 123.7, 121.3, 118.7, 116.2, 113.0, 111.8, 
65.4, 49.5, 27.6     
 
91: 6-(4-aminobenzamido)hexanoic acid: White solid (80%) 1H NMR (500 MHz, DMSO-d6) 
δ 12.00 (br. s., 1H), 7.94 (br. s., 1H), 7.53 (d, J = 8.31 Hz, 2H), 6.50 (d, J = 8.31 Hz, 2H), 
5.55 (br. s., 2H), 3.15 (d, J = 5.87 Hz, 2H), 2.18 (t, J = 7.09 Hz, 2H), 1.40 - 1.53 (m, 4H), 
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1.27 (d, J = 6.85 Hz, 2H) 13C NMR (126 MHz, DMSO-d6) δ 174.7, 166.5, 152.4, 129.0, 
121.9, 112.9, 34.1, 29.6, 26.5, 24.8 
 
92: 4-amino-N-hexylbenzamide White solid (56%) 1H NMR (500 MHz, CHLOROFORM-d) 
δ 7.58 (d, J = 8.80 Hz, 1H), 6.63 (d, J = 8.31 Hz, 2H), 6.09 (br. s., 2H), 3.99 (br. s., 2H), 
3.39 (q, J = 6.68 Hz, 2H), 1.50 - 1.61 (m, 2H), 1.18 - 1.41 (m, 6H), 0.86 (t, J = 6.85 Hz, 
3H) 13C NMR (126 MHz, CHLOROFORM-d) δ 167.2, 149.4, 128.5, 124.3, 114.1, 39.9, 
31.8, 29.8, 29.0, 27.0, 22.6, 14.1 
 
5.1.6	  Beta-­‐Carbolines	  
 
 
93: 2,6-dimethoxy-4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenol Trifluoroacetic 
acid (0.229 mL, 3.0 mmol) was added to a solution of trypatmine (320 mg, 2mmol) and 
4-hydroxy-3,5-dimethoxybenzaldehyde (437 mg, 2.4 mmol) in CH2Cl2 at 0o C and stirred 
at room temperature for 24 h and then evaporated. The obtained residue was triturated 
with a 5% K2CO3 aqueous solution (8 mL) and extracted with CH2Cl2. The organic layer 
was dried over magnesium sulfate and evaporated to dryness under reduced pressure. The 
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crude product was purified by column chromatography using methanol-EtOAc (10%) to 
give a yellow solid (302 mg, 46.2%)  1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 
7.43 (d, J = 7.53 Hz, 1H), 7.27 (d, J = 7.78 Hz, 1H), 6.94 - 7.06 (m, 3H), 6.63 (s, 2H), 
5.02 (s, 1H), 3.73 (s, 6H), 3.19 - 3.26 (m, 2H), 2.97 (td, J = 3.86, 8.09 Hz, 1H), 2.79 (d, J 
= 7.28 Hz, 1H), 2.64 - 2.71 (m, 1H) 13C NMR (101 MHz, DMSO-d6) δ 147.8, 136.0, 
135.9, 135.0, 132.8, 126.9, 120.4, 118.1, 117.5, 111.1, 105.9, 57.4, 56.0, 42.2, 22.2 
 
94: 1-(4-ethoxy-3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Trifluoroacetic 
acid (0.229 mL, 3.0 mmol) was added to a solution of trypatmine(320 mg, 2mmol) and 4-
ethoxy-3-methoxybenzaldehyde (432 mg, 2.4 mmol) in CH2Cl2 at 0o C and stirred at 
room temperature for 24h and then evaporated. The obtained residue was triturated with a 
5% K2CO3 aqueous solution (8 mL) and extracted with CH2Cl2. The organic layer was 
dried over magnesium sulfate and evaporated to dryness under reduced pressure. The 
crude product was purified by column chromatography using methanol-EtOAc (10%) to 
give a yellow solid (321 mg, 49.9%).  1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 
7.45 (d, J = 7.53 Hz, 1H), 7.29 (d, J = 7.78 Hz, 1H), 6.97 - 7.08 (m, 3H), 6.91 (d, J = 8.03 
Hz, 1H), 6.78 (dd, J = 1.88, 8.16 Hz, 1H), 5.10 (s, 1H), 4.01 (q, J = 6.94 Hz, 2H), 3.75 (s, 
3H), 3.11 - 3.22 (m, 1H), 2.99 (ddd, J = 4.89, 7.22, 12.23 Hz, 1H), 2.67 - 2.85 (m, 2H), 
1.35 (t, J = 6.90 Hz, 3H))  13C NMR (101 MHz, DMSO-d6) δ 148.9, 147.4, 136.0, 135.5, 
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135.2, 126.9, 120.5, 118.2, 117.5, 112.6, 112.5, 111.1, 108.0, 63.8, 56.6, 55.4, 41.6, 22.1, 
14.8 
 
95: 1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Trifluoroacetic acid (0.1 
mL, 1.5 Mmol) was added to a solution of trypatmine(160 mg, 1mmol) and 4-
Nitrobenzaldehyde(181 mg, 1.2 mmol) in CH2Cl2 at 0o C and stirred at room temperature 
for 24 h and then evaporated. The obtained residue was triturated with a 5% K2CO3 
aqueous solution (3 mL) and extracted with CH2Cl2. The organic layer was dried over 
magnesium sulfate and evaporated to dryness under reduced pressure. The crude product 
was purified by column chromatography using methanol-EtOAc (10%) to give a yellow 
solid (181 mg, 61.7) 1H NMR (400 MHz, DMSO-d6) δ 10.53 (br. s., 1H), 8.12 - 8.37 (m, 
2H), 7.60 (d, J = 7.53 Hz, 2H), 7.46 (d, J = 7.78 Hz, 1H), 7.26 (d, J = 7.53 Hz, 1H), 6.96 
- 7.09 (m, 2H), 5.26 (s, 1H), 3.34 (br. s., 1H), 2.98 - 3.06 (m, 2H), 2.69 - 2.78 (m, 2H) 13C 
NMR (101 MHz, DMSO-d6) δ 151.0, 146.7, 136.0, 134.1, 129.7, 126.8, 123.3, 120.8, 
118.3, 117.7, 111.1, 108.6, 55.7, 41.0, 22.1 
 
96: 1-(4-isopropylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Trifluoroacetic acid 
(0.229 mL, 3.0 mmol) was added to a solution of trypatmine (320 mg, 2mmol) and 4-
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isopropylbenzaldehyde (355.68 mg, 2.4 mmol) in CH2Cl2 at 0o C and stirred at room 
temperature for 24 h and then evaporated. The obtained residue was triturated with a 5% 
K2CO3 aqueous solution (8 mL) and extracted with CH2Cl2. The organic layer was dried 
over magnesium sulfate and evaporated to dryness under reduced pressure. The crude 
product was purified by column chromatography using methanol-EtOAc (10%) to give a 
yellow solid ( 299.5 mg, 51.7%).  1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 7.43 
(d, J = 7.28 Hz, 1H), 7.18 - 7.27 (m, 5H), 6.93 - 7.05 (m, 2H), 5.07 (s, 1H), 3.05 - 3.13 
(m, 2H), 2.85 - 2.99 (m, 2H), 2.64 - 2.80 (m, 2H), 1.19 - 1.25 (m, 6H) 13C NMR (101 
MHz, DMSO-d6) δ 147.3, 140.6, 135.9, 135.4, 128.4, 126.9, 126.0, 120.4, 118.1, 117.5, 
111.0, 108.2, 56.3, 41.2, 33.2, 24.0, 22.3 
 
 
97: 4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)benzonitrile Trifluoroacetic acid (0.1 
mL, 1.5 mmol) was added to a solution of trypatmine(160 mg, 1 mmol) and 4-
Cyanobenzaldehyde(157 mg, 1.2 mmol) in CH2Cl2 at 0o C and stirred at room 
temperature for 24 h and then evaporated. The obtained residue was triturated with a 5% 
K2CO3 aqueous solution (3 mL) and extracted with CH2Cl2. The organic layer was dried 
over magnesium sulfate and evaporated to dryness under reduced pressure. The crude 
product was purified by column chromatography using methanol-EtOAc (10%) to give a 
yellow solid (181 mg, 62.3%) 1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 7.79 - 
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7.85 (m, 2H), 7.51 (d, J = 8.28 Hz, 2H), 7.45 (d, J = 7.53 Hz, 1H), 7.25 (d, J = 7.78 Hz, 
1H), 6.95 - 7.08 (m, 2H), 5.20 (s, 1H), 3.35 (br. s., 1H), 2.94 - 3.05 (m, 2H), 2.64 - 2.79 
(m, 2H) 13C NMR (101 MHz, DMSO-d6) δ 148.9, 136.0, 134.2, 132.1, 129.4, 126.8, 
120.8, 118.9, 118.3, 117.7, 111.1, 109.9, 108.6, 56.0, 41.0, 22.1 
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